




A Comprehensive Model and Modulation of
Cellular Signaling Involved in Early Mammary
Development and Aggressive Cancer Using a




Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Elliott, Kathryn Adrian, "A Comprehensive Model and Modulation of Cellular Signaling Involved in Early Mammary Development










A COMPREHENSIVE MODEL AND MODULATION OF CELLULAR SIGNALING 
INVOLVED IN EARLY MAMMARY DEVELOPMENT AND AGGRESSIVE 










In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 









Dr. Thomas Scott, Committee Chair 
Dr. Zhicheng Dou 
Dr. Scott Pratt 





  The mammary gland is a unique and specialized epidermal organ; mammary 
organogenesis begins in the embryo but is not fully complete until puberty. As such, 
formation of the mammary gland depends on temporally and spatially regulated 
developmental steps that require coordination of multiple biological and cell signaling 
processes; many of which have parallels with cancer development. Research describing 
the events that occur between birth and puberty is lacking and little is known about 
human breast development of youth. Since mammary gland development requires a 
coordinated balance between cell growth, proliferation, and apoptosis, it is critical to 
understand which signaling pathways are utilized to relay developmental signals, and 
how these pathways and their targets interact and cooperate with age. Additionally, 
interactions between integrin molecules and their laminin ligands, especially Laminin-5 
(Ln-5; also known as Laminin-332), regulate multiple facets of both embryonic 
development and tumor growth, invasion, and metastasis. α6β4 integrin serves as a 
marker to detect distant metastases in the early stages of specific malignancies and β4 
integrin overexpression has been found in basal-like breast cancers, correlating with 
aggressiveness to institute a prognostic β4 signature that increases with tumor grade. The 
mechanism α6β4 integrin utilizes to modulate oncogenic signaling through association 
with Ln-5 molecules in the ECM is the basis for the recombinant protein (rG3, the third 
of five G domains of Ln-5) produced for the work reported in this dissertation. Here, it is 
shown there are specific transcriptional differences and a unique interaction of a gene set 
over time that contributes to postnatal mammary gland development, and this model 
 iii 
clearly shares similarities and signaling pathways with oncogenic development. 
Especially important are pathways of the adaptive and innate immunities, ECM 
remodeling and integrin interactions, and extrinsic and intrinsic TP53-mediated 
apoptosis, greater understanding of which could lead to early detection of potential 
tumorigenic growth and identification of potential treatment avenues. Presented is a 
comprehensive model of early mammary development along with several panels of 
biomarkers that possess a role in normal mammary development, are involved in 
aggressive cancers, and are affected by apoptosis induced by rG3 treatment. rG3 has 








I would like to dedicate this dissertation to my advisor, mentor, and friend, Dr. 
Thomas R. Scott. The success of my work is in large part due to his support, 
encouragement, and patience. During my time at Clemson University, I have grown 
substantially as a scientist and on a personal level; Dr. Scott deserves credit for both of 
those achievements. I will be forever grateful for the generosity he has shown me and the 




Without several other important individuals, my success would not have been 
possible. I am grateful to my committee for their advice and sharing their passion for 
scientific research. Thank you, Drs. Dou, Pratt, and Bridges, for serving as excellent role 
models and investing your valuable time in me. Additionally, I’d like to express my 
gratitude to Dr. Vijay Shankar for patiently sharing his expertise with me and helping me 
become a more versatile scientist.  
To my family, especially Dr. Robert Schalkoff, Leslie Schalkoff, and future-
doctor Chrissie Schalkoff for their unwavering support and guidance. Thank you for 
raising me to be strong and independent, and for providing the solid groundwork for my 
achievement.  
To my husband, Blake Elliott, for his encouragement, loyalty, and providing a 
stable and steady foundation during this wavering and sometimes unsteady process.  You 
have shared in my joys and my many failures; thank you for remaining by my side 
always.  
To Summer Chandler, for her wisdom, laughs, comfort, and friendship. Without 
you, hard decisions would have been impossible and football season would have been 
unbearable. I am a better person for knowing you.  
I am indebted to all of you and immensely grateful for your love and support; I 
humbly share this success with you.  
  
 vi 





TITLE PAGE .................................................................................................................... i 
 
ABSTRACT ..................................................................................................................... ii 
 
DEDICATION ................................................................................................................ iv 
 
ACKNOWLEDGMENTS ............................................................................................... v 
 
LIST OF TABLES ........................................................................................................ viii 
 




 I. MAMMARY DEVELOPMENT ................................................................... 1 
 
   Overview .................................................................................................. 1 
   Significance .............................................................................................. 2 
   Embryonic mammary gland development ............................................... 2 
   Postnatal mammary gland development .................................................. 6 
   Human breast development ...................................................................... 6 
   Signaling pathways and the ECM ............................................................ 7 
   Immune involvement ............................................................................... 8 
   Cytokeratins, integrin molecules, and laminins ..................................... 10 
   The swine model .................................................................................... 13 
   Novel techniques .................................................................................... 14 
   Hypothesis.............................................................................................. 16 
 
 
 II. BREAST CANCER ..................................................................................... 16 
 
   Overview ................................................................................................ 16 
   Basal-like vs. TNBC .............................................................................. 18 
   TNBC complications ............................................................................. 18 
   Signaling pathways in TNBC ................................................................ 19 
   Integrin molecules in cancer .................................................................. 22 
   Wnt in cancer ......................................................................................... 24 
   Macrophages in cancer .......................................................................... 26 
   Mammary stem cells .............................................................................. 27 
 vii 
   TNBC cell lines ...................................................................................... 29 
   TNBC treatment ..................................................................................... 30 
   rG3 overview ......................................................................................... 31 
   Laminin-5 ............................................................................................... 31 
   rG3 production history ........................................................................... 33 
   Hypothesis.............................................................................................. 34 
 
 
 III. MATERIALS AND METHODS ................................................................. 35 
   Animal sampling .................................................................................... 35 
   Necropsy ................................................................................................ 36 
   Collection for RNA isolation and histology .......................................... 36 
   Contingency analysis ............................................................................. 37 
   RNA isolation and sequencing: tissue ................................................... 38 
   Functional analysis ................................................................................. 40 
   rG3 production, isolation, and purification ............................................ 41 
   Western Blotting: rG3 ............................................................................ 44 
   Cell culture ............................................................................................. 45 
   Primary cell culture and fibroblast isolation .......................................... 46 
   Subculture and rG3 treatment ................................................................ 47 
   RNA isolation and sequencing: cells ..................................................... 49 
   RNA-seq data analysis ........................................................................... 50 
   Western Blotting: cells ........................................................................... 51 
   Viability assay ........................................................................................ 52 
   Statistical analysis .................................................................................. 53 
 
 
 IV. RESULTS AND DISCUSSION .................................................................. 53 
   Chapter 1 results and discussion ............................................................ 53 
   Chapter 2 results and discussion .......................................................... 149 
    
 
 V. SUMMARY AND CONCLUSIONS ........................................................ 194 
    
 
APPENDICES ............................................................................................................. 198 
 
 A: PRC Top 50 positive gene transcripts ........................................................ 198 
 B: PRC Top 50 negative gene transcripts ....................................................... 201 
 C: rG3 treated MDA-MB-231 gene transcript shift changes .......................... 204 
 
REFERENCES ............................................................................................................ 231 
 viii 
LIST OF TABLES 
 
 
Table                                                                                                                               Page 
 
 1 Phenotype of mammary gland biopsies for RNA-seq ................................. 40 
 
 2 QC values for swine mammary tissue RNA ................................................ 58 
 
 3 CLA indicates genes cluster into functional groups .................................... 66 
 
 4 Common gene IDs identified using DFA .................................................... 69 
 
 5 Reactome pathway characterization of DFA genes ..................................... 70 
 
 6 Gene name reference for genes identified using DFA ................................. 76 
 
 7 PRC positive weights ................................................................................. 111 
 
 8 PRC negative weights ................................................................................ 113 
 
 9 Summary of PRC trends ............................................................................ 116 
 
 10 Functional roles of top ten network modules ............................................. 123 
 
 11 Reactome pathway summary ..................................................................... 126 
 
 12 Gene families contained in each module (cluster) ..................................... 127 
 
 13 Reactome analysis of top 15 pathways utilized by  
  fibroblasts in vitro after 24 hr growth ........................................................ 158 
 
 14 Top 75 Reactome pathways utilized by differentially  
  expressed genes – rG3 treated fibroblasts .................................................. 160 
 
 15 Shift change values for rG3 treated fibroblasts .......................................... 163 
 
 16 Reactome pathways utilized by MDA-MB-231 cells 
   after 24 hrs growth in vitro .................................................................. 166 
 
 17 Top 75 Reactome pathways utilized by differentially  




List of Tables (Continued) 
 
Table                                                                                                                               Page 
 
18   Top 75 pathways utilized by upregulated genes in  
  MDA-MB-231 cells after rG3 treatment ................................................... 172 
 
19   Top 75 pathways utilized by downregulated genes  












LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
 1 H&E visualization of developmental index levels ....................................... 38 
 
 2 Swine growth rates during sampling ............................................................ 54 
 
 3 Formalin fixed, paraffin embedded, H&E stained  
  sections of swine mammary tissue at a) 4 days,  
  b) 8 days, c) 11 days, d) 18 days, e) 25 days, and  
  f) 32 days of age demonstrating histological  
  differences in mammary tissue morphology over time ................................ 55 
 
   4      Weighted scores can quantify histological trends in  
  mammary tissue collected over time ............................................................ 57 
 
 5 PCA presents large patterns of variability within gene  
  expression data contributing to specific ordination trends .......................... 60 
 
 6 RDA confirms that variability in pigs does exist, but  
  does not contaminate variability over time .................................................. 62 
 
 7 CLA confirms trends are present in the transcriptomic  
  data set that correlate to time ....................................................................... 64 
 
 8 DFA of mammary development over time indicates  
  temporal regulation during 4-18 days vs 25-39 days  
  after birth ...................................................................................................... 75 
 
          9      PRC indicates there are specific trends and interactions 
between sets of genes that have developmental and  
biological significance over time ................................................................. 94 
 
 10 WGCNA demonstrates functional modules in early  
  mammary gland development .................................................................... 120 
 
 11 MCODE algorithm identifies highly correlated gene  
  networks within RNA-seq dataset ............................................................. 122 
 
 12 Functional annotation of MCODE clusters from  
  WGCNA demonstrates biological significance ......................................... 125 
 
 xi 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 13 rG3 Western Blot comparison between in-house  
  and Vanderbilt ............................................................................................ 150 
 
 14 Evaluation of hsp-60 effect on MDA-MB-231 
  cell viability ............................................................................................... 152 
 
 15 MTT results for MDA-M-231, MCF-10A, and  
  primary swine fibroblast cell line after 24 hr  
  treatment in vitro with 0 – 30µg/mL rG3 ................................................... 153 
 
 16 Western Blotting for p53 after treatment with  
  20ug/mL rG3 in vitro using MCF-10A, MDA-MB-231,  
  and primary swine fibroblast lysate. .......................................................... 154 
 
 17 Western Blotting for integrin ß4 in vitro using MCF-10A,  
  MDA-MB-231, and primary swine fibroblast lysate ................................. 155 
 
 18 Panther biological Process analysis; primary fibroblasts  
  after 24 hr growth in vitro .......................................................................... 159 
 
 19 Panther Biological Processes utilized by MDA-MB-231  
  transcriptome after 24 hrs growth in vitro ................................................. 167 
 
 20 Panther Biological Process utilized by top genes  
  expressed with negative zscore (downregulated)  
  in MDA-MB-231 cells in vitro .................................................................. 178 
 
 21 Panther Pathway utilized by top genes expressed  
  with positive z-score (upregulated) in MDA-MB-231  
  cells in vitro ................................................................................................ 179 
 
 22 Panther Biological Process utilized by top genes  
  expressed with positive zscore (upregulated) in  
  MDA-MB-231 cells in vitro ...................................................................... 180 
 
 23      Integrin transcript expression in MDA-MB-231 cells  
  at 0 and after 24 hours of in vitro treatment. .............................................. 181 
 
 24 α6β4 integrin modulation and signaling in  
  MDA-MB-231 cells with and without rG3 treatment. ............................... 183 
 xii 
List of Figures (Continued) 
 
Figure                                                                                                                             Page 
 
 25 Apoptosis modulation and signaling in MDA-MB-231  
  cells with and without rG3 treatment. ........................................................ 192 
 
 26      TP53 signaling modulation and signaling in  









 The mammary gland is a unique and specialized epidermal organ in that mammary 
organogenesis begins in the embryo but is not fully complete until puberty and pregnancy. As 
such, formation of the mammary gland depends on temporally and spatially regulated 
developmental efforts that require coordination of multiple biological and cell signaling 
processes; many of which have parallels with cancer development 1. Three main stages of 
mammary organogenesis exist: embryonic, pubertal, and reproductive 2. Of importance, 
research describing the events that occur between birth and puberty is lacking. Similarly, 
little is known about human breast development 3. Much of the research regarding genetic 
interactions and mammary organogenesis cell signaling has been performed in the mouse 
model, but initial data from humans indicates the same pathways are utilized in both models 
4. Since mammary gland development requires a coordinated balance between cell growth, 
proliferation, and apoptosis 5, the current challenges in the field are to determine how 
mammary cell identity is decided, which signaling pathways are utilized to relay 
developmental signals, and how these pathways and their targets interact and cooperate 
throughout time 4. This research aims to generate a model from transcriptomic data of 
postnatal mammary gland development over time in the swine system to provide insight into 







Research in the field of mammary organogenesis is significant largely due to the 
suspected links between development and invasive caner and highly conflicting views of 
researchers on the presence of developmental activity between birth and puberty. It is the 
perspective of many that after birth, the mammary gland exists as a rudimentary organ that 
remains quiescent and dormant until puberty, when development is truly completed 6–9. 
However, reports also suggest that there is growth occurring from birth to puberty, ranging 
from allometric growth of the gland 10 to significant proliferation, branching, and expansion 
11–14. If  epithelial cell proliferation in the mammary gland can persist for weeks after birth, 
detection and characterization of stromal influences on epithelial patterning in this phase of 
development are integral 2,10. Also, there are conflicting views of post-natal/pre-pubertal 
mammary gland development that need to be resolved. Despite advances in the clinical 
treatment of breast cancer, the disease is still prevalent due to incomplete understanding of 
mechanisms involved in normal mammary development and physiology 15. In humans 
especially, the formation of the breast in the embryo and early postnatal development 
contains some events akin to early breast carcinogenesis 16.  Identifying and characterizing 
the signaling pathways responsible for mammary development and patterning over time, and 
their downstream effects, can advance our understanding of developmental biology and could 
have momentous implications for breast cancer treatment 17.  
 
Embryonic mammary gland development 
 Although the mammary gland is not functional at birth and the majority of 
organogenesis occurs postnatally under hormonal control, development begins as a ventral 
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skin derivative in the embryo independently of hormones and is very well characterized 4,10. 
Embryonic mammary gland development requires precise communication between different 
cell types, specifically those of the epidermis, epithelium, and mesenchyme, and is regulated 
both temporally and spatially by numerous signaling pathways, which will be discussed 18–21. 
There are three distinct developmental steps during mammary gland organogenesis in the 
embryo, each requiring activation of specific genes and signaling pathways: the formation of 
bilateral milk lines, formation of placodes along the milk lines, and lastly, formation of 
mammary buds in the mesenchyme 4. The initial step, formation of the bilateral milk lines, 
generates an embryonic region that will be committed to mammary cell fate 22. The gland 
will eventually form in locations along two lines that run from the axilla to the groin of the 
animal, known as the bilateral milk lines. These lines begin to develop around embryonic day 
10-11 of gestation in mice 22. At this point, Wnt/ß-catenin signaling activity localizes along 
these lines, and then quickly just to the positions of future mammary buds, making Wnt 
signaling pathway members molecular markers of the milk lines 23,24. The mammary line is 
marked by the presence of Wnt10b and the Wnt signaling reporter T-cell factor optimal 
promoter (TOP) ß-galactosidase (GAL) 23. Formation of the mammary line and expression of 
Wnt10b is the earliest detectable ectodermal event in mammary gland organogenesis in the 
mouse model 24 and within these lines, the previously single-layered ectodermal cells of the 
embryo become morphologically columnar and multilayered, forming a definitive ridge that 
is more mature than the primitive epidermis and rises above and below this layer 22,24.  
 During the second stage of embryonic mammary organogenesis, mammary milk line 
cells migrate to the locations of future mammary buds along the lines 4,18,25. When the 
mammary cells have arrived at these specific locations, five pairs of small lens-shaped 
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placodes begin to form around E11.5 in mice; placodes are multilayered ectodermal 
structures that will eventually become epithelial bulbs and are also under the control of 
WNT/ß-catenin signaling and the transcriptional mediator Lymphoid Enhancer Binding 
Factor 1 (LEF1) 24,26,27. In humans, the mammary lines form during the first trimester and 
contain only one pair of placodes 3. Several other signaling mechanisms promote placode 
formation, growth, and positional direction along the milk line, including Parathyroid 
hormone-related protein (PTHrP), fibroblast growth factor 10 (FGF10), Polo-like kinase 2 
(Plk2), and bone morphogenetic protein 4 (BMP4) 28–32. During the third step, around E13.5 
in the mouse, the placodes begin to increase in size and cells within each placode invade the 
underlying dermal tissue to form mammary buds 1,10,22–24. These buds are bulb-shaped 
structures containing mammary epithelial cells that are connected to the embryonic epidermis 
by a stalk. Neighboring cells begin to condense, concentrically surrounding the buds and 
becoming more densely packed and slightly more organized than other epidermal tissue, 
forming what is known as the initial mammary mesenchyme 28,29. The mammary 
mesenchyme aids in continued early development by maintaining epithelial cell identity, 
secreting growth factors and other key proliferative signals, and supporting ductal invasion 
2,20. By E16, the mammary epithelial cells have proliferated and elongated the mammary bud 
to form a small sprout that is primed to invade the fat precursor (an immature collection of 
pre-adipocytes at this stage) 2,22. The mammary bud is now a rudimentary mammary ductal 
tree that will contain multi-laminate club-shaped terminal end buds (TEBs) at their distal 
ends responsible for leading proliferation out through the adipose and stroma, further 
branching to generate the primary ductal tree 33. TEBs are supported by dense stroma 
containing fibroblasts, macrophages, mast cells, and eosinophils 34–36 as they are forming. 
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Basophils, T cells, and B cells are not detected 37. In contrast to mice, the pre-pubertal 
mammary glands of humans and swine contain a greater degree of ductal branching and 
terminal ductal units (TDUs) are present instead of TEBs. The TDUs reside in a collagenous 
stroma and have a higher degree of inter and intra-lobular heterogeneity than TEBs 38. By 
E18 in mice and 21 weeks in humans, the TEBs or TDUs, respectively, divide rapidly to 
generate a rudimentary ductal tree with lumen that begins to embed in the immature fat pad 
39,40. At the conclusion of embryonic development, the framework has been established for 
pubertal expansion. Existing is a rudimentary bi-layered ductal tree with an inner luminal 
layer of epithelial cells facing the central cavity and an outer layer of basal (mainly 
myoepithelial, termed from high concentrations of actin microfilaments and α smooth muscle 
actin present) cells that are adhered to the basement membrane (BM) predominantly through 
integrin-mediated interactions 3,41–43. It is widely accepted that during embryonic, and 
postnatal, mammary gland development, crosstalk and interactions between stromal, 
epithelial, luminal, and myoepithelial cells are critical for normal development and expansion 
of the gland 44. This signaling relies heavily upon the extracellular matrix (ECM), ECM 
receptors, and ECM degrading enzymes such as matrix metalloproteinases (MMPs), 
cytokines, and growth factors 45. At birth, it is believed that growth halts until puberty but 
conflicting work has been published on this matter. Shortly after birth, adipocytes densely 
packed in the fat pad begin to mature and become capable of supporting further epithelial 
morphogenesis 46,47. Increased recognition has been given to the significance of the stroma 





Postnatal mammary development 
 Postnatal mammary growth in the mouse can be classified into five periods: neonatal 
(1-3 weeks of age), juvenile (3-4 weeks of age), pre-pubertal (4-5 weeks of age), pubertal (5-
7 weeks of age), and mature virgin (7-9 weeks of age) 49. In these phases, mammary 
epithelial ducts activate invasive cell signaling to penetrate the surrounding mesenchyme 
populated by fibroblasts and adipocytes 9,10. This activity is known as branching 
morphogenesis, which is a fundamental process in development utilized to increase epithelial 
surface area in organs such as the lung, kidney, salivary gland, and mammary gland. 
Branching morphogenesis consists of iterative steps of epithelial bud formation, extension, 
branching and remodeling; the process has been thoroughly reviewed 50.  
 
Human breast development 
 A considerably smaller amount of information regarding human breast development 
exists, but the bulk of knowledge can found in the review by Howard and Gusterson 3. 
Comprehensive studies of mammary gland development in humans have not been executed, 
in comparison with rodent models, due to constraints on tissue availability and ethical 
concerns, so the best that can be reported is parallels and obvious differences in 
developmental stages between humans and rodents 51. Similar comparisons can identify gaps 
that need to be addressed in a more appropriate model animal 3. Importantly, in humans, the 
infant mammary gland completes involution once separated from maternal hormones and 
these changes are similar to events that can be found in breasts of post-menopausal women 3. 
Collection of mammary tissue from humans, and relevant animal models, across ages during 
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all developmental stages would be a valuable tool to understand developmental variations 
and disease implications 3. 
 
Signaling pathways and the ECM 
 A multitude of common cell signaling pathways and molecular factors integral in 
mammary development across species have been detected and thoroughly reviewed, 
including: Human epidermal growth factor receptor 2 (ErbB-2), fibroblast growth factor 
(FGF), Wingless-related integration site (Wnt), hedgehog, GATA3, Hepatocyte growth factor 
like protein (HGFL), nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), 
Phosphatidylinositol-4,5-bisphosphate 3-kinase/ Protein kinase B (PI3K/AKT), Janus 
kinase/Signal Transducer and Activator of Transcription (JAK-STAT), T-box transcription 
factor (TBX), epidermal growth factor receptor (EGFR or ErbB-1), Β-Interferon Gene 
Positive-Regulatory Domain I (Blimp-1) and insulin-like growth factor (IGF) 5,52–71. 
Importantly, the ECM, immune system, and cytoskeleton and constituted molecular factors 
have been implicated to influence both embryonic and postnatal mammary organogenesis. 
The ECM and stroma, including growth factors, cytokines and proteinases within these 
niches, have long been known for morphogenesis 72 and are essential for development of a 
functional mammary gland 7,73 where these also play important roles in breast cancer 
development (reviewed by 74–78). The branching morphogenesis of the mammary gland is 
controlled partially by the basement membrane (BM), interacting epithelial and mesenchymal 
cell populations, and cell-cell/cell-matrix adhesions, but this crosstalk is not comprehensively 
understood 79. It is accepted that post-natal stroma (previously embryonic mesenchyme) 
influences cell fate and differentiation throughout mammalian adulthood 80,81. After birth, 
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mammary epithelial cells are tightly connected to both each other and surrounding stroma, 
relying on tight adhesion to transmit biochemical signals, allow cell migration, and function 
normally 7,41,82. Interestingly, epithelial cell movement utilizes many of the same molecules 
that modulate activity of the actomyosin network, including Ras-related C3 botulinum toxin 
substrate (Rac), rho-associated, coiled-coil-containing protein kinase (ROCK) and myosin 
light chain kinase, implying that actomyosin contractility possesses a critical role in 
mammary gland morphogenesis 83.  
 
Immune involvement in mammary development 
 Another seemingly unrelated organ system that compasses a major portion of prenatal 
and postnatal mammary development is the immune system 11,84–88. The well-known 
cytokines interleukin-4 (IL-4) and IL-13 have been shown to support differentiation and 
maturation of luminal epithelial cells 89, and macrophages, in addition to their roles in 
pathogen clearing and wound healing, are important regulators of branching morphogenesis 
during embryonic and post-natal development of the mammary gland 36,90,91. Other innate 
immune cells have been found in pre-pubertal mammary tissue, likely influencing 
development prior to puberty 11. Macrophages are abundant cells in nipple aspirates from 
reproductive age women 92 and taken together with previous reports of this cell type 
localizing with mammary epithelial cells 36, it can be inferred that immune cells play roles 
throughout all stages of mammary development. Macrophages can be visualized lining the 
mammary ducts where they secrete growth factors, chemokines, and cytokines to support 
epithelial cell proliferation 91. Previous work has shown that the cytokines IL-4 and IL-13 are 
critical for promoting the differentiation and maturation of luminal epithelial cells 89; 
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reciprocally, data from genetically modified mouse models show that Colony stimulating 
factor 1 (CSF1,) Transforming growth factor ß1 (TGFB1) and C-C Motif Chemokine Ligand 
2 (CCL2), all secreted by mammary epithelial cells, regulate macrophages during mammary 
development 34,93–97. This relationship creates a positive developmental loop, wherein 
mammary epithelial cells signal to macrophage populations to secrete factors that provide 
support and promotion of further epithelial development 93. In humans, high amounts of 
CSF1 protein and mRNA were found in normal and lactating breast epithelium 98–100. In 
response to IL-4/IL-13 stimulation, macrophages can produce members of the MMP family 
in vitro 101,102. In the context of mammary gland development, MMPs function in ECM 
remodeling to allow ductal branching into the fat pad 14,103–107. Importantly, MMP3 is an 
extracellular regulator of the Wnt signaling pathway and an effector of epithelial stem cell 
function 108, and MMP11 has a paracrine function during development that can be exploited 
to promote tumor progression, providing another link between development, immune 
molecules, and malignancy 109. MMP14 and MMP15 also regulate adipocyte fate 
determination in the developing mammary gland 14. In addition to their roles during normal 
mammary organogenesis, macrophages are often present in the breast tumor 
microenvironment, where they correlate with reduced overall survival 110–113. The importance 
of immune cells in mammary gland development is well known 34,35, but more research is 
needed to elucidate the molecular signaling that guides them within the gland, and largely 
unexplored are the roles of chemokines and the adaptive immune system 86,114. Accordingly, 
understanding the function of immune molecules in normal development and their concert 





Cytokeratins, integrin molecules, and laminin molecules in mammary development 
 Several other molecules that are commonly implicated in early mammary 
development are cytokeratins, integrin molecules, and laminins. Cytokeratins can be found in 
most epithelial cells where they function as intermediate filament proteins. In the mouse 
mammary gland, K5 and K14 are markers of basal/myoepithelial cells and K8 and K18 are 
luminal cell markers 115,116 and K5 and K14 are co-expressed during the first few postnatal 
weeks of development 117. The role of integrin molecules in mammary development has been 
thoroughly reviewed by Ramovs et al118. As previously mentioned, remodeling of cell–cell 
and cell–ECM interactions is critical in both normal mammary development and oncogenic 
development; integrin molecules and laminins are both significant components of the ECM. 
Integrin molecules function to sense and integrate signals between the ECM and 
cytoskeleton, influencing intracellular signaling and cell proliferation, migration, and 
differentiation 119. Integrin molecules can also respond to intracellular signals (inside-out 
signaling) and mediate cell adhesion and transmission of contractile forces for migration 
119,120. More than 150 proteins have been detected to interact with integrin molecules at sights 
of adhesion, known as adhesomes 121–123. Interacting proteins at the adhesome include 
cytoskeletal components, enzymes, and adaptor proteins that control downstream signaling 
cascades and regulate proliferation, differentiation, and migration of cells 124. Cells must 
utilize integrin-mediated adhesion to progress through the G1/S cell cycle checkpoint 125 
through signaling using mitogen-activated protein kinases/extracellular signal-regulated 
kinase (MAPK/ERK), PI3K/Akt, and the small GTPase Rac pathways 124. Two of the most 
critical integrin molecules for mammary branching morphogenesis are integrin molecules β1 
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and β4 126,127. Both β1 and β4 are involved throughout mammary morphogenesis 128, but it is 
important to note that β1 can form integrin heterodimers with α1, α2, α3, α5 and α6 chains, 
whereas β4 can only associate with α6 119,129, appointing β4 as an indicator of α6 presence. β1 
integrin, while associated with laminin molecules, has been shown to transmit signals to 
mammary epithelial cells during pregnancy and lactation 130. β4 is more controversial; 
although its contribution to epithelial biology has been investigated for over two decades, its 
role in mammary gland biology is unclear and confusing 131. β4 is expressed mainly on the 
basal surface of epithelial ducts and like β1, is an adhesion receptor for laminins 132. This 
association allows formation and mediation of stable hemidesmosomes (HDs) on the basal 
cell surface that link the cellular cytoskeleton with the BM 133. β4 and its exclusive partner α6 
are organized primarily in basal/myoepithelial cells or basal luminal cells, appearing to prefer 
the basal plasma membrane surface where they provide an anchor to the BM 131,134. The 
upregulation of integrin expression by several growth hormones and growth factors in the 
bovine model proved that integrin α6β4 was critical for mammary development 134, but 
studies in mice suggest α6β4 integrin is actually not essential for proper branching 
morphogenesis in vivo 135. In immortalized mammary epithelial cell lines such as MCF10A, 
α6β4 integrin is critical in the formation of HDs and branching morphogenesis is disrupted 
without their presence 136. Additionally, studies using three-dimensional cultures seem to 
prove α6β4 is necessary for mammary gland development and function 137. Li et al 
hypothesize that β4 contributes to mammary gland development by sustaining Parathyroid 
hormone-related protein (PTHrP) expression and enabling PTHrP signaling, but the 
mechanism and function of α6β4 integrin in mammary organogenesis is still poorly 
 
 12 
understood compared to other molecules 131. α6β4 integrin involvement in cancer will be 
discussed in Chapter 2.  
 
Laminin molecules in mammary development  
 Through basally located integrin molecules and laminins, direct attachment of 
mammary epithelial cells to the ECM can occur 138,139. Laminin-binding integrin molecules 
commonly are found in focal adhesions (FAs) and HDs, which are two adhesion complexes 
that form mechanical links between the ECM and the actomyosin cytoskeleton 140. Laminins 
are large heterotrimeric ECM glycoproteins and major components of the BM 141. Four 
integrin molecules recognize laminins as their extracellular ligands: α3β1, α6β1, α7β1 and 
α6β4 (reviewed in 142). Laminin-5 can precisely interact with integrin α6β4 in 
hemidesmosomes to support stromal adhesion 133. The first study to implicate Laminin 
molecules in mammary morphogenesis was completed by Barcellos-Hoff et al using Matrigel 
73. Since then, a study with MCF-10A cells in vitro confirmed Laminin-5 and α6β4 integrin 
are needed for hemidesmosome assembly and branching morphogenesis 136. Using the 
murine model, it was confirmed that both laminin and integrin molecules are required to 
support migration and cellular traction through the stromal, therefore critical in normal 
mammary gland development 143. Although evidence is strong for a supportive role of 
integrin molecules and laminins in mammary development, much remains to be discovered 






The swine model of mammary development 
 Currently lacking in the field of mammary biology is continuous developmental data 
collected from the same live animal over time, which would allow a deeper understanding of 
developmental processes involved in the period between birth and puberty. Previous attempts 
commonly used necropsy samples from different animals at different ages 144 which does not 
completely control for variability between animals. Additionally, much previous research 
utilizes a mouse or rat model because despite many anatomical and physical differences with 
humans, these small mammals can be manipulated easily 2. Due to tissue availability 
constraints, comprehensive studies of human breast development do not exist. The best that 
could be accomplished is to draw parallels between the human and the mouse mammary 
gland 3 and studying the infant breast has been difficult and inconclusive 145. Difficulty in 
maintaining cultures of primary human cells and continuous human mammary epithelial cells 
also prove controversial, as exemplified by the MCF-10A human mammary epithelial line 
which will be discussed 146. Moreover, in vitro and ex vivo model systems have not been able 
to truly represent mammary gland architecture or stromal cell interactions; reviewed by 79. 
Anatomically and physiologically, the swine model is more closely related to that of the 
human. Sullivan et al conducted a comprehensive review of the swine model for wound 
healing and concluded it is an excellent tool for the evaluation of therapeutic agents destined 
for use in human wounds 147. Miller & Ulrey concluded the swine model was appropriate to 
study human nutrition 148 while Meurens et al concluded that domestic pigs are related 
enough to humans in terms of anatomy, genetics and physiology that they represent a perfect 
model to study various microbial infectious diseases, vaccine development, and contribute 
significant knowledge to improve human health 149. The use of swine biomedical models has 
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been well-reviewed by Lunney in 2007; some highlights of the swine model’s suitability for 
human disease include its similarity in size and physiology, organ development, disease 
progression, allowance of deliberately timed studies and imaging of vessels and organs using 
clinical technology, and collection of repeated samples 150. It is valuable to have the ability to 
study multiple pigs from the same litter as well as access to numerous swine cell lines 
developed from a broad range of tissues 150. Especially useful for genomic and transcriptomic 
studies is the existence of the swine genome sequence that shows high homology with 
humans, resulting in the development of advanced genetic and proteomic tools 150. Lastly, the 
immune system of humans differs considerably from that of the mouse; the swine model may 
address the limitation of the mouse model to study the immune system in a living animal. 
With the assessment of key immune regulators and markers in swine, it is now viewed as a 
better model of human innate immunity and disease than rodents 151.  
 
Novel techniques to study mammary development  
 Nearly all previous studies of postnatal mammary gland development have used 
microarrays 152. Recently, next-generation sequencing (NGS) technology has emerged as a 
revolutionary tool in genomics due to its high throughput, reasonable cost, and genome-wide 
investigation capabilities 153,154. One application of NGS, and a major improvement over 
microarrays, is RNA sequencing (RNA-Seq), which uses NGS technology to sequence, map, 
and quantify mRNA transcripts 155,156. It can be used to directly survey RNA content of 
mammalian cells and has been used effectively for human samples 157. Technical reviews of 
RNA-Seq conclude that this technology is an effective way to study the transcriptome of a 
cell or animal 153,154,158–160. Successful use of RNA-Seq to analyze transcriptomes of the sheep 
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mammary gland 161, the lactating bovine mammary gland 162, MDA-MB-231 mammary 
carcinoma cells 163, B-cell lymphoma biopsies compared with normal biopsies in dogs 164 and 
whole mouse 165 have been published. In 2014, Zhao et al predicted that the RNA-Seq 
platform will become the predominant tool for transcriptome analysis after demonstrating the 
benefits over microarrays by performing a T-cell transcriptome comparison using both 
methods 166. They concluded RNA-Seq was superior in detecting low abundance transcripts, 
able to better differentiate biologically critical isoforms, allowed for the detection of more 
differentially expressed genes, and avoided many of the technical issues present in 
microarrays 166. Mantione et al, also in 2014, compared RNA-Seq and microarrays for whole 
genome profiling and concluded RNA-Seq has a bright future in bioinformatics 167. There are 
numerous software packages available to use with the technology 168,169 and it has been 
fruitful for both coexpression analysis 170 and miRNA expression analysis during mammary 
gland development 171.  
 Despite the complexity of RNA-sequencing for gene expression, studies often only 
use a small number of biological replicates due to tissue availability, invasiveness, or cost 
limitations. This poses a statistical problem that can be mitigated with the use of specialized 
statistical techniques, particularly multivariate statistics to assess dependency of inherent 
variabilities on each other, to extract the most value out of the data 172. These techniques are 
currently commonly used in microbial and community ecology; multivariate techniques for 
exploratory analysis 173 and application of multivariate statistics in microbial ecology 174 have 
been expertly reviewed. Benefits compared to traditional statistical methods are seen from 
utilization in community ecology 175,176, microbial ecology 177, gut microbiology 178,179, and 




Chapter 1 Hypothesis: There are specific transcriptional differences and unique interaction 
of gene set over time that play critical roles in postnatal mammary gland development  
 Based on our current knowledge of mammary gland development in the post-natal 
period up to puberty, the hypothesis for this study is that there are specific transcriptional 
differences and unique interactions of gene sets over time that contribute to postnatal 
mammary gland development, which have not been fully documented. Since we have high 
throughput data from mammary development over time in a post-natal swine model analyzed 
by RNA-Seq, it is both novel and appropriate to use multivariate statistical techniques to 
identify trends although not currently commonly used in developmental biology. Here, we 
use a clinically relevant swine model to repeatedly sample mammary tissue throughout early 
post-natal development in the same animal using minimally invasive technology. In this 
manuscript, we will provide novel information about the postnatal but pre-pubertal gene 
expression in swine, insight into the unique developmental trends over time characterized by 
gene sets, novel pathways utilized and support of currently known pathways in embryonic 
and pubertal development, and for the first time (to our knowledge) show the transcriptome 
of mammary development over time in the same animal.  
 
 
CHAPTER TWO: BREAST CANCER 
Overview 
 Breast cancer is a heterogeneous disease and is currently classified into subtypes 
based on similar molecular features 181. There currently exist five molecular breast cancer 
subtypes: luminal A, luminal B, normal breast-like, HER2, and basal-like 182–186. Of the five 
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subtypes, basal-like breast cancer (also sometimes known as triple negative breast cancer 
(TNBC)) is the deadliest form of breast cancer 181,187. TNBC lacks the hormone receptors 
(HRs) present on the cell surface of other cancer varieties (estrogen (ER), progesterone (PR), 
and human epidermal growth factor 2 (HER2)) 188.  In the U.S., TNBC represents 12% of all 
breast cancers and is more prevalent in pre-menopausal women, African-American women, 
and women with the breast cancer 1 (BRCA1) gene mutation 181,187,189. For the purpose of this 
dissertation, the definition of TNBC will be a group of malignant tumor cells that lack the 
expression of ER, PR and HER2.  
 In contrast with TNBC, approximately 70% of breast cancers do possess ER and PR 
on their cellular surface 190. Termed luminal cancers, they can additionally be classified based 
on HER2 status to represent the luminal A and B subtypes 185. ER positive breast cancers 
represent the majority of HR positive cases and the estrogen cell surface receptor has long 
been a major target for therapy with relatively good prognosis 191. HER2 overexpression 
occurs in about 15–20% of luminal cases and also holds a favorable projection 192.  In 
contrast to the well characterized HR positive subtypes of breast cancer, there remains a rare 
case with a variable phenotype termed Inflammatory Breast Cancer (IBC) 193. This is an 
extremely aggressive form titled by the extremely swollen condition of IBC patients 194. This 
swollen presentation, due to cancerous cells obstructing lymph vessels underneath the skin, 
resembles inflammation 195,196. IBC occurs in approximately 1-5% of breast cancers in the 
U.S 194. Interestingly, although IBC is a heterogeneous disease with the ability to express all 
(or none) of the HRs, the tumors are frequently HR negative, resemble TNBC, and are very 




Basal-like vs TNBC 
 Basal-like breast cancer is a subtype with defining features that has some overlap 
with characteristics of TNBC. Some adopt the two terms interchangeably and claim basal-
like breast cancer is composed of almost entirely TNBC tumors 187,199–203. However, other 
researchers believe this usage is misleading and that TNBC and basal-like tumors do have 
significant differences 182,204–210. Expression of basal markers such as CK5, CK6, CK14, 
CK17, and EGFR are associated with a higher histological and morphological grade, 
presence of BRCA1 mutation, and poor prognosis when compared to TNBC tumors without 
basal phenotype 209,211,212. If basal-like tumors were classified based on IHC expression of 
basal markers, 10-30% of HR positive tumors would be termed basal-like, leading to this 
discrepancy 213,214; TNBC tumors that do express basal markers are a subgroup with an 
especially poor outcome 209,211. These disparities, combined with the fact that both types are 
distinct classes with high overlap 204, expose the need for a more defined set of biomarkers 
for each class.  
 
TNBC complications 
Despite its grave short-term prognosis and a 300% higher recurrence rate than other 
types of breast cancer, there are presently no FDA-approved targeted therapies for TNBC 215–
217.  An improved clinical outcome is possible for patients suffering from other breast cancers 
through the use of targeted therapies toward defective cellular signaling pathways assuming 
the cells express common surface receptors; this is demonstrated by the success of 
trastuzumab, pertuzumab, and lapatinib in HER2-overexpressing breast cancer 218–221. TNBC 
patients have a dismal prognosis from the sheer lack of available targeted therapies, and 
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sadly, most cases eventually develop therapeutic resistance and capitulate to the cancer 222. In 
addition to the absence of targeted therapies, TNBC lacks a definitive panel of biomarkers for 
phenotypic correlation 220. If a panel existed, it could aid in one of the most critical 
intervention steps in cancer development: early disease detection. Without any predictive 
factors, mammography remains the most powerful advanced detection approach, but often 
presents over diagnoses as the method cannot distinguish between threatening and non-
threatening cancers. Because of the shortcoming in detection, approximately 5%-30% of 
women are misdiagnosed and undergo unnecessary and costly surgeries, procedures, and 
undue agony 223. TNBC is a diverse and complicated set of diseases, each consisting of 
extended intratumoral heterogeneity and a distinct molecular subtype, resulting in 
unpredictable responses to chemotherapy 224. Inherent heterogeneity has severe consequences 
related to treatment resistance even when targeted therapeutics are administered 225. Targeted 
therapy for TNBC has been inadequate due to the lack of specific targets and partial 
understanding of the pathways involved 226,227. 
 
Signaling pathways in TNBC  
 One of the most important and well known mutations of TNBC and basal-like breast 
cancer is that of the BRCA1 (BReast CAncer 1) and BRCA2 (BReast CAncer 2) genes and 
associated pathways 228–230. Tumors from BRCA1 mutation carriers show dysfunctional cell 
cycle progression 231–234 and express low levels of Cyclin-dependent kinase inhibitor 1B 
(p27), high levels of S-Phase Kinase Associated Protein 2 (Skp2), cyclin E, and caspase-3 in 
comparison with sporadic tumors and tumors with BRCA2 mutations 232,234. Other genes 
found mutated with or without BRCA1 and BRCA2 mutations are ATM serine/threonine 
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kinase (ATM) and tumor protein 53 (TP53); these have a potential role in TNBC metastasis 
through interaction with BRCA1, BRCA2, and additional proteins that will be discussed 
subsequently 183,235–238. An inherited TP53 mutation causes a condition known as Fraumeni-
Li syndrome, which has been proven to predispose women to breast cancer at an early age 
235,238.  
 A second pathway critical in cell cycle maintenance and cellular proliferation (and a 
possible contributor to oncogenic development) is the Phosphatidylinositol 3-
kinase/mammalian target of rapamycin (PI3K/mTOR) pathway 239–241. PI3K/mTOR is a 
common focus of clinical research; it is one of the most frequently altered pathways in 
human breast tumors and controls central aspects of cancer, which include cell proliferation, 
survival, metabolism, and genomic stability 242. It has also become a desirable target for 
therapy 243,244. Mutations are commonly found in the PIK3CA gene in TNBC 245 with 
dysfunction in supporting genes of this pathway including AKT3, Phosphatase and tensin 
homolog (PTEN), and Tuberous Sclerosis 1 (TSC1) 245,246. Functional PI3K molecules 
transduce upstream signals from receptor tyrosine kinases (RTKs) and G protein-coupled 
receptors (GPCRs) by phosphorylating the 3′-hydroxyl group of the inositol ring of 
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to generate phosphatidylinositol-3,4,5-
trisphosphate (PIP3) 247,248. PIP3 then can recruit cytosolic proteins to the plasma membrane 
to promote activation or co-localization with other proteins 249–251. AKT, a protein with 
multiple roles in metabolism, growth, and cancer, is able to bind PIP3 252,253 and activate a 
wide range of target proteins. The 3′ phosphatase PTEN is a lipid phosphatase that converts 
PIP3 back to PIP2, blocks and regulates PI3K signaling 254, and has been characterized as a 
major tumor suppressor in humans 255,256. The PI3K-AKT pathway regulates cell cycle 
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progression at the G1/S transition through inhibition of degradation of cyclin D1 and Myc, 
two proteins that drive S phase entry 257,258. Specifically, FOXO transcription factors inhibit 
cyclin D1 expression and promote the cell cycle regulators p27kip1 and p130Rb2 259. When 
phosphorylated by AKT, FOXO supports cyclin D1 expression and inhibits expression of cell 
cycle inhibitors. Human tumors often show overexpression of cyclin D1 or Myc and 
reduction in expression of p27kip1, which allows cancerous cells to proliferate 260,261. p53 is a 
critical tumor suppressor protein involved in cell cycle regulation and apoptosis; in normal 
cells p53 is negatively regulated by the p53-binding protein Mouse double minute 2 homolog 
(MDM2), which blocks the apoptotic properties of p53 and targets it for ubiquitination 262,263. 
p53 selectively regulates cell cycle arrest, DNA repair, and apoptosis to protect genomic 
stability and prevent tumor formation 264. Instinctively, p53 is often mutated in metastatic 
tumors; somatic p53 mutations occur in greater than 50% of tumors and almost every cancer 
type 235,265,266. PI3K-AKT is critical in the survival, growth, and proliferation of normally 
functioning cells; inhibitors of this pathway would require the tumor to be more sensitive 
than normal tissue which complicates therapeutic development 267.  
 Additionally, several critical AKT-independent PI3K signaling pathways exist, 
including the PDK1-mTORC2-SGK axis, Rac signaling, and the TEC family kinases 268. It is 
important to note that the Rac proteins (RAC1, 2, and 3) are a subfamily of the Rho GTPase 
family that function to remodel the actin cytoskeleton 269 to promote invasion and metastasis 
270. Additional pathways potentially exhibiting causal involvement in TNBC are the 
RAS/RAF/MEK pathway, including amplifications or mutations in Fibroblast Growth Factor 
Receptor 1 (FGFR1), Insulin-Like Growth Factor 1 Receptor (IGF1R), B-Raf Proto-
Oncogene, Serine/Threonine Kinase (BRAF), KRAS Proto-Oncogene, GTPase (KRAS), 
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HRas Proto-Oncogene, GTPase (HRAS), and Dual Specificity Phosphatase 4 (DUSP4) 245,246. 
Furthermore, cell cycle checkpoints, including amplifications or deletions of RB 
Transcriptional Corepressor 1(RB1), Cyclin Dependent Kinase 6 (CDK6), Cyclin D1 
(CCND1), and Cyclin D2 (CCND2) can lead to tumorigenesis when dysfunctional 239,246,271–
276. Other pathways commonly studied are the Janus kinase/signal transducers and activators 
of transcription (JAK/STAT) pathway (amplification in JAK2), and the Notch pathway 
(including amplification or mutation in WNT and β catenin) 61,276–283.  
 
Integrin molecules in cancer 
 As discussed in Chapter 1, the interactions between integrin molecules and their 
laminin ligands, especially laminin-5, regulate multiple facets of embryonic development. 
However, they also effect cell proliferation, tumor growth and the capability of human breast 
tumors to metastasize 284–290. During progression from tumor growth to metastasis, specific 
integrin signals enable cancer cells to detach from neighboring cells, re-orientate their 
polarity during migration, and survive and proliferate in foreign areas, similar to their 
function in normal mammary development 291. In mature normal tissue, laminin-5 is 
primarily involved in adhesive function; however, in cancer, it has a more complex role in 
cell migration and tumor invasion 292. The most common integrin molecules that function as 
laminin receptors on cancer cells are α2β1, α3β1, α6β1, and α6β4 293. Integrin heterodimers 
comprised of the α6 subunit can pair with either the β1 or β4 subunit, while integrin β4 
subunit can only pair with the α6 subunit, making β4 an indicator of the presence of α6β4 291. 
Increased expression of integrin α6 has been observed in invasive ductal carcinomas 294, skin 
squamous cell carcinomas 295,296, oral squamous cell carcinomas 297, ovarian carcinoma 298, 
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prostate tumors 299, bladder cancer 300, pancreatic cancer 301 and colorectal cancer 302. 
Furthermore, a range of studies implicate α6β4 integrin as a contributor to oncogenic 
development in breast cancer 137,303–305. In advanced breast carcinomas, α6β4 integrin 
localizes to the leading edge of invasive cells, cooperating with ErbB2/3 and associating with 
F-actin to promote metastasis, which leads to deregulation of adhesion, liberation from 
hemidesmosomes, loss of cell polarity, and hyper-proliferation 306. In contrast with 
development, α6β4 is not limited to the basal layer of epithelial cells in cancer and in tumors 
it can be found in multiple cell layers of the tissue 285,289. Many normal cellular signaling and 
ECM pathways containing integrin receptors are deregulated in cancer to allow cellular 
migration, as evidenced by differential integrin expression among normal breast, simple 
hyperplasia, atypical hyperplasia, ductal carcinoma in situ (DCIS) and invasive tumors 307. 
α6β4 integrin is thought to remodel the ECM through interaction with the PI3K and RhoA 
cell signaling pathways previously discussed and induction of traction forces generated by 
the actomyosin cytoskeleton 308,309. Additionally, α6β4 can induce the production of MMP1 
and MMP2 310,311, which as discussed in Chapter 1, drive normal mammary development in 
conjunction with macrophages. α6β4 supports PI3K activation through different receptor 
tyrosine kinases (RTKs) which is necessary for cell survival 312. PI3K signaling induced by 
integrin molecules can also activate the transcription factors STAT3 and c-Jun 313. Moreover, 
α6β4 serves as a marker to detect distant metastases in the early stages of specific 
malignancies 289,314 and β4 overexpression was found in basal-like breast cancers, correlating 
with aggressiveness to institute a prognostic β4 signature 288 that increases with tumor grade 
289,315. Integrin β1 and β4 signaling also leads to resistance to treatments including 
radiotherapy, chemotherapy, hormone therapy and targeted therapies 137. Notably, α6β4 
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integrin may modulate oncogenic signaling through association with Laminin molecules in 
the ECM.  
 
Wnt in cancer 
 The Wnt gene family consists of 19 Wnt genes encoding closely related proteins and 
are the most critical family of signaling molecules in embryonic and postnatal development 
316. As described in Chapter 1, formation of the mammary line and expression of Wnt10b is 
the earliest detectable ectodermal event in mammary gland organogenesis in the mouse 
model 24 and the Wnt family continues to support placode development and TEB expansion 
throughout mammary organogenesis 24,26,27. In fact, expression of Wnt2, Wnt4, Wnt5a, 
Wnt5b, Wnt6, Wnt7b, and Wnt10b regulate growth and differentiation in the developing 
mammary gland; in other tissues, Wnt proteins influence analogous processes including cell 
fate determination, cell growth, apoptosis, maturation, and differentiation 317. In human breast 
tumors, overexpression of WNT2, WNT4, WNT5A, WNT7B, WNT10B, and WNT13 has 
been detected 318–322. Specifically, WNT2 is normally expressed in mammary stroma while in 
breast carcinomas is present in both the epithelium and the stroma 320. Defining the functional 
significance of Wnt overexpression in breast cancer is difficult due to additional oncogenic 
mutations found in downstream signaling components in the pathway 280. Recently, data 
suggest that Wnt signaling can promote stem cell self-renewal 283,323–326. 
 Cell surface receptors for the Wnt proteins are composed of a transmembrane domain 
plus one low density lipoprotein receptor related protein, either LRP5 or LRP6 316,327–329. A 
critical downstream signaling component, β catenin, aids in cell adhesion and transcriptional 
regulation. It is cytosolically degraded in the absence of Wnt signaling and in the presence of 
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Wnt is translocated to the nucleus to form a complex with LEF-1 family members, allowing 
regulation of target genes such as c-Myc and cyclin D1 317,326,327. This is classified as the 
canonical Wnt signaling pathway 54,316,327. It is important to note that many Wnt and β catenin 
target genes are tumor suppressors or oncogenes; in colon cancer, 85% of tumors have a 
mutation in the APC protein, a negative Wnt regulator that normally destabilizes β catenin 
327. Elevated β catenin activity has been shown in many breast cancer cell lines and in the 
nucleus and cytosol of close to 60% of human breast cancer tissue samples, correlating with 
poor prognosis 330. In addition, elevated levels have also been found in tumor lysates 
confirmed by Western Blotting 331. Transgenic mouse models containing stabilized 
expression of β catenin in their mammary gland result in tumor formation 332,333. Importantly, 
many researchers suspect Wnt signaling in breast cancer may be influenced by other 
members of the Wnt pathway that have not yet been comprehensively studied 334. Several 
studies have reported altered expression of regulators of the Wnt pathway in breast cancer at 
the RNA and protein level 335,336.  Of significance is the crosstalk between Wnt and the 
PI3K signaling pathways in breast cancer; mutations in or inactivation of PTEN occurs in a 
significant portion of breast cancers 337. When PTEN is silent, it acts as a PI3K suppressor 
and leads to the hyperactivation of AKT and nuclear accumulation of β catenin 338. Upon 
binding growth factors such as Insulin, IGF1, and FGF1, the PI3K/AKT pathway may 
contribute to the stimulation of β catenin signaling 339. An important downstream signaling 
molecule in the PI3K pathway, p53, may rely on β catenin degradation to function 317. The 
p53 gene is mutated in 20-40% of human breast cancers and can trigger β catenin 
degradation; this may be a method utilized by the cell to prevent excessive β catenin levels 
340. Loss of TP53 function in cancer would then result in overexpression and stability of β 
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catenin and increased expression of transcriptional targets- potentially oncogenes 317. Finally, 
kinases of the NF-κB signaling pathway (IκB kinases IKKα and IKKβ) can regulate β-
catenin transcription and activity, further supporting the large network of signaling pathways 
converging with the Wnt pathway 341. Data currently indicate activation of the Wnt signaling 
pathway is frequently one of the most critical signaling abnormalities in breast cancer 
276,283,318,327,334,342,343 and may be a source of novel therapeutic targets for treatment of TNBC 
344.  
 
Macrophages in cancer 
 As reviewed in Chapter 1, MMPs secreted by macrophages function in ECM 
remodeling to allow ductal branching into the mammary fat pad 14,103–107. One MPP, MMP3, 
serves as an extracellular regulator of the Wnt signaling pathway and effector of epithelial 
stem cell function 108, offering a link between the Wnt pathway and the immune system that 
can impact adult epithelial cell function 108. Similar to normal mammary organogenesis, the 
stroma and ECM play a vital role in tumorigenesis 345. There are conflicting opinions on 
whether macrophages present in the tumor stroma environment are involved in tumor 
rejection or promotion of tumor growth and invasion 346, but a detailed review by Lin et al 347 
provides significant evidence that macrophages support tumorigenesis in a comparable 
manner to their function in normal mammary organogenesis. CSF-1, a regulator of 
macrophage recruitment, is frequently overexpressed in human breast cancer tissues and 
correlates with poor prognosis 348,349. Furthermore, several clinical studies provide strong 
evidence in a causal role for CSF-1 in breast cancer progression and metastasis 347. The 
current hypothesis implies CSF-1 produced by tumors, in conjunction with other cytokines 
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(especially TGFB1 and CCL2), recruits macrophages to the tumor microenvironment and 
simultaneously inhibits development of immune cells that may present tumor antigens to T-
cells. This strategy provides an attractive site of therapeutic intervention 347. The role of 
TGFB1 in breast cancer is not fully understood; data show that it can both suppress tumor 
development and promote tumor invasion 350 and possess a pro-tumorigenic effect at later 
stages of cancer progression where it modulates EMT 351,352. CCL2, secreted by mammary 
epithelial cells during development, recruits macrophages and can be found in high levels in 
tumor tissue and surrounding stromal cells 353, where its expression is highly correlated with 
macrophage infiltration 354–357. It is evident that mammary epithelial cell interactions with 
macrophages, mediated by a range of cytokines, can significantly affect the risk of breast 
cancer by supporting tumor development 347. Future studies should investigate the specific 
signaling pathways utilized in mammary gland development that involve cytokines, 
macrophages, and if dysfunctional, promote tumor growth and metastasis.  
 
Mammary stem cells 
 Given that normal stem cells, mammary stem cells (MaSCs), and cancer stem cells all 
share the ability to self-renew, differentiate, initiate anti-apoptotic pathways, increase 
membrane transporter activity, and migrate, understanding mammary stem cell profiles and 
their role in normal development aids in identifying the mechanisms involved in 
carcinogenesis. These properties make mammary stem cells ideal candidates for the initial 
events that drive tumor growth and metastasis 358. Adult mammary stem cells are older, and 
they have had more exposure to damage, leaving them susceptible to accumulate cancerous 
mutations. It is believed that the deregulation of self-renewal is a key event in cancer 
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progression, and many of the dysfunctional pathways seen in breast cancer are just 
reactivated developmental pathways 57,76,281,286,359–362. It is hypothesized that MaSCs could be 
the original cancer-initiating cell for at least some classes of breast cancer 81,325,358,363,364. Liu 
et al characterized breast cancer stem cells as a subpopulation of mammary stem cells 
containing the cell surface marker phenotype of ESA+/CD44+/CD25-/low and found that if 
these cells were isolated and purified from primary human breast cancers, only 100 were 
required to form tumors in NOD/SCID mice in contrast with tens of thousands of unpurified 
cells 365. Each time this purified population of cells was passaged, the cells were capable of 
generating both differentiated cells and a stem cell population, consistent with the original 
stem cell theory365. These cancer stem cells were better able to form colonies under low-
adherence conditions and also displayed increased resistance to chemical compounds 365. Liu 
et al also identified multiple normal developmental pathways involved and extensive 
interaction between them, including Hedgehog, Notch, and Wnt, which were discussed in 
Chapter 1. The hedgehog signaling pathway mediates communication between the epithelial 
cells and stroma during mammary duct development and is also involved in MaSC self-
renewal 279,365,366. The notch signaling pathway contains proteins commonly found in a 
variety of stem and progenitor cells, functioning to modify cell fate and differentiation along 
lineages and regulating asymmetric cell divisions 365. Many of the notch genes can function 
as proto-oncogenes, which are normal genes that could become an oncogene if specific 
mutations are induced 365. Wnt signaling plays a role in self-renewal of MaSCs 326. Liu et al 
used mammosphere cultures to demonstrate the interaction between these different pathways 
and found that activation of the notch pathway leads to subsequent activation of the hedgehog 
pathway, and that deregulation of this positive feedback loop could induce cancer 326. Like 
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TNBC, it is known that mammary stem cells lack ER/PR/HER2 receptors suggesting that 
they may be the original cell that undergoes a mutation and leads to carcinogenesis and tumor 
formation in basal breast cancers 364. Additionally, the regulatory pathways utilized by 
MaSCs such as notch ligands, p63, and Wnt pathway are also known to be involved in basal 
like tumors and are associated with poor prognosis 278,367–371 Breast cancers that are positive 
for ER, PR, and Erb2 most likely arise in a committed progenitor cell population and are 
generally easier to treat 372. Recent research has shown a linear relationship in the number of 
cancer stem cells in breast tumors and the aggressiveness of the cancer and likelihood that it 
will spread 361,365. 
 
TNBC cell lines 
 Proper in vitro models for breast cancer are necessary for accurate and reproducible 
results. In this dissertation, three cell lines are used: MDA-MB-231, MCF-10A, and primary 
swine fibroblasts. MDA-MB-231 cells and primary swine fibroblasts are used for RNA-seq 
due to complications with the MCF-10A cells which will be discussed. Frequently used in 
breast cancer research are the human cancer cell line MDA-MB-231 and the normal human 
mammary epithelial cell line MCF-10A. Both of these cell lines express some level of 
integrin α6 and varied expression levels of integrin ß4 284,312,373–377. The MDA-MB-231 line is 
an invasive breast cancer cell line that lacks expression of estrogen (ER) α, progesterone (PR) 
and human epidermal growth factor receptor 2 (HER2), and is classified as a TNBC line 378. 
In addition to showing high expression of integrin α6 and integrin ß4, the α6ß4 complex is 
necessary for the tumorigenic properties of these cells 303. The MCF-10A cell line, a normal 
human mammary epithelial cell model, is commonly used as a normal control, but recent 
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research suggests that these cells may not represent phenotypically normal epithelial cells 146 
as these cells exhibit a basal phenotype but also share features of mesenchymal cell 
populations. In order to alleviate this concern, swine primary fibroblasts were used as a 




 As mentioned, TNBC patients have a poor prognosis and therapeutic outcome in 
comparison to HR positive breast cancer because of the aggressive nature and lack of 
targetable cell surface receptors. Current molecular targets include EGFR, vascular 
endothelial growth factor (VEGF), Poly (ADP-ribose) polymerase (PARP), PI3K, MEK, heat 
shock protein 90 (HSP90), and histone deacetylases (HDAC) 216,380. TNBC has been shown 
to express EGFR at a higher level in comparison to other subtypes 381. EGFR is involved in 
tumor growth and survival, and inhibition of this molecule via monoclonal antibodies or 
small molecule inhibitors induces cell cycle arrest, initiation of apoptosis, and inhibition of 
angiogenesis, invasion, and metastasis 382–384. Tumors require a blood vessel system in order 
to obtain nutrients for metastasis, growth, and invasion; one of the most important 
proangiogenic factors and mediators of this activity is VEGF (Hoeben et al., 2004). VEGF 
expression within tumors in TNBC is higher than non-TNBC tumors 386. Currently, VEGF 
can be blocked using specific antibodies and small molecule oral tyrosine kinase inhibitors 
387. Further investigation of the cellular signaling pathways utilized by TNBC could provide 




rG3- Overview  
 
 As discussed, the interactions between integrin molecules and their laminin ligands, 
especially Laminin-5 (Ln-5; also known as Laminin-332), regulate multiple facets of both 
embryonic development and tumor growth, invasion, and metastasis in many carcinoma 
types 284–287,289,290,292,294,308,388–391. Additionally, integrin heterodimers comprised of the 
integrin β4 subunit can only pair with the α6 subunit, making β4 an indicator of the presence 
of α6β4 291. α6β4 integrin serves as a marker to detect distant metastases in the early stages of 
specific malignancies 289,314 and β4 integrin overexpression was found in basal-like breast 
cancers, correlating with aggressiveness to institute a prognostic β4 signature 288 that 
increases with tumor grade 289,315. The mechanism α6β4 integrin utilizes to modulate 
oncogenic signaling through association with Ln-5 molecules in the ECM is the basis for the 
recombinant protein (rG3) produced in this dissertation.  
 
Laminin-5 
 Ln-5 is a trimeric glycoprotein present in the ECM and basal lamina; each laminin 
molecule forms a cruciform structure with three chains, α, β, and γ, linked by disulfide bonds; 
five α, three β, and three γ chains have been identified 132,388. These chains combine to form 
at least 15 laminin isoforms that are uniquely distributed in tissues and carefully regulated 
during early development 392,393. Ln-5 can be degraded by proteases during tissue remodeling; 
the γ2 subunit is proteolyzed by MMP-2 to promote cell migration 394. Within the Ln-5 
subunit, distinct functional domains are able to bind with other ECM molecules and integrin 
cell surface receptors 395. Importantly, the globular (G) domain at the carboxy-terminal of the 
laminin α chain interacts with high affinity for the α6β4 integrin 396,397 and the complex 
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promotes hemidesmosome formation 398,399 and stromal adhesion 133. The G3 domain is 
essential for the unique biological activity of Ln-5 400; deletion of the G3 domain in 
recombinant forms of Ln-5 leads to a drastic loss of cell adhesion and motility 401. Studies 
have shown the G3 domain to contain at least two sites that regulate cell adhesion and 
motility in different ways, and activities of Ln-5 are largely dependent on these sites 388. 
When cleaved during proteolytic processing, the G4/G5 fragment that is released from the G3 
domain also functions to support cell migration 397. 
  Ln-5 is associated with each of the seven defined cancer stages: mutation of normal 
cells, cancer cell proliferation, infiltration/invasion, migration, metastasis, angiogenesis, and 
additional cell proliferation in the metastatic lesion 402 and its expression is altered at the 
transcriptional, translational, and posttranslational levels in many types of cancer 403,404. 
Notably, overexpression of Ln-5 is controlled by additional molecules of the Wnt pathway; in 
colorectal carcinoma, β-catenin upregulation activates the laminin γ2 subunit resulting in 
enhancement of tumor development and cancer cell invasion 405,406. High levels of Ln-5 are 
correlated with poor prognosis in cervical cancer, pancreatic carcinoma, hypopharyngeal 
cancer, urinary bladder urothelial cancer, small-sized lung adenocarcinoma, malignant 
glioma, gastric cancer, squamous cell carcinoma (SCC) of the tongue, colorectal adenoma 
and hepatocellular carcinoma 407–414. The accepted consensus is that Ln-5 is overexpressed in 
the leading edge of tumorigenic cells 395. Although Ln-5 is best known as an epithelial BM 
component, it has also been reported in the BM of blood vessels along with α6β4 integrin on 
endothelial cells 415,416 and is thought to play critical roles in angiogenesis 417. 
 The role of Ln-5 in tumor invasion and metastasis makes it a popular target for cancer 
therapy and several synthetic peptides have been developed to inhibit Ln-5 expression or 
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mitigate its biological function in tumors 418–420. To develop effective reagents that limit 
ability of Ln-5 to induce cellular proliferation through association with α6β4 integrin, a better 
understanding is needed of signaling cascades regulated by this adhesion 395. Therefore, we 
have developed a recombinant form of the G3 domain of Ln-5 (rG3) in order to assess Ln-
5/α6β4 integrin signaling and the critical pathways utilized in tumorigenic cells.  
 
rG3 production history 
 The G3 domain of the rat Ln-5 α3-chain was expressed in a prokaryotic system 
engineered with chaperone proteins, allowing for soluble protein expression in a cold 
temperature environment 421. Turner confirmed recombinant rG3 had a molecular weight 
(MW) of approximately 27 kDa based on the G3 input sequence and the addition of a 
histidine tag for purification and detection 421. After expression, Turner purified the 
recombinant protein using chromatography and performed adhesion and proliferation assays 
on three cancer cell lines (MDA-MB-231, MDA-MB-435 and MCF-7). For all cell lines, rG3 
demonstrated dose-dependent adhesion and an inhibitory effect on proliferation and produced 
an apoptotic phenotype with elevated caspase levels present after varied hours of rG3 
treatment 421. Further studies by Turner showed altered levels of phosphorylated AKT and 
reduced cell viability through pro-apoptotic signaling induced by the binding of rG3 to the α 
subunit of α6β4 integrin 421. These results induced the activity of rG3 on the PI3K/AKT 
pathway to be studied in depth 422. Results from those studies showed significant differences 
in protein expression of PI3K/AKT pathway members in MDA-MB-231 after rG3 treatment 
compared to untreated cells; higher levels of AKT and phosphorylated AKT were seen in 
untreated cells, indicating the inhibitory effect the rG3 protein has on this pathway. Both 
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IKKαβ and the phosphorylated IKKβ catalytic subunit were expressed at a significantly 
higher level in untreated cells, as were the levels of phosphorylated nuclear NFκB. 
Importantly, the greatest change in expression was seen in p53; in treated cells, it was present 
at higher levels than in the untreated cells, confirming Turner’s conclusions that rG3 is able 
to significantly reduce cell viability of tumorigenic cells through specific PI3K/AKT 
signaling events 422.  
  
Hypothesis: There are transcriptional similarities in normal development and TNBC that can 
be affected through rG3 signaling pathways 
 As evidenced in Chapter 1, normal mammary development requires finely 
coordinated signaling between mammary epithelial cells, stromal molecules, and the ECM in 
order to produce a fully functional gland. This involves drastic tissue remodeling, 
degradation of the ECM, immune system regulation, and EMT- all key processes also 
implicated in TNBC. Although TNBC manifests in the mammary epithelium, surrounding 
cells play important roles in tumor growth and metastasis. Many critical signaling factors are 
shared between normal mammary development and cancer, especially those of the Wnt 
pathway, integrin and laminin association, ECM, PI3K pathway, and macrophage functions. 
Here, transcriptomic data collected over time in a post-natal swine model is analyzed by 
RNA-Seq from Specific Aim 1 to compare trends with the MDA-MB-231 TNBC cell line 
and primary swine fibroblasts. It is suspected that the postnatal but pre-pubertal gene 
expression in swine utilizes a unique set of developmental genes over time that is shared 
closely with cancer development.  
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Additionally, rG3 production will be optimized and the resulting recombinant protein 
will be characterized to determine suitability and purity for treatments; additional protein 
complexes in the sample will be identified by mass spectrometry. Next, dose-dependency of 
rG3 will be determined on MDA-MB-231 cells and a non-tumorigenic cell line and cell-
signaling pathways and potential biomarkers affected by rG3 treatment in vitro will be 
compared to biomarkers in Chapter 1. It is hypothesized that signaling pathways effected by 
rG3 will share similarities with those present in early mammary development and tumor 
development, generating a panel of significant biomarkers for further study. 
 
CHAPTER THREE: MATERIALS AND METHODS 
 
Animal sampling 
 In order to identify signals involved in early mammary development, a fine needle 
biopsy sampling method was developed to collect mammary tissue of multiple species 
(bovine, ovine, and porcine) across different pre-pubertal ages (U.S. patent application 
number 62/256,416). A 14-gauge spring activated needle was used (Jorgenson Labs Inc. 
J0528) with a dual setting specimen notch of 8 mm or 16 mm depending on animal age and 
size. According to AUP 2015-064 approved 10/2015, each animal was manually restrained 
for no longer than about 10 minutes. The sample site was cleaned with a triple wash of 
chlorhexidine (2%; Durvet) and βdine (Purdue Products). A body weight was taken during 
each sampling and recorded. Based on weight, 1-4 CCs of Lidocaine (2%) was administered 
at the sample site via intradermal and subcutaneous routes and a core tissue sample was then 
removed from the parenchyma of the mammary gland below the nipple using the biopsy 
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needle. Mammary gland locations were alternated week to week to decrease risk of tissue 
damage. The animal was evaluated for 5 minutes following the procedure to ensure any 
bleeding had stopped from the biopsy sample site.  If bleeding was observed, pressure was 
applied.  After being released from the restraint the animal returned to a normal diet and 
housing with daily observation for 3-5 days for observation of any signs of infection. During 
the sampling procedure, the animal was closely monitored for any signs of pain. Post-
sampling, tissue was handled according to downstream methods below.  
 
Necropsy 
 Per AUP 2015-064 approved 10/2015, two euthanized animals were used to measure 
how deep the mammary tissue expands into the body and to compare necropsied tissue 
sample with live biopsy samples to confirm there is low or no variability in sampling live 
animals with the needle.  Intravenous euthanasia was performed according to accepted 
practices under Godley-Snell Research Center veterinary supervision. After death was 
confirmed, a tissue sample was removed from the parenchyma of the mammary gland either 
using the biopsy needle for a small core sample or a sterile scalpel for a larger sample 
representative of past sampling technology. Post-sampling, tissue was handled according to 
downstream methods below. 
  
Collection for RNA isolation 
 If RNA was to be extracted from the tissue, after sampling, each biopsy was placed 
directly into a sterile 1.5 mL microcentrifuge tube containing 1mL of RNAlater (Thermo 




Collection for histology 
 If the sample was to be processed histologically, each biopsy was immediately placed 
in a tissue cassette (VWR) with 0.67mm pore openings and fixed in 10% neutral buffered 
formalin (supplier) for 18-24 hours at room temperature. Fixed tissues were then dehydrated 
in ethanol, cleared in xylene, embedded in paraffin blocks, sectioned to a thickness of 6-8µ 
using a rotary microtome (Leica Microsystems), mounted onto glass slides, and dried 
overnight on a slide warmer at 37°C. Slides were then visualized for morphology with 
hematoxylin and eosin (H&E). 
  
Contingency analysis and developmental index 
 A contingency analysis was conducted for two necropsied animals to confirm that the 
mammary biopsy procedure produces a tissue sample that is representative of the results 
obtained by necropsy.  In the contingency analysis, H&E stained tissue sections obtained by 
each method were visually assigned a development index (DI) score.  The development index 
can be seen in Fig. 1.  As illustrated in Fig. 1, cells with a maturity index of 0 are a cluster of 
cells without lumen and 1 ring layer, cells with a maturity index of 1 present as a cluster of 
cells without lumen and more than 1 ring layer of cells, cells with a maturity index of 2 
present as loosely organized cells with lumen, cells with a maturity index of 3 present as 
semi-organized cells with lumen, cells with a maturity index of 4 present as dense and 
organized cells with lumen, cells with a maturity index of 5 present as dense and organized 
cells with lumen and branching. Tissue was prepared histologically according to previous 
section and development index scores were statistically compared between the two methods 
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using JMP Pro 12 software (SAS, Cary, NC).  
 
Sequential H&E in swine mammary tissue collected over time proves ability of method to 




RNA isolation  
 RNA sequencing was performed with RNA isolated from the tissue using an RNeasy 
Figure 1: H&E stained formalin fixed, paraffin embedded sections of swine mammary tissue 
demonstrate developmental index levels 0-5.  
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Kit (Qiagen Inc., Valencia, CA) according to manufacturer’s instructions and a TissueRuptor 
(Qiagen Inc., Valencia, CA) according to manufacturer’s instructions. After disruption with 
the TissueRuptor, the RNA samples were also treated with an on-column DNase (Qiagen 
Inc., Valencia, CA) to remove any possible genomic DNA contamination. Isolated RNA 
samples were quantified and integrity validated on a Nano Drop 1000 Spectrophotometer 
(Thermo Scientific, Waltham, MA) and Bioanalyzer 2100 (Agilent Technologies) and stored 
in 1.5mL microcentrifuge tubes at -20°C until library preparation.  
 
Library preparation and RNA sequencing 
 Each mammary tissue sample was normalized to a standard input concentration of 
total RNA and an Illumina compatible sequencing library was prepared robotically on a 
Microlab STAR (Hamilton) with the TruSeq stranded total RNA library prep kit (Illumina) 
following the manufacturer’s recommended procedures (Illumina). The resulting sequencing 
libraries were assessed for size on a 2100 Bioanalyzer (Agilent) and sequence data collected 
on 1 lane of an Illumina HiSeq2500 with a 2x125 bp PE read on high-output mode (Hollings 
Cancer Center, MUSC) up to a depth of at least 22 million reads. Raw sequence reads were 
assessed for run quality with the FastQC analysis package (Babraham Bioinformatics) and 
then preprocessed to remove adapter and low quality bases with the Trimmomatic software 
package423. Trimmed reads were aligned to the Sscrofa 10.2 genome using gsnap424. 
SAMtools was used to generate sorted and indexed bam files425. Subread’s featureCounts was 
used to identify paired-end reads that were concordantly assigned to known genes in the 
correct order of transcription426,427. Raw read counts were normalized for each technique 
using MATLAB (MathWorks) and RStudio version 1.0.136 (The R Foundation).   
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 From the resulting dataset, more advanced statistical analysis methods were utilized 
using MATLAB and R. Preprocessing of redundant variables was completed using 
correlation analysis (Caret R) with a cutoff of 0.95. Details for RNA-seq input are shown in 
Table 1.  
 









1 Swine mammary 4.0 0.6 1-8 
5 Swine mammary 11.0 1.6 1-8 
6 Swine mammary 18.0 2.6 1-8 
11 Swine mammary 25.0 3.6 1-8 
13 Swine mammary 32.0 4.6 1-8 
16 Swine mammary 39.0 5.6 1-8 
3 Swine mammary 11.0 1.6 1-13 
7 Swine mammary 18.0 2.6 1-13 
9 Swine mammary 25.0 3.6 1-13 
12 Swine mammary 32.0 4.6 1-13 
15 Swine mammary 39.0 5.6 1-13 
2 Swine mammary 8.0 1.1 1-10 
4 Swine mammary 11.0 1.6 1-10 
8 Swine mammary 18.0 2.6 1-10 
10 Swine mammary 25.0 3.6 1-10 
14 Swine mammary 32.0 4.6 1-10 




 From the resulting transcriptomic dataset, in depth biological analysis was performed 
to determine functional significance of transcriptomic trends in the data using Panther 
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(Thomas Lab at the University of Southern California), Genesis428, Cytoscape429, 
Reactome430,431 for pathway analysis, NCBI (U.S. National Library of Medicine), and 
GeneCards (Weizmann Institute of Science).  
 
Recombinant G3 (rG3) Protein production, isolation, and purification  
 In Turner's work, the G3 cDNA was cloned into a vector including an ampicillin 
resistance gene to allow for selection of the plasmid and an N-terminal 6X-histidine tag was 
added 432. ArcticExpress™ cells were used for expression of rG3 421. Once cells were induced 
for protein expression and harvested, they were prepared for separation by SDS-PAGE to 
confirm rG3 expression. Once soluble rG3 expression was confirmed, a culture was prepared 
to yield a larger volume of the recombinant protein for purification and the fraction was 
applied to a G50 Sephadex column for size exclusion separation. As previously 
demonstrated, the molecular weight of rG3 including the histidine tag is ~27 kDa421. To 
determine which fractions contained the protein, an OD reading was taken, and to confirm 
the identity of the expressed soluble protein as rG3, a Western Immunoblot was performed 
using an anti-polyHistidine monoclonal antibody 421.   
 For this dissertation, production was modified to get the purest form of rG3. 
ArcticExpress™ cells were still used for expression. Transformed cells were cultured by 
streaking for isolation on LB agar plates containing ampicillin (62.5µl 100mg/mL stock per 
125 mL agar) and gentamicin (250 µl 10mg/mL stock per 125 mL agar) and incubating at 
37°C overnight until colonies were clearly identified the next day. One isolated colony was 
chosen from the plate and added to 10mL sterile LB broth with 5µl ampicillin and 20µl 
gentamicin into a 125mL flask, which was incubated overnight at 37°C with shaking at 250 
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RPM. The next day, 2.5mL of the overnight culture was added to 247.5 mL sterile LB broth 
without antibiotics and incubated at 30°C with shaking at 250 RPM. The OD was checked 
periodically until the culture reached absorbance of approximately 0.4, or the exponential 
growth phase. At this point, cells were induced for protein expression with IPTG (1mM) and 
incubated at 11.5°C with shaking at 250 RPM for 24 hours. The flask was transferred to a 
sterile bottle and spun to pellet at 5250 RPM for 10 minutes at 4°C. The pellet was either 
snap-frozen in liquid nitrogen and sent to Vanderbilt (MSRC Proteomics Laboratory, 
Vanderbilt Medical University, Nashville, TN) for further purification using their equipment 
or purified in house using the Ni-NTA Fast Start purification kit for His-tagged proteins 
(Qiagen, Germantown, MD).  
 At Vanderbilt, the pellet was lysed using an Emulsiflex C3 homogenizer (Avestin) 
and spun down in an ultracentrifuge. After filtering, the lysate was applied to a Roche 
cOmplete nickel column (Roche Life Science) using a GE AKTAxpress purification system 
(GE Healthcare Life Sciences). The system applied the lysate to the column and the column 
was washed with binding buffer until a stable UV baseline was achieved. A gradient elution 
of 0mM Imidazole and increasing to 500mM Imidazole was used to elute into different wells 
of a 96-well deep well plate based on single, separate peaks. The wells were examined via 
coomassie staining to find wells containing protein of the appropriate size. Protein was 
quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific).  
 Mass spectrometry analysis of the purified protein components after separation by 
SDS-PAGE was performed by the MSRC Proteomics Laboratory (Vanderbilt University, 
Nashville, TN). All MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific, 
San Jose, CA, USA; version 27, rev. 12) and X! Tandem (The GPM, thegpm.org; version 
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CYCLONE (2010.12.01.1)). Sequest was set up to search the ecoli-uniprot-012309-
200901_rev_4292_20151111_rev database assuming the digestion enzyme trypsin. X! 
Tandem was set up to search the ecoli-uniprot-012309-200901_rev_4292_20151111_rev 
database (unknown version, 9378 entries) also assuming trypsin. Sequest was searched with a 
fragment ion mass tolerance of 0.00 Da and a parent ion tolerance of 2.5 Da. X! Tandem was 
searched with a fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 2.5 Da. 
Glu->pyro-Glu of the n-terminus, ammonia-loss of the n-terminus, gln->pyro-Glu of the n-
terminus, oxidation of methionine and carbamidomethyl of cysteine were specified in X! 
Tandem as variable modifications. Oxidation of methionine and carbamidomethyl of cysteine 
were specified in Sequest as variable modifications. Scaffold (version Scaffold_4.4.8, 
Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and 
protein identifications. Peptide identifications were accepted if they could be  
established at greater than 99.0% probability by the Peptide Prophet algorithm 433. Protein 
identifications were accepted if they could be established at greater than 99.0% probability 
and contained at least 2 identified peptides.  Protein probabilities were assigned by the 
Protein Prophet algorithm 434. Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony.      
 For in house purification using the Ni-NTA Fast Start purification kit for His-tagged 
proteins (Qiagen, Germantown, MD) according to the manufacturer’s protocol with the 
addition of a liquid nitrogen freeze-thaw cycle for cell lysis and 4°C incubation for binding. 
A cleanup process to eliminate salts and smaller fragments was conducted with Pall spin 




Western Blotting – rG3 
 In preparation for protein separation by SDS-PAGE, purified rG3 and pure HSP60 
(Prospec Bio, Israel) samples were added to an equal volume of Laemmli Buffer with 5% 2-
mercaptoethanol. Samples were mixed and loaded onto a 10-20% Ready Gel Precast Gel 
(Bio-Rad Laboratories, Inc., Hercules, CA) together with a protein ladder (Precision Plus 
Protein™ Kaleidoscope™ Prestained Protein Standards #1610375). The gel was run in the 
Ready Gel System (Bio-RadLaboratories, Inc., Hercules, CA) with running buffer (15g Tris 
Base, 72g glycine, 5g SDS per 1L) at 200 V for 30 minutes. Meanwhile, a sheet of Immuno-
Blot™ PVDF Membrane and two pieces of 14 x 11 cm filter pads (Bio-Rad Laboratories) 
were soaked in chilled Western transfer buffer (3.03g Tris Base, 14.4g glycine per 1L) for 
least 30 minutes. Following electrophoresis, the gel was washed in cold Western transfer 
buffer for 30 min. The filter pads, gel, and PVDF membrane were arranged in a layered 
fashion, and protein transfer was completed at 100 V for 45 minutes using a Mini Trans-
Blot® Cell (BioRad Laboratories). Non-specific proteins were blocked with 5% non-fat dry 
milk in TBS at room temperature on a shaker, followed by three washes of 5 minutes each in 
TBS with 0.5% Tween (Sigma, St. Louis, MO) (TTBS) added.  An overnight primary 
antibody incubation at 4°C was performed with the following antibodies (insert anti-his and 
hsp ab specs) at dilutions according to manufacturer’s instructions (Cell Signaling 
Technology, Inc.). Following primary antibody incubation, a 15 min wash with TTBS was 
performed to remove unbound antibody. Next, a secondary anti-rabbit IgG HRP-linked 
antibody (Cell Signaling Technology®, Inc. #7074) was added for 1 hr at RT. Protein 
detection was obtained through the use of the HR Peroxidase Visualization Kit (Vector 
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Laboratories, Burlingame, California).  
 
Cell Culture  
 MDA-MB-231, MCF-10A, and primary fibroblast cells were used for biological 
assays. The MDA- MB-231 cells (ATCC HBT-26) are a metastatic breast cancer cell line 
obtained from a 51-year old female patient, derived from a pleural effusion removed on 
October 17, 1974. MDA-MB-231 cells were maintained in Dulbecco’s Modified Eagles’ 
Medium (DMEM) with 4.0 mM L-glutamine and 4500 mg/L glucose (HyClone, Logan, 
Utah). The culture medium was supplemented with 10% bovine growth serum, penicillin G 
(100 units/ml)/streptomycin sulfate (100 µg/ml) and sodium pyruvate (0.11 µg/ml). MCF-
10As (ATCC CRL-10317) are a non-tumorigenic human mammary epithelial cell line. 
MCF10A cells were maintained in DMEM/ high glucose supplemented with 5% horse 
serum, 20 ng/mL human epidermal growth factor (Sigma Chemical Co.), 0.05 mg/mL 
hydrocortisone (Sigma Chemical Co.), 100 ng/mL of cholera toxin (Calbiochem), 10 µg/mL 
of insulin (Sigma Chemical Co.), and penicillin G (100 units/ml)/streptomycin sulfate (100 
µg/ml). The primary fibroblasts were obtained from swine mammary tissue in our laboratory; 
details are below. All cell lines were grown in 75 cm2 tissue culture flasks (Corning inc., 
Corning, NY) and maintained at 37°C and 5% CO2. To prevent overcrowding of cells, they 
were routinely passaged using Cell stripper (Corning, NY) or 1X Trypsin/EDTA (HyClone, 
Logan, Utah), which removed the cells from the bottom of the flask. Before cells were 
transferred into a new culture flask, they were washed at least one time with fresh culture 




Primary cell culture and fibroblast isolation: 
 After collection in the field, fresh biopsy tissue was immediately placed in a 1.5 mL 
microcentrifuge tube containing warm primary cell culture medium. Culture medium for 
mammary epithelial cells, per 100mL of medium, consisted of: 4ug/mL insulin (40ul from 
10mg/mL stock), 10ng/mL EGF (5ul from 200ug/mL stock), 10% Fetal Bovine Serum 
(10mL), 1% Penicillin-Streptomycin solution (Cellgro #30-002-CI) (1mL), and Hyclone 
DMEM/high glucose media (Thermo #SH300222) to volume. In the lab, immediately before 
digestion, collagenase solution was prepared which consisted of (per 10mL of solution): 5% 
Fetal Bovine Serum (500ul), 1mg/mL Type 1 collagenase (EMD Millipore, 234153) (10mg), 
and Hyclone DMEM/high glucose media (Thermo #SH300222) to volume. All media was 
sterile filtered using vacuum filtration. Biopsy samples were minced using sterile supplies 
into pieces smaller than 1mm3. Tissue pieces were transferred into a sterile dish and washed 
until clear of blood with sterile PBS. Clean pieces were transferred into a small autoclaved 
beaker with the collagenase type 1 solution and incubated at 37°C O/N with gentle shaking to 
stir. Following O/N incubation, the tissue fragments were disrupted with a sterile 1mL pipette 
and spun to pellet at 820 RPM and 23°C for 5 minutes. Liquid and fat were removed with a 
sterile pipette and organoids pelleted at the bottom were resuspended in fresh media and 
plated in T25 flasks with 10 mL culture media. After several days of incubation at 37°C and 
5% CO2 for several days, the cells were adhered and ready for differential trypsinization. 
 To separate mammary epithelial cells from fibroblasts, differential trypsinization was 
performed on adhered cells. Media was aspirated and flasks were gently washed with warm 
culture media. 2-3 mL of trypsin was added and the flasks were incubated at 37°C and 5% 
CO2 for 2-3 minutes or until fibroblasts began to lift off. Fresh media was added to 
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deactivate the trypsin and this layer was removed and transferred to a new culture flask with 
fresh media. After 2-3 days at 37°C and 5% CO2, the fibroblasts were ready for subculture.  
 
Subculture: rG3 treatment and cell collection for RNA isolation  
 Once flasks were confluent, medium was aspirated and each flask was washed with 
5-7 mL of warm, sterile PBS. For human cell lines, 3-4 mL of Cell Stripper was added to 
each flask with incubation at 37°C with 5% CO2 for 5 min or until most cells are detached. 
For primary mammary epithelial cells, trypsin was added to form a thin layer on top of the 
cells with incubation at 37°C with 5% Co2 for 25-20 minutes or until the cells were detached. 
The flask was tapped lightly on the counter to loosen cells and the cell suspension was 
transferred into a 15 mL tube. For human cell lines, sterile PBS was added and for primary 
mammary cells, sterile media was added to get to 10-12 mL in the tube. Tubes were 
centrifuged at 820 RPM for 5 min at 23°C. Supernatant was discarded and pellets were 
washed again with either sterile PBS or media, vortexing to mix. Tubes were centrifuged a 
second time at 820 RPM for 5 min at 23°C and pellet resuspended in 1mL fresh culture 
medium. Cells were counted by adding 180µl trypan blue to 20 µl cells in media and loading 
20µl of mix onto a hemacytometer. Cells were plated at 1x106 cells per well in a 6-well plate 
in 1mL fresh media and let adhere overnight at 37°C and 5% CO2. After overnight adhesion, 
all wells were treated with either 20µg/mL rG3 diluted in fresh media or equal amounts 
media for controls. Cells were then collected immediately after addition of rG3 for time 0 
followed by 3, 6, 9, 12, and 24 hours after treatment. To collect cells from well, culture 
medium was removed from the well of interest and well was gently washed with sterile PBS. 
400ul cell stripper (for human lines) or trypsin (for primary lines) was added to well and 
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plates incubated at 37°C and 5% CO2 for 10 minutes. Cells were added to a sterile 1.5 mL 
microcentrifuge tube along with 500ul PBS, spun at 12,000 rpm for 2 minutes at room 
temperature. Supernatant was removed and wash repeated with 500ul PBS and another 2-
minute spin at 12,000 rpm. Pellet was resuspended in 100ul RNA later and stored at -20° C 
for RNA isolation.  
 
Subculture: Cell collection for Western Blotting  
 Once flasks were confluent, medium was aspirated and each flask was washed with 
5-7 mL of warm, sterile PBS. For human cell lines, 3-4 mL of Cell Stripper was added to 
each flask with incubation at 37°C with 5% CO2 for 5 min or until most cells are detached. 
For primary mammary epithelial cells, trypsin was added to form a thin layer on top of the 
cells with incubation at 37C with 5% Co2 for 25-20 minutes or until the cells were detached. 
The flask was tapped lightly on the counter to loosen cells and the cell suspension was 
transferred into a 15 mL tube. For human cell lines, sterile PBS was added and for primary 
mammary cells, sterile media was added to get to 10-12 mL in the tube. Tubes were 
centrifuged at 820 RPM for 5 min at 23°C. Supernatant was discarded and pellets were 
washed again with either sterile PBS or media, vortexing to mix. Tubes were centrifuged a 
second time at 820 RPM for 5 min at 23°C and pellet resuspended in 1mL fresh culture 
medium. Cells were counted by adding 180µl trypan blue to 20 µl cells in media and loading 
20µl of mix onto a hemacytometer. Cells were plated at 1x106 cells per well in a 6-well plate 
in 1mL fresh media and let adhere overnight at 37°C and 5% CO2. After overnight adhesion, 
all wells were treated with either 20µg/mL rG3 diluted in fresh media or equal amounts 
media for controls. Cells were then collected immediately after addition of rG3 for time 0 
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followed by 3, 6, 9, 12, and 24 hours after treatment. Before each collection, fresh lysis 
buffer was prepared using 100 µl of cold 10X lysis buffer (Cell Signaling #9803), 890 µl 
sterile water, and 10 µl of protease inhibitor cocktail (Thermo Scientific #78410) and kept on 
ice. To collect cells from well, culture medium was removed from the well of interest and 
well was gently washed with cold sterile PBS. 100 µl of lysis buffer was added directly on 
the well and plates were incubated on ice for 5 minutes. After incubation, wells were scraped 
and cell suspension collected in a 1.5 mL microcentrifuge tube. Tubes were spun at 12,000 
rpm at 4°C for 15 min after which supernatant was transferred to a fresh tube and stored at -
20° C until Western Blotting. 
 
RNA isolation for cells  
 RNA sequencing will be performed with RNA isolated from the cells using an 
RNeasy Kit (Qiagen Inc., Valencia, CA) according to manufacturer’s instructions. The RNA 
samples will be treated with an on-column DNase (Qiagen Inc., Valencia, CA) to remove any 
possible genomic DNA contamination. Isolated RNA samples will be quantified and integrity 
validated on a Nano Drop 1000 Spectrophotometer (Thermo Scientific, Waltham, MA) and 
Bioanalyzer 2100 (Agilent Technologies).  
 
RNA seq of cells 
 Quality control checks, library preparation, and sequencing of RNA collected from 
cells was performed by Vanderbilt University Medical Center. Total RNA quality was 
assessed using the 2100 Bioanalyzer (Agilent). At least 200ng of DNase-treated total RNA 
with a RNA integrity number greater than 6 was used to generate polyA (mRNA) enriched 
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libraries using TruSeq Stranded mRNA sample kits with indexed adaptors (Illumina). Library 
quality was assessed using the 2100 Bioanalyzer (Agilent) and libraries were quantitated 
using KAPA Library Quantification Kits (KAPA Biosystems). Pooled libraries were 
subjected to 75 bp paired-end sequencing according to the manufacturer’s protocol (Illumina 
HiSeq3000). Bcl2fastq2 Conversion Software (Illumina) was used to generate de-multiplexed 
Fastq files. 
 
RNA-seq data analysis 
 To analyze differential gene expression using RNA-sequencing data, three unique 
and independent methods were utilized: shift change with normalization by control, shift 
change with normalization by treatment, and statistically significant differences between 
treated samples and untreated samples assuming normal data distribution and calculating z-
scores for each individual gene. Formulas for shift change are below. For shift change with 
normalization by control, ((Raw count of treated sample – raw count of control sample) / 
(raw count of control sample)) was used. For shift change with normalization by treated 
sample, ((Raw count of treated sample – raw count of control sample) / (raw count of treated 
sample)) was used. 
RNA seq shift change values between rG3 treated and untreated MDA-MB-231 cells 
were used to curate pathways using PathVisio and WikiPathways 435–438; raw counts for rG3 
treated and untreated MDA-MB-231 cells and primary swine fibroblasts were normalized 
and prepared into heat maps in Genesis 428. Blue represents downregulation (negative shift 
change) or low expression, as noted in figure legends. Red represents upregulation (positive 
shift change) or high expression, as noted in figure legends. In PathVisio, gray indicates no 
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shift change; in Genesis heat maps, gray indicates gene or gene ortholog not found in dataset. 
For comparison of human and swine genes, swine gene orthologs were included if possible 
using OrthoDB 439.  
 
Western blotting for cells 
 In preparation for protein separation by SDS-PAGE, cell lysate samples were added 
to an equal volume of Laemmli Buffer with 5% 2-mercaptoethanol. Samples were mixed and 
loaded onto a 10-20% Ready Gel Precast Gel (Bio-Rad Laboratories, Inc., Hercules, CA) 
together with a protein ladder (Precision Plus Protein™ Kaleidoscope™ Prestained Protein 
Standards #1610375). The gel was run in the Ready Gel System (Bio-Rad Laboratories, Inc., 
Hercules, CA) with running buffer (15g Tris Base, 72g glycine, 5g SDS per 1L) at 200 V for 
30 minutes. Meanwhile, a sheet of Immuno-Blot™ LF-PVDF Membrane and two pieces of 
14 x 11 cm filter pads (Bio-Rad Laboratories) were soaked in chilled Western transfer buffer 
(3.03g Tris Base, 14.4g glycine per 1L) for least 30 minutes. Following electrophoresis, the 
gel was washed in cold Western transfer buffer for 30 min. The filter pads, gel, and PVDF 
membrane were arranged in a layered fashion, and protein transfer was completed at 100 V 
for 45 minutes using a Mini Trans-Blot® Cell (BioRad Laboratories). Non-specific proteins 
were blocked with 5% non-fat dry milk in TBS at room temperature on a shaker, followed by 
three washes of 5 minutes each in TBS with 0.5% Tween (Sigma, St. Louis, MO) (TTBS) 
added.  An overnight primary antibody incubation at 4C was performed with p53 (Cell 
Signaling Technology, Inc.), beta4 integrin (Abcam, Cambridge, MA, Cambridge, MA), and 
beta actin (Cell Signaling Technology, Inc.) at dilutions according to manufacturer’s 
instructions (Cell Signaling Technology, Inc.). Following primary antibody incubation, a 15 
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min wash with TTBS was performed to remove unbound antibody. Next, a secondary anti-
rabbit IgG HRP-linked antibody (Cell Signaling Technology®, Inc. #7074) was added for 1 
hr at RT. Protein detection was obtained through the use of the Pierce ECL Plus 
Chemifluorescent kit (Thermo Fischer), visualized on the Typhoon FLA 7000 (GE 
HealthSciences), and quantified using Image Studio Lite (Licor).  
 
Viability Assay 
 To assay for cellular activity (viability), replicate MTT (3-[4,5-Dimethylthiozol –2-
yl] –2, 5-diphemyltetrazolium bromide) assays were performed with purified rG3 and 
appropriate controls.  Different dilutions of rG3 were made in fresh culture medium.  One 
hundred µl of each concentration was added in triplicate to wells of a treated Falcon 96-well 
tissue culture plate (Falcon, Franklin Lakes, NJ).  All cell lines were collected following the 
same method described previously.  Cells were plated at 1 x 104 per well (in 100 µl), and the 
plate was incubated for 24 hr at 37°C in a humidified incubator (5% CO2).  Cells were either 
treated immediately with rG3, or allowed to adhere for 6-18 hr before treatment.  Four hr 
prior to the end of incubation, 20 µl of MTT (Sigma-Aldrich Co., St. Louis) was added to all 
wells.  At the end of the 24 hr incubation, the culture supernatant was removed from the 
wells and 150 µl of dimethylsulfoxide (DMSO) were added to solubilize cells.  The plate was 
shaken for 15 min and absorbance values for MTT were recorded using a BioTek plate reader 
at dual wavelengths of 570/640 nm.  Optical Density (OD) values of dissolved MTT were 
used to create a stimulation index (SI), which was calculated using the ratio of treatment OD 





  Statistical models were developed to relate responses (including stimulation index, 
differential gene expression, and protein expression) to experimental factors (including rG3 
dosage, treatment, and cell type). Analysis of Variance (ANOVA) was used to test 
significance of the experimental factors on responses. When ANOVA indicated the responses 
were significantly affected by the experimental factors, Tukey HSD and Student’s t tests 
were used accordingly. All statistical tests used α = 0.05 and were performed using the 
Statistical Analysis System (SAS, Research Triangle Park, NC) and/or JMP Pro 12 software 
(SAS, Cary, NC). 
 
 
CHAPTER FOUR: RESULTS AND DISCUSSION 
 
 
Chapter 1 results and discussion 
Mammary tissue sampling procedure causes minimal adverse effects 
Growth curves for animals sampled are shown in Fig. 2. Numerical representation for each 
sample indicates the litter and animal, respectively.  For example, a numerical representation 
such as “1-10” would indicate the tenth animal of the first litter with the assigned number 
having no significance except as a system to ensure consistency and monitor the animals.  
Weights were taken before each sampling period weekly, and animals maintained a similar 
growth curve throughout sampling, gaining a similar amount of weight throughout the study.  
  Several studies have implicated adverse effects of repeated sampling of the mammary 
gland 440,441, especially when bluntly dissecting the tissue requiring wound closure 441. It is 
necessary to utilize a sampling technique that is minimally invasive, yet still tissue specific. 
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The results presented in this figure demonstrate that the animals gained a similar and healthy 
amount of weight over the course of sampling, and along with histological results below that 
show tissue specificity, indicate minimal or no effects of the sampling procedure causing 














Sequential H&E in swine mammary tissue collected over time proves ability of method to 
study time course of development 
Figure 3 represents samples taken from the same pig at 4 days, 8 days, 11 days, 18 
days and 32 days, respectively. Samples are formalin fixed, paraffin embedded, and H&E 
stained to show histological differences in mammary tissue morphology over time. These 
samples demonstrate normal differentiation of mammary tissue 442,443 over time with no noted 
Figure 2. Swine growth rates during sampling demonstrate that the animals gained a 
similar and healthy amount of weight over the course of sampling. “1-10” indicates 































biasing or alteration of the tissue differentiation due to repeated sampling compared to the 
first sampling taken. This indicates the fine needle biopsy method is adequate to sequentially 
monitor mammary growth in a single animal at the cellular level without detriment to the 
animal or alteration of the morphology or differentiation. 
 
Necropsy and fine needle biopsy comparison utilizing novel development index confirms 
biopsy method is histologically representative of larger core sampling 
 The development maturity index can be seen in Fig 1. As illustrated, tissue areas with 
a developmental index of 0 are a cluster of cells without lumen and 1 ring layer, areas with a 
Figure 3: Formalin fixed, paraffin embedded, H&E stained sections of swine mammary tissue at 
a) 4 days, b) 8 days, c) 11 days, d) 18 days, e) 25 days, and f) 32 days of age demonstrating 
histological differences in mammary tissue morphology over time. These samples show normal 
differentiation of mammary tissue with no noted biasing or alteration of the tissue differentiation 
due to repeated sampling compared to the first sampling taken. 
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developmental index of 1 present as a cluster of cells without lumen and more than 1 ring 
layer of cells, areas with a developmental index of 2 present as loosely organized cells with 
lumen, areas with a developmental index of 3 present as semi-organized cells with lumen, 
areas with a developmental index of 4 present as dense and organized cells with lumen, and 
areas with a developmental index of 5 present as dense and organized cells with lumen and 
branching. This developmental index was used to score mammary tissue sections obtained by 
both live fine needle biopsy and tissue necropsy post-euthanasia. A contingency analysis was 
conducted for pigs 19-12 and 20-7, at the age of 4 weeks to confirm that the mammary 
biopsy procedure produces a tissue sample that is representative of, and no different than, the 
results obtained by necropsy. After tissue sections collected by both techniques were 
assigned a numerical developmental index, a contingency analysis was performed. For pig 
19-12, a p ³ 0.3267 indicates that any differences in the samples are likely due to chance and 
therefore the null hypothesis is correct and there is no statistical difference in the responses 
for the two methods. For pig 20-7, a p ³ of 0.4835 also confirms tissue sections obtained via 
the fine needle biopsy technique are statistically equivalent to the tissue sections obtained by 
necropsy. Once confirmed that the sampling method is appropriate, data obtained could be 








Weighted scores over time can quantify histological trends in mammary tissue collected over 
time 
In an effort to quantify mammary development using histology, several weighted scoring 
methods were evaluated. These took into account the developmental index score of each 
tissue area as well as the total count of tissue areas and percent of tissue compared to stroma, 




Figure 4: Weighted scores calculated for Pig IDs 1-10 and 1-8 over time. Weighted 
Score 1: (:Index 0 * 0 + :Index 1 * 1 + :Index 2 * 2 + :Index 3 * 3 + :Index 4 * 4 + 
:Index 5*5) / (:Index 0 + :Index 1 + :Index 2 + :Index 3 + :Index 4 + :Index 5). New 
Weighted Score: Weighted Score * (1 + Total Count for week/total count for 
sampling period). A split is seen at 18 DOA that can be used for discriminate analysis 
using Weighted Score 1 and Weighted Score 2. Weighted Score 3 attempted to take 
into account the percentage of mammary tissue in comparison to adipose and stroma, 




Formulas used were: 
1. Weighted Score: (:Index 0 * 0 + :Index 1 * 1 + :Index 2 * 2 + :Index 3 * 3 + :Index 4 
* 4 + :Index 5 
• 5) / (:Index 0 + :Index 1 + :Index 2 + :Index 3 + :Index 4 + :Index 5) 
2. New Weighted Score: Weighted Score * (1 + Total Count for week/total count for 
sampling period)	 
 
It proved difficult to quantify consistently over time, but a split is seen at 18 DOA in Fig. 
4 that can be used for discriminate analysis using Weighted Score 1 and Weighted Score 2. 
Weighted Score 3 attempted to take into account the percentage of mammary tissue in 
comparison to adipose and stroma, but did not represent the histological results as well as the 
first two methods.  
 
Mammary biopsy technique produces tissue samples with high quality and quantity for 
downstream RNA isolation and sequencing 
 Table 2 shows quantity, quality, and integrity values of RNA isolated from swine 
mammary tissue collected via the fine needle biopsy technique.  
 
Table 2: Quality Control for swine mammary tissue samples submitted for RNA sequencing 
Sample 
labels 
















1 Swine mammary 4.0 1-8 2.11 5.04 10 
2 Swine mammary 8.0 1-10 2.15 1.47 10 
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3 Swine mammary 11.0 1-13 2.12 1.34 10 
4 Swine mammary 11.0 1-10 2.16 2.41 10 
5 Swine mammary 11.0 1-8 2.15 2.98 9 
6 Swine mammary 18.0 1-8 2.13 2.10 9.7 
7 Swine mammary 18.0 1-13 2.13 1.57 9.8 
8 Swine mammary 18.0 1-10 2.18 0.56 10 
9 Swine mammary 25.0 1-13 2.17 1.22 9.9 
10 Swine mammary 25.0 1-10 2.29 0.81 10 
11 Swine mammary 25.0 1-8 2.13 2.97 8.8 
12 Swine mammary 32.0 1-13 2.14 1.85 NA 
13 Swine mammary 32.0 1-8 2.13 2.97 9.1 
14 Swine mammary 32.0 1-10 2.14 1.85 9.5 
15 Swine mammary 39.0 1-13 2.27 0.26 10 
16 Swine mammary 39.0 1-8 2.40 1.16 10 
17 Swine mammary 39.0 1-10 2.17 0.95 9.9 
 
These high quality and quantity values indicate the fine needle biopsy sampling, 
method and intermediate processing procedures are adequate to generate a tissue sample 
enabling accurate library preparation, RNA sequencing, and data analysis. RNA integrity and 
quality is vital to reproducible RNA sequencing results, and contaminated or degraded 
mRNA can have a detrimental effect on downstream analysis444–447. RIN is calculated using a 
software algorithm developed by Schroeder et al; values range from 1-10 with 10 possessing 
the least amount of RNA degradation and being ideal for transcriptome analysis 448. There 
was an issue with sample quantity for sample 12, so an RIN could not be established, but 
based on the NanoDrop values for quality and quantity, it was safe to proceed with library 
preparation for all samples. Once it was confirmed through the above results that the fine 
needle biopsy was an appropriate method of sampling, data could be confidently interpreted 




 PCA presents large patterns of variability within the gene expression data contributing to 
specific ordination trends 
PCA is an exploratory technique used at the beginning of study to confirm whether 
there are any trends in data. The color of the dots in Fig. 5 corresponds to pig ID, and size of 
the dot represents the time at which the biopsy sample was collected (age; 4 days smallest – 
39 days largest). As shown in the figure, the younger samples are on the top left corner and as 
Figure 5: PCA plot for PC2 vs PC3 of developing swine mammary 
gland transcriptome. Dot color corresponds to Pig ID; size of dot 
corresponds to age (days). PCA presents large patterns of variability 





one moves away toward the right, the sample dot sizes become larger indicating older pigs 
were sampled.  
 PCA is commonly used as a simple visualization tool to summarize data variance and 
present the dominant factors contributing to variance in a large data set 174,449,450. When 
dealing with multiple variables, as are present in large scale gene expression and 
transcriptomics studies such as the present, relationships between variables (here, gene 
expression and age) can be quickly assessed. PCA assumes that the data set contains linear 
combinations of variables and that large variances have important dynamics, such as 
contribution to a trend over time; this exploratory technique is appropriate for the large 
transcriptomic data set 450,451. The first PC axis, PC1, of the PCA output represents the largest 
gradient of variability in the data set 174 with the PC2 axis containing the second largest, 
followed by PC3 until all of the data set variability has been accounted for. Here, variables 
were displayed in the first three PC dimensions and PC2 and PC3 were found to contain the 
most important gradients. Fig. 5 shows significant variability due to age of the animal across 
the PC2 axis and little organization by animal (Pig ID) across the PC3 axis. This suggests 
animal age is the dominant gradient in the data set that effects the data distribution. It also 
suggests there is a functional pattern within the variability of the RNA-sequencing data that 
corresponds to time of sample collection. This supports the hypothesis that there are unique 
signaling events occurring over time; PCA confirms the transcriptomic data set allows for 
evaluation of mammary development throughout time without interference from variability 




RDA confirms that variability in pigs does exist, but does not contaminate variability over 
time (age) 
The color of the dots in Fig. 6 corresponds to pig ID, and size of the dot represents 
the time at which the biopsy sample was collected (age; 4 days smallest – 39 days largest). 
Redundancy analysis (RDA) is a constrained ordination technique that analyzes how much 
variation in one set of variables (i.e. pig ID) explains variation in a second set of variables 
(i.e. time/age). 174,452–455.  In multivariate statistics, RDA is the equivalent of linear regression; 
it assumes a linear dependence between the response variables on the explanatory variables 
Figure 6: RDA of swine mammary transcriptome. Color of dots 
corresponds to Pig ID; size of dot corresponds to pig age (size 
increases with age). RDA shows orthogonal variabilities in the two 
axes (canonical axis 1 representing Pig ID and canonical axis 2 
representing time/age) indicating that the variabilities are 
independent and very low redundancy is present in the data set.  
 
 63 
and is appropriate for use with the transcriptomic data set. RDA is widely used in community 
ecology and has been reviewed in depth by Paliy et al 174; it is not currently used to assess 
trends in mammary development.  For the transcriptomic data set collected from different 
pigs over a period of time, RDA shows orthogonal variabilities in the two axes (canonical 
axis 1 representing Pig ID and canonical axis 2 representing time/age) indicating that the 
variabilities are independent and very low redundancy is present in the data set. Therefore, 
trends in gene expression can be attributed mainly to age with little contamination from 
variability in Pig ID, providing higher confidence in the dataset. 
 
CLA confirms trends are present in the transcriptomic data set correlating to time 
The panels in Fig. 7 show k-means clustering for genes present in the RNA 
sequencing data set. Two panels are for downward trend (downregulated expression over 
time; clusters 19 and 13), one panel for upward trend (upregulated expression over time; 
cluster 16), and two panels are shown that have a periodic or sinusoidal trend and one with no 
trend or change across time (clusters 2 and 10). The objective of a cluster analysis (CLA) is 
to separate variables into groups based on the similarity of their scores, generating functional 
clusters; the variables contained in each cluster are more similar to each other than variables 
in other groups (minimizing within-group distances and maximizing between-group 
distances) 174. Like PCA, DCA, CCA, and RDA, CLA is an exploratory technique to confirm 
trends in a data set and is becoming a popular choice for use in high-throughput microarray 
gene expression data, suggesting that it also could be a valuable tool in transcriptomic data 
sets from RNA-seq. CLA assumes data independence; the RDA results in Fig. 6 suggest CLA 
is appropriate for use. K-means clustering was utilized in Genesis 428 to group all variables 
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defined by RNA-seq counts into 20 individual clusters (k=20) based on the different 
variability patterns over time in the dataset. 
In the literature, K-means clustering has been used to: define groups of genera that 
are modified by the faecal microbiota transplantation (FMT) in patients with Clostridium 
difficile-associated disease 179, reveal molecular cascades underlying adult neurogenesis 456, 
dissect the multicellular ecosystem of metastatic melanoma 457, identify novel gene 
expression signatures of heart failure 458, tie macrophage polarization to growth rates of 
Figure 7: K-means cluster analysis in Genesis. Two panels are for downward trend 
(downregulated expression over time; clusters 19 and 13), one panel for upward trend 
(upregulated expression over time; cluster 16), and two panels are shown that have a 





intracellular bacteria 459, and reveal cell type-specific transcriptional signatures at the 
maternal-fetal interface 460. However, most of these studies use single-cell RNA-seq, and k-
means clustering not yet been used to analyze developmental gene expression data in the 
mammary gland. K-means clustering of the RNA-seq data set created clusters of genes 
containing distinct patterns over time, which can be further dissected into biologically 
significant functions and pathways.  
Clusters containing genes with distinct patterns over time are dispersed into various 
functional biological categories. Reactome pathway analysis is shown in Table 3 for clusters 
with downward trend (downregulated expression over time; clusters 19 and 13), upward 
trend (upregulated expression over time; cluster 16), and periodic or sinusoidal trend and one 
with no trend or change across time (clusters 2 and 10). K-means clustering of our RNA-seq 
data set in Genesis generated twenty clusters of genes containing distinct patterns over time, 
which were then further analyzed for functional significance and pathways using Reactome. 
All clusters revealed signaling pathways expected to be present in early mammary 
development, including immune system, metabolism, signal transduction, cell cycle 
regulation, gene transcription, and protein translation, as shown in Table 3. Interestingly, 
gene expression contributing to the upward trend in cluster 16 utilized signal transduction 
pathways in conjunction with those of the immune system, innate immune system, cytokine 
signaling, interleukin signaling, and the adaptive immune system. Clusters 13 and 19, 
displaying downward trends over time, contained genes that utilized mainly metabolic, gene 
expression, transcription and translation, and cell cycle pathways. Clusters 2 and 10, 
displaying periodic trends over time, contained genes that utilized a mix of pathways. 
Clusters containing distinct patterns of gene expression over time indicate that the 
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transcriptomic data can be partitioned based on specific developmental trends present, many 
of which contain immune system components, which will be further elucidated with more 
advanced methods.  
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Discriminant function analysis of mammary development over time indicates temporal 
regulation during 4-18 days (phase one) vs. 25-39 (phase two) 
Based on histological trends seen in Fig. 4, the RNA-seq dataset was partitioned into 
two groups representing early postnatal prepubertal (4 days after birth through 18 days after 
birth, hereafter referred to as phase one) and late postnatal prepubertal development (25 days 
after birth through 39 days after birth, hereafter referred to as phase two). Discriminant 
function analysis using three different widely accepted methods showed significant biological 
differences in the two groups, summarized in Table 4.  
The objective of discriminant function analysis (DFA) is to find linear combinations 
of observed variables that maximize the grouping of objects into separate classes; DFA 
assumes multivariate normal distribution and homogeneity of variance and covariance 461. 
Here, three DFA methods were used to isolate two significantly different groups of 
transcriptomic variables based on a split in time. Early development and late development 
were chosen and defined as 4-18 days and 25-39 days, respectively (19-24 days fell in 
between two sampling weeks). In DFA, the numeric weights (discriminant coefficients) can 
be used to define the relative importance of each predictor variable 174 (in our case, gene) to 
the observed discrimination between two classes of objects (early phase one vs. late phase 
two). DFA is appropriate for extremely large data sets and has been successfully employed 
to: predict clinical outcomes from microarray data 462, study reprogramming of cancer 
metabolism 463, identify lipodomic biomarkers for NAFLD 464, compare hepatocellular 
carcinoma miRNA expression profiles 465, discriminate gene expression profiles of plants to 
melatonin 466, and assess sex differences in the human skeletal muscle transcriptome 467. 
However, this method has not been used to study early mammary gland development. 
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Therefore, three individual DFA methods were utilized to characterize the two phases seen 
initially in histological analysis: partial least-squares (PLS), support vector machine (SVM), 
and random forest (RF). PLS assumes linear relationships within the data while SVM and RF 
can be used with any distribution; the basis of these DFA techniques has been reviewed in 
depth by Paliy et al 174. Here, all three methods were utilized to find the most significant 
differences in gene expression during early and late phases of postnatal/pre-pubertal 
development.  
 
Table 4: Common genes identified in mammary transcriptome using three DFA methods 
GENE ID SVM PLS RF 
COL8A1 SVM PLS RF 
DTX3L  SVM PLS RF 
MAP3K14 SVM PLS RF 
SLC29A4 SVM PLS RF 
TBC1D8 SVM PLS RF 
ANP32A PLS  RF 
ARHGAP9 SVM PLS   
ARL16 SVM   RF 
ATP8  PLS RF 
BHLHE40 SVM PLS   
CDYL2 SVM  RF 
DENND5B SVM PLS  
GPAT3  PLS RF 
GRB10 SVM PLS  
HSPA4L   PLS RF 
IF2   PLS RF 
ITIH4 SVM  RF 
KCND2  PLS RF 
MAP3K8 SVM PLS   
NT5DC1   PLS RF 
PAX8 SVM PLS  
PCGF1 SVM PLS  
PCGF5 SVM PLS  
PRUNE2 SVM  RF 
RAP1GAP2 SVM PLS  
RBP5   PLS RF 
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RHOBTB2 SVM PLS  
RNF217 SVM PLS  
SLC47A2 SVM PLS  
THPO SVM PLS  
VAMP5 SVM   RF 
 
Table 5: Reactome pathway characterization of genes identified using DFA  
GENE ID SVM PLS RF Reactome Pathway 
COL8A1 SVM PLS RF Assembly of collagen fibrils and other 
multimeric structures 
Collagen biosynthesis and modifying 
enzymes 
Collagen formation 
Extracellular matrix organization 
DTX3L  SVM PLS RF Adaptive Immune System 
Antigen processing- Ubiquitination and 
Proteasome degradation 
Class I MHC mediated antigen processing 
and presentation 
Immune System 
MAP3K14 SVM PLS RF Adaptive Immune System 
CD28 co-stimulation 
CD28 dependent PI3K/Akt signaling 
CLEC7A (Dectin-1) signaling 
Costimulation by the CD28 family 
C-type lectin receptors (CLRs) 
Cytokine Signaling in Immune system 
Dectin-1 mediated noncanonical NF-κB 
signaling 
Immune System 
Innate Immune System 
NIK-->noncanonical NF-κB signaling 
TNF receptor superfamily (TNFSF) members 
mediating non-canonical NF-κB pathway 
TNFR2 non-canonical NF-κB pathway 
SLC29A4 SVM PLS RF SLC-mediated transmembrane transport 
Transmembrane transport of small molecules 
Transport of nucleosides and free purine and 
pyrimidine bases across the plasma 
membrane 




TBC1D8 SVM PLS RF Unknown 
ANP32A PLS  RF Gene Expression 
HuR (ELAVL1) binds and stabilizes mRNA 
Regulation of mRNA stability by proteins 
that bind AU-rich elements 
ARHGAP9 SVM PLS   Immune System 
Innate Immune System 
Rho GTPase cycle 
Signal Transduction 
Signaling by Rho GTPases 
ARL16 SVM   RF  
ATP8  PLS RF Formation of ATP by chemiosmotic coupling 
Metabolism 
Respiratory electron transport, ATP synthesis 
by chemiosmotic coupling, and heat 
production by uncoupling proteins. 
The citric acid (TCA) cycle and respiratory 
electron transport 
BHLHE40 SVM PLS   BMAL1-CLOCK,NPAS2 activates circadian 
gene expression 
Circadian Clock 
CDYL2 SVM  RF  
DENND5B SVM PLS  Membrane Trafficking 
Vesicle-mediated transport 




Metabolism of lipids and lipoproteins 
Phospholipid metabolism 
Synthesis of PA 
Triglyceride Biosynthesis 
GRB10 SVM PLS  Axon guidance 
Developmental Biology 







Signaling by Insulin receptor 
Signaling by SCF-KIT 
HSPA4L   PLS RF Cellular response to heat stress 
Cellular responses to stress 
Regulation of HSF1-mediated heat shock 
response 
IF2   PLS RF Cap-dependent Translation Initiation 
Eukaryotic Translation Initiation 
Gene Expression 
GTP hydrolysis and joining of the 60S 
ribosomal subunit 
Metabolism of proteins 
Translation 
ITIH4 SVM  RF Hemostasis 
Platelet activation, signaling and aggregation 
Platelet degranulation 
Response to elevated platelet cytosolic Ca2+ 
KCND2  PLS RF Cardiac conduction 
Muscle contraction 
Neuronal System 
Phase 1 - inactivation of fast Na+ channels 
Potassium Channels 
Voltage gated Potassium channels 
MAP3K8 SVM PLS   Activated TLR4 signaling 
Adaptive Immune System 
CD28 co-stimulation 
CD28 dependent PI3K/Akt signaling 
Costimulation by the CD28 family 
Cytokine Signaling in Immune system 
Immune System 
Innate Immune System 
Interleukin-1 signaling 
MAP kinase activation in TLR cascade 
MAP3K8 (TPL2)-dependent MAPK1/3 
activation 
MyD88 cascade initiated on plasma 
membrane 
MyD88 dependent cascade initiated on 
endosome 
MyD88-independent TLR3/TLR4 cascade 
MyD88-Mal cascade initiated on plasma 
membrane 
Signaling by Interleukins 
Toll Like Receptor 10 (TLR10) Cascade 
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Toll Like Receptor 2 (TLR2) Cascade 
Toll Like Receptor 3 (TLR3) Cascade 
Toll Like Receptor 4 (TLR4) Cascade 
Toll Like Receptor 5 (TLR5) Cascade 
Toll Like Receptor 7/8 (TLR7/8) Cascade 
Toll Like Receptor 9 (TLR9) Cascade 
Toll Like Receptor TLR1-TLR2 Cascade 
Toll Like Receptor TLR6-TLR2 Cascade 
Toll-Like Receptors Cascades 
TRAF6 mediated induction of NFkB and 
MAP kinases upon TLR7/8 or 9 activation 
NT5DC1   PLS RF  
PAX8 SVM PLS   
PCGF1 SVM PLS  Developmental biology 
PCGF5 SVM PLS  Developmental biology 
PRUNE2 SVM  RF  
RAP1GAP2 SVM PLS  Immune System;Rap1 signaling; Adaptive 
Immune System 
RBP5   PLS RF  
RHOBTB2 SVM PLS  Signal Transduction; Signaling by Rho 
GTPases;Rho GTPase cycle 
RNF217 SVM PLS  Adaptive Immune System 
Antigen processing- Ubiquitination and 
Proteasome degradation 





SLC47A2 SVM PLS  SLC-mediated transmembrane transport 
Transmembrane transport of small molecules 
Transport of glucose and other sugars, bile 
salts and organic acids, metal ions and amine 
compounds 
THPO SVM PLS  Hemostasis; Platelet activation, signaling and 
aggregation; Platelet Aggregation (Plug 
Formation) 








Figure 8: DFA of mammary development over time indicates temporal regulation 
during 4-18 days of age vs 25-39 days of age: heatmap visualization performed in 
Genesis of top discriminant genes. Genes in bold were identified using all three 
DFA methods; others were identified using two out the three methods. 
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Table 6: Gene name reference for genes identified during DFA 
GENE ID SVM PLS RF Gene Name, Gene Symbol, Ortholog 
COL8A1 SVM PLS RF Collagen α-1(VIII) chain;COL8A1;ortholog 
DTX3L  SVM PLS RF E3 ubiquitin-protein ligase DTX3L;DTX3L;ortholog 
MAP3K14 SVM PLS RF Mitogen-activated protein kinase kinase kinase 
14;MAP3K14;ortholog 
SLC29A4 SVM PLS RF Equilibrative nucleoside transporter 4;SLC29A4;ortholog 
TBC1D8 SVM PLS RF TBC1 domain family member 8;TBC1D8;ortholog 
ANP32A PLS  RF Acidic leucine-rich nuclear phosphoprotein 32 family 
member A;ANP32A;ortholog 
ARHGAP9 SVM PLS   Rho GTPase-activating protein 9;ARHGAP9;ortholog 
ARL16 SVM   RF ADP-ribosylation factor-like protein 16;ARL16;ortholog 
ATP8  PLS RF ATP synthase protein 8;MT-ATP8;ortholog 
BHLHE40 SVM PLS   Class E basic helix-loop-helix protein 
40;BHLHE40;ortholog 
CDYL2 SVM  RF Chromodomain Y-like protein 2;CDYL2;ortholog 
DENND5B SVM PLS  DENN domain-containing protein 5B;DENND5B;ortholog 
GPAT3  PLS RF Glycerol-3-phosphate acyltransferase 3;AGPAT9;ortholog 
GRB10 SVM PLS  Growth factor receptor-bound protein 10;GRB10;ortholog 
HSPA4L   PLS RF Heat shock 70 kDa protein 4L;HSPA4L;ortholog 
IF2   PLS RF Eukaryotic translation initiation factor 5B;EIF5B;ortholog 
ITIH4 SVM  RF Inter-α-trypsin inhibitor heavy chain H4;ITIH4;ortholog 
KCND2  PLS RF Potassium voltage-gated channel subfamily D member 
2;KCND2;ortholog 
MAP3K8 SVM PLS   Mitogen-activated protein kinase kinase kinase 
8;MAP3K8;ortholog 
NT5DC1   PLS RF 5'-nucleotidase domain-containing protein 
1;NT5DC1;ortholog 
PAX8 SVM PLS  Paired box protein Pax-8;PAX8;ortholog 
PCGF1 SVM PLS  Polycomb group RING finger protein 1;PCGF1;ortholog 
PCGF5 SVM PLS  Polycomb group RING finger protein 5;PCGF5;ortholog 
PRUNE2 SVM  RF Protein prune homolog 2;PRUNE2;ortholog 
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RAP1GAP2 SVM PLS  Rap1 GTPase-activating protein 2;RAP1GAP2;ortholog 
RBP5   PLS RF Retinol-binding protein 5;RBP5;ortholog 
RHOBTB2 SVM PLS  Rho-related BTB domain-containing protein 
2;RHOBTB2;ortholog 
RNF217 SVM PLS  Probable E3 ubiquitin-protein ligase 
RNF217;RNF217;ortholog 
SLC47A2 SVM PLS  Multidrug and toxin extrusion protein 2;SLC47A2;ortholog 
THPO SVM PLS  Thrombopoietin;THPO;ortholog 
VAMP5 SVM   RF Vesicle-associated membrane protein 5;VAMP5;ortholog 
 
 
Discriminate analysis of gene expression during early (Day 4 – Day 18) and later (Day 25 – 
Day 29) postnatal mammary development reveals temporal regulation of important signaling 
events   
 Discriminate analysis between the mammary transcriptome during 4-18 days of age 
(DOA) (phase one) and 25-39 DOA (phase two) implicated important biological differences 
that are temporally regulated during early postnatal mammary development and support the 
two phases suggested by histology (see histology Fig. 3). As shown in Table 4, five known 
genes were found using all three discriminate analysis methods (SVM, PLS, and RF): 
COL8A1, DTX3L, MAP3K14, SLC29A4, and TBC1D8. 26 known genes were found in two 
out of the three discriminate analysis methods: ANP32A, ARHGAP9, ARL16, ATP8, 
BHLHE40, CDYL2, DENND5B, GPAT3, GRB10, HSPA4L, IF2, ITIH4, KCND2, 
MAP3K8, NT5DC1, PAX8, PCGF1, PCGF5, PRUNE2, RAP1GAP2, RBP5, RHOBTB2, 
RNF217, SLC47A2, THPO, and VAMP5. Genes found using all three or two out of the three 
methods were deemed significant and will be discussed along with their upregulation or 
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downregulation during phase one (and respectively, downregulation and upregulation during 
the phase two). 
 Discriminate analysis data was assembled into a heat map using hierarchical 
clustering in Genesis428. As shown in Fig. 8., genes identified using all three discriminate 
methods are bolded; generation using three separate methods indicates the highest 
significance of differential gene expression between the two phases. Differential expression 
of all five highly significant genes was upregulated during phase two of postnatal 
mammary gland development in comparison to their downregulated expression 
immediately after birth in phase one. Importantly, the large majority (75%) of discriminately 
expressed genes identified with all three DA methods were expressed highly during phase 
two with significantly lower expression during phase one. Overall, common Reactome 
pathways utilized by the top 31 known differentially expressed genes were (from most often 
to least): Immune System, Adaptive Immune System, Signal Transduction, SLC-mediated 
transmembrane transport, Transport of small molecules, Innate Immune System, CD28 
dependent PI3K/Akt signaling, CD28 co-stimulation, Rho GTPase cycle, Costimulation by 
the CD28 family, BMAL1:CLOCK,NPAS2 activates circadian gene expression, Transport of 
glucose and other sugars, bile salts and organic acids, metal ions and amine compounds, 
Antigen processing: Ubiquitination & Proteasome degradation, Circadian Clock, Class I 
MHC mediated antigen processing & presentation, Signaling by Rho GTPases, and Cytokine 
Signaling in Immune system. Greater than 50% of the pathways utilized by differentially 
expressed genes were direct components of the immune system, indicating significant impact 
of both innate and adaptive immune system factors in regulation of postnatal developmental 
events. The immune system’s involvement in prenatal and postnatal mammary development 
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has been gaining acceptance 11,84–88, and this data further confirms significant involvement, 
specifically suggesting critical roles in temporal regulation during the first two months after 
birth. Although the importance of immune cells in mammary gland development is well 
known 34,35, the molecular signaling that guides them, the roles of chemokines, and the 
importance of the adaptive immune system remain unexplored 86,114. 
 Pathway analysis was performed on each phase of discriminately expressed genes 
separately. Pathways utilized by the smaller subset of differentially expressed genes that are 
upregulated during phase one were (from most often to least): signal transduction, 
metabolism of proteins, lipids, and RNA, and organelle biogenesis. CLA analysis using k-
means clustering in Fig. and Table 5 also indicated that gene expression contributing to the 
downward trends over time in Clusters 13 and 19 utilized mainly metabolic, gene expression, 
transcription and translation, and cell cycle pathways. In stark contrast, the larger subset of 
differentially expressed genes that were upregulated during phase two utilized mainly 
immune system pathways, including (from most often to least): immune system, adaptive 
immune system, innate immune system, CD28 dependent PI3K/AKT signaling, CD28 co-
stimulation, co-stimulation by the CD28 family, Class I MHC mediated antigen processing 
and presentation, platelet activation, signaling, and aggregation, and cytokine signaling in 
immune system. These immune system pathways were not found in differentially expressed 
genes of phase one. Pathway analysis on the differentially expressed genes during early 
mammary development indicates that the adaptive immune system is highly utilized 
beginning in the period of 18-25 days after birth and remains active until at least 39 days 
after birth, during which it contributes to developmental trends. The adaptive immune system 
pathway is only preceded in use by differentially expressed genes by the generic immune 
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system category, which includes both adaptive and innate components. This is especially 
novel because adaptive immune roles in mammary development are currently unexplored. 
CLA analysis using k-means clustering in Fig. 7 and Table 3 also indicated that gene 
expression contributing to the upward trend in cluster 16 utilized signal transduction 
pathways in conjunction with those of the immune system, innate immune system, cytokine 
signaling, interleukin signaling, and the adaptive immune system, further supporting the 
notion that the immune system’s role in early mammary development does increase over time 
during the period of 4-19 days after birth. Taken together, these results do indicate significant 
involvement and regulation of innate and adaptive immune system genes and components in 
early postnatal, but prepubertal, mammary gland development. Genes of functional 
significance will be discussed individually below. 
  
Differentially expressed genes that are upregulated during Phase one: Day 4- Day 18 after 
birth 
 Differentially expressed genes that are suspected, as a result of DFA analysis, to hold 
important roles in mammary development will be individually discussed, beginning with the 
small subset that are upregulated during phase one (from 4-18 days after birth) and 
expressed at lower levels from days 25-39. As mentioned, pathway analysis initially 
indicated that these genes mainly utilize signal transduction and metabolic pathways and are 
not present in innate or adaptive immune system pathways. Still, several functionally 
significant genes are present in phase one. HSPA4L, Heat shock 70 kDa protein 4L, encodes 
a heat shock inducible chaperone protein that is highly expressed in leukemia cells 468–472. 
Current evidence supports a role of HSPA4L in normal spermatogenesis 470, but little to no 
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data exist explaining its function in normal mammary development. Results suggest that this 
chaperone protein may play a role in very early protection of developing mammary cells 
from heat stress and aids in osmotolerance. KCND2, Potassium voltage-gated channel 
subfamily D member 2, encodes a voltage-gated potassium channel protein that is known to 
mediate transmembrane potassium transport in excitable membranes 472. Since voltage-gated 
potassium (Kv) possesses diverse functions including regulation of neurotransmitter release, 
heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth 
muscle contraction, and cell volume 473, it is possible that this gene is upregulated during 
phase one in order to immediately regulate electrolyte transport of mammary epithelial cells 
after birth. ANP32A, or Acidic leucine-rich nuclear phosphoprotein 32 family member A, 
encodes a protein implicated in a number of cellular processes, including proliferation, 
differentiation, caspase-dependent and caspase-independent apoptosis, suppression of 
transformation (via acting as a tumor suppressor) and is aberrantly expressed in multiple 
types of cancers 474–477. ANP32A is a member of the ANP32 family, that contains a large 
group of proteins implicated in a wide range of functions: modulation of cell signaling, 
transduction of gene expression, hormone-receptor interactions, cell adhesion, cellular 
trafficking, early mammalian development, apoptosis signaling, and regulation of 
cytoskeleton morphology 478,479. The high expression of ANP32A during phase one in 
contrast to its downregulation in phase two suggests it supports one or more of these 
functions in very early postnatal mammary gland development. The function of NT5DC1, 5'-
nucleotidase domain-containing protein 1, remains unknown 472 and to our knowledge no 
data exist to elucidate its role in early mammary development; this data suggest a role in the 
first few weeks after birth. ATP8, ATP synthase protein 8, encodes a protein that functions as 
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a subunit of mitochondrial ATP synthase 480. ATP8 supports normal mitochondrial 
performance 481, therefore it is possible that this differentially expressed gene supports 
mitochondrial function in young mammary cells of phase one. IF2, or Eukaryotic translation 
initiation factor 5B, is a general transcription factor that supports initiation of translation by 
promotion of 60S ribosome subunit joining and pre-40s subunit proofreading 482–486. 
Recently, Lee at al uncovered a critical role for IF2 in specific developmental stages, 
including those of immature oocytes and ES cells, and during growth-factor deprivation of 
mammalian cells, inducing the transition to cell-cycle arrest 483. Importantly, these 
researchers demonstrate that IF2/eIF5B controls and regulates cell-cycle transition and 
developmental stages 483, which is likely akin to its function in early mammary development. 
Taken together, the subset of genes that are highly differentially expressed during phase one 
of postnatal mammary development likely promote signaling pathways of cellular biogenesis, 
metabolism, epithelial and stromal differentiation, and widespread expansion of the gland. 
Interestingly, functional characterization of the small subset of DFA genes found upregulated 
in phase one immediately after birth suggests that this time period of early mammary 
development is one of generic growth rather than advanced differentiation. The presence of 
genes aiding in early protection of developing mammary cells from heat stress, 
osmotolerance, regulation of electrolyte transport of mammary epithelial cells, modulation of 
cell signaling, transduction of gene expression, hormone-receptor interactions, cell adhesion, 
cellular trafficking, mitochondrial function, and cell-cycle transition provide a model for 
widespread growth focused on cellular activity in phase one, rather than differentiation with 
support from stromal and immune factors that is seen in phase two. It may be that 
immediately after birth, the mammary gland requires three to four weeks to adjust to growth 
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and expansion postnatally, after which advanced differentiation and maturation of the organ 
begins. 
 
Differentially expressed genes that are upregulated during Phase two: Days 25-39 after birth 
 Next, the major subset of differentially expressed genes (those that are downregulated 
phase one and upregulated during later phase two) will be discussed, beginning with the five 
significant genes identified using all three DA methods. COL81A encodes type VIII 
collagen, a matrix protein widely expressed during tissue remodeling, wound repair, and cell 
migration; little is known about its functional mechanism, especially in mammary 
development 472,487–496. As discussed previously, postnatal mammary epithelial cells are 
tightly connected to both each other and surrounding stroma, relying on this both collagen 
and this stable adhesion to transmit biochemical signals, promote cell migration, and function 
normally 7,41,82. Cell migration is a carefully coordinated process during which attachment to 
matrices and subsequent release for translocation are regulated by MMPs, forming a physical 
path through the ECM 497. This process is also commonly mediated by integrin and laminin 
molecules: Ln-5 can be degraded by proteases (including MMP-2 and MMP-9) during tissue 
remodeling to promote cell migration 394. When cleaved during proteolytic processing, the 
G4/G5 fragment of Ln-5 that is released from the G3 domain also functions to support cell 
migration 397. Hou et al investigated smooth muscle cell (SMC) migration via type VIII 
collagen and concluded its effects are mediated by α2β1 and α1β1 integrin receptors as well 
as MMP-2 and MMP-9 expression. This demonstrates a critical role for type VIII collagen in 
cellular invasion and migration 488. As reviewed in Chapter 1, MMPs secreted by 
macrophages function in ECM remodeling to allow ductal branching into the mammary fat 
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pad 14,103–107, so it is not surprising that MMPS coordinate with type VIII collagen in this 
suggested model. During tumorigenesis, reduction of COL8A1 expression leads to decreased 
invasion of hepatocarcinoma cells 498, indicating that type VIII collagen has a functional role 
in both cancer development and the migration and adhesion required for normal 
development. However, little data exist to elucidate the role of type VIII collagen in early 
postnatal mammary development or TNBC. This data show that COL81A is significantly 
upregulated during phase two of early postnatal mammary development, and taken together 
with the accepted role in general tissue remodeling, wound repair, cell migration, and integrin 
molecule interaction, it is hypothesized that type VIII collagen has a functional role in early 
postnatal mammary development and epithelial cell signaling in conjunction with MMPS and 
other immune system components.  
 The Deltex (DTX)-3-like E3 ubiquitin ligase (DTX3L), also known as B-lymphoma 
and BAL-associated protein (BBAP), is overexpressed in many high-risk, chemo-resistant, 
diffuse large B cell lymphoma (HR-DLBCL) subtypes 499, is associated with both IFN-
gamma and STAT1 signaling 499–502, and functions as a binding partner to ADP-
ribosyltransferase-9 (ARTD9) (also known as B-aggressive lymphoma protein (BAL1)) 
499,502. These genes have also been found overexpressed in myeloma, Ewing tumors, head and 
neck cancers, and cervical cancer 502–507. Functionally, DTX3L responds to cellular exposure 
of DNA damaging agents and its inhibition is thought to increase the efficacy of DNA-
targeting chemotherapeutic agents, but the mechanism utilized in the response is unclear 508. 
In melanoma cells, DTX3L has been shown to mediate proliferation, invasion, and metastasis 
through FAK/PI3K/AKT signaling 509, suggesting a similar role for this gene during tissue 
remodeling in the early mammary gland during phase two while upregulated because studies 
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investigating its function in mammary development do not exist. 
 The MAP3K14 gene, also known as NF-κB-inducing kinase (NIK), encodes a 
serine/threonine protein-kinase that promotes activity of the noncanonical NF-κB pathway to 
regulate cell proliferation and survival both normally and in tumorigenesis 510,511. NF-κB is a 
well-characterized transcription factor family that influences cellular immune responses, 
survival, proliferation, angiogenesis, and metastasis 512. NIK regulation occurs at the post-
translational level through the translocon associated protein complex (TRAF), a cellular 
inhibitor of apoptosis 513, promoting differentiation, development, embryogenesis, and tumor 
cell invasion through phosphorylation of either IKK α and IKK β subunits 514–519. 
Additionally, Osman et al showed that both NIK and AKT are necessary for activation of 
NF-κB, suggesting involvement of NIK in the PI3K/AKT pathway 520. Importantly, NIK is 
overexpressed in basal breast cancer cell lines, leading to constitutive activation and 
uncontrolled tumor proliferation 521–523. NIK overexpression also increases the activity of 
breast cancer stem cells in vitro through the ERK pathway and is correlated with ALDH 
overexpression in a tissue microarray of in vivo breast cancer samples, implicating NIK in 
regulation of the breast cancer stem cell phenotype 524. Since NIK is essential for the 
canonical NF-κB pathway activation normally, inhibition of NIK could be a better 
therapeutic strategy in cancer. It is clear that NIK is involved in regulation of breast cancer 
stem cells, tumor invasion, and basal cell expansion, but the mechanism remaining poorly 
understood 524. This data identifies NIK as a highly significantly differentially expressed gene 
that is upregulated during phase two of early postnatal mammary development, suggesting 
NIK functions to promote differentiation and proliferation of mammary epithelial cells 
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during this period in the immature gland and also may regulate growth of the mammary 
gland through apoptotic cell signaling pathways.  
 TBC1D8, TBC1 domain family member 8, which may act as a GTPase-activating 
protein for Rab family protein(s)472 and SLC29A4, Equilibrative nucleoside transporter 4, 
which functions as a polyspecific organic cation transporter472, have lesser characterized 
functions in development and to our knowledge data does not exist to elucidate their 
function. Since these two genes are highly upregulated during phase two of postnatal 
mammary development, our data suggest a role for them in this area.  
Taken together, the presence of COL81A, DTX3L, MAP3K14 in the top subset of 
genes upregulated during phase two suggest contribution of the ECM, immune system, and 
tissue remodeling to differentiation and proliferation of mammary epithelial cells during this 
period in the immature gland. Importantly, in contrast with the generic cell growth model 
provided by discriminately expressed phase one genes, phase two appears to contain more 
advanced regulatory and differentiation activities along with the presence of stromal 
influence. Many of the phase two genes have functions in tissue remodeling, wound repair, 
and cell migration while relying on stable adhesions. It is known that cell migration is a 
carefully coordinated process, and this data suggests growth due to migration and 
differentiation begins in phase two rather than phase one, in part due to regulation by immune 
system components such as MMPS. Importantly, DFA analysis suggests that during phase 
two, proliferation, invasion, and maturation may begin to rely more heavily on 




In addition to genes identified using all three discriminant analysis methods, several 
functionally important genes were generated by two of the three methods, which will be 
discussed individually, including: ARHGAP9, BHLHE40, GRB10, ITIH4, MAP3K8, PAX8, 
PCGF1, PCGF5, PRUNE2, RNF217, THPO. All of these genes were upregulated during 
phase two of early postnatal mammary development.  
 ARHGAP9 encodes Rho GTPase-activating protein 9, a G-protein modulator that is a 
member of the Rho-GAP family of GTPase activating proteins that has been implicated in 
regulating adhesion of hematopoietic cells to the extracellular matrix 525 and interacting with 
Erk2 and p38α to sequester the MAP kinases in their inactive states 526, which is a novel 
mechanism of cross-talk between Rho GTPase and MAP kinase signaling. Given that matrix 
adhesion is a critical activity for cell migration and mammary development, it is 
hypothesized that this gene has a similar adhesion function in phase two of early postnatal 
mammary development.  
 BHLHE40 encodes Class E basic helix-loop-helix protein 40, which is a 
transcriptional repressor believed to be involved in control of circadian rhythm (through 
negative regulation of clock and clock-controlled genes), cell differentiation, proliferation, 
and apoptosis 527–533. Also commonly known as Differentiated embryo-chondrocyte 
expressed gene 1 (DEC1), this gene has been shown to assist BHLHE41 in the suppression of 
EMT effectors and tumor cell invasion in vitro 529 and its loss may promote tumor 
progression in through upregulation of cyclin D1 534. Conflictingly, data suggest its presence 
also promotes the invasiveness of breast cancer through downregulation of claudin-1 531. 
Overexpression of this gene has been reported to contribute to the cellular differentiation, 
proliferation, and apoptosis of various cancers 527–538 although the mechanism is poorly 
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understood. This data suggests a significant role for BHLHE40 during phase two, which 
could consist of either promotion of cellular differentiation and proliferation (positive role) or 
cell cycle regulation (negative/regulatory role). Given that cell cycle regulation was a 
hallmark of phase one genes, it is possible BHLHE41 in phase two contributes to 
differentiation of mammary epithelial cells, a focus of this larger subset of DFA results. 
 GRB10, Growth factor receptor-bound protein 10, is a common adapter protein 
which modulates interaction of several surface receptor kinases by interfering with 
downstream signaling pathways and receptor degradation 472. GRB10 is widely accepted to 
influence cell proliferation, apoptosis, and metabolism in varied cell types 539–541. It can bind 
to, and suppress signals from, activated RTKs including the insulin (INSR) 542 and insulin-
like growth factor (IGF1R) receptors 543 via delay and reduction of AKT1 phosphorylation. 
GRB10 has a widespread functional impact in both development and cancers- it has been 
shown to bind to the intracellular portion of Low-density lipoprotein receptor-related protein 
6 (LRP6) and negatively influence Wnt signaling, as a negative regulator of the pathway 544. 
Loss of GRB10 can also induce hyperproliferation and tumor development 545 and its 
presence has also been found to negatively correlate with lactation performance 546, 
illustrating its wide range of function. Interestingly, the phenotype resulting from GRB10 
dysfunction is dependent on the parental origin of the mutation, a phenomenon known as 
genomic imprinting 547. Genomic imprinting, reviewed in depth 548, can influence 
developmental programming that links growth in early stages of life to overall health at 
adulthood. Expression of GRB10 is gained from the maternal chromosome in most tissues 
and presents a complex and tissue-specific expression pattern 547. Data has identified 
imprinted GRB10 as a mediator of nutrient supply and demand in the postnatal period and a 
 
 89 
negative regulator of growth-related pathways and insulin signaling in development 547; 
reduction in GRB10 expression results in widespread postnatal overgrowth and insulin 
sensitivity 549–552. This data suggests that GRB10 is upregulated during phase two in order to 
perform similar negative regulatory roles in early postnatal mammary development. 
 ITIH4, Inter-α-trypsin inhibitor heavy chain H4, is a type II acute phase protein that 
is involved in the inflammatory trauma response 472,553. Predominantly expressed in liver 
tissue, mRNA expression levels of this protein have been seen upregulated in response to 
administration of IL-6 553, but data regarding the involvement of this protein in mammary 
development does not exist.  This data indicates upregulation of ITIH4 during phase two, 
where it could be involved in the developing epithelial cells and the immune system in 
response to cytokines present in the postnatal mammary gland. 
 MAP3K8, mitogen-activated protein kinase kinase kinase 8, is a potent oncogene that 
encodes a member of the serine/threonine protein kinase family 472. Widely expressed in 
skeletal muscle and the immune system 554, MAP3K8 is a tumor suppressor that can activate 
the ERK, JNK, and p38 MAPK pathways 555, support IL-12 production and Th cell 
differentiation 556, and possesses a critical role in promotion of cancer-associated 
inflammation in the TME when induced by IL-22 557. IL-22 signaling can promote 
aggressiveness in human breast cancer through the induction of MAP3K8, leading to 
epithelial transformation; knockdown of MAP3K8 decreases tumorigenicity in MCF-7 cells 
557. It is well-known that the MAP3K8 pathway components can have both tumorigenic or 
apoptotic functions that are dependent on the stimuli and the other stromal cells involved 558; 
its involvement in normal mammary development can either be hypothesized as regulatory or 
promotional or both, depending on the time period. Our data show that this gene is 
 
 90 
upregulated during phase two and downregulated during phase one, leading us to believe that 
it could have a regulatory role in postnatal mammary development- possibly controlling 
growth after initial widespread metabolic and biogenesis events during phase one growth.  
 PAX8, Paired box protein 8, encodes a transcription factor that is known to control 
cellular fate and embryonic development of the central nervous system, eye, kidney, thyroid 
gland, and mesonephric gut organs 559–565 and has a critical role in maintaining the normal 
function of certain cells, especially epithelial cells, of these organs after birth 566,567. Ozcan et 
al showed through an immunohistochemical study that PAX 8 expression occurs in a tissue 
and organ specific manner in both non-neoplastic adult tissue and transformation and 
metastasis 568. During phase two of postnatal mammary gland development, this transcription 
factor is likely upregulated to support and control normal epithelial cell differentiation and 
organ development. 
 Two polycomb group RING finger proteins are upregulated during phase two. 
PCGF1, Polycomb group RING finger protein 1, encodes a protein component of the 
polycomb group (PcG) multiprotein BCOR complex, which functions to maintain several 
genes in a transcriptionally repressed state and regulate developmental genes 472. PCGF5, 
Polycomb group RING finger protein 5, is also a component of a PcG complex (PRC1-like) 
required to maintain the transcriptionally repressed state of HOX (homeobox) genes 
throughout development 569. Target genes repressed by PCGF1 include BCL6 and CDKN1A. 
CDKN1A functions as a regulator of cell cycle progression at G1 phase and its expression is 
also controlled by p53 in order for cell cycle arrest to occur if needed 570–572. PCGF1, as part 
of a PcG complex, can promote cell cycle progression and can enhance proliferation by 
repressing various cell cycle regulators 572–579. Importantly, PcG proteins have been 
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implicated in both cancer development and maintenance of embryonic and adult stem cells; it 
is possible that PCGF1 and PCGF5 play a role in stem cell pluripotency 570. Recent data show 
that PCGF5 is expressed preferentially in hematopoietic stem cells (HSCs) and multipotent 
progenitors (MPPs) compared with differentiated cells 580. Dupret et al showed through a 
zebrafish model that PCGF1 is critical in early development; zebrafish without normal 
PCGF1 gene function had significantly lower early developmental growth rates and later, 
signs of premature aging 581 . PCGF1 and PCGF5 are likely functioning in early postnatal 
mammary development in a similar fashion as described above in order to regulate and 
promote growth of the mammary gland, specifically during phase two. 
 PRUNE2, Protein prune homolog 2, encodes a protein of the B-cell CLL/lymphoma 
2 and adenovirus E1B 19 kDa interacting family 472, where it functions in apoptotic processes 
as tumor suppressor 582–584. However, little data exist for a role in mammary development. 
Similarly, RNF217, E3 ubiquitin-protein ligase RNF217, encodes a protein that interacts with 
a known anti-apoptotic protein, HAX-1, via its C-terminal RING finger motif, suggesting a 
role in apoptosis signaling. Our data suggest that presence of both PRUNE2 and RNF217 
upregulation phase two supports their regulatory roles in growth and proliferation of the 
mammary gland, but further study is needed since literature is lacking for these genes. 
 THPO encodes the protein Thrombopoietin, the major cytokine that regulates platelet 
production, controls differentiation and proliferation of megakaryocyte progenitor cells, and 
maintainins normal thrombopoiesis levels 585,586. This indispensable cytokine has been shown 
to activate the JAK/STAT 587 and PI3K 588 pathway as well as activate in an inside-out 
manner integrin α2bβ3 589. Matsumura et al proved that THPO induced differentiation of a 
human megakaryoblastic leukemia cell line through transcriptional activation of p21 by 
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STAT5 590. THPO is vital for the regulation and maintenance of HSC quiescence and data 
suggests it supports stem cell renewal after bone marrow transplantation 591,592. The 
upregulation during Days 25-39 in the early postnatal mammary gland shown by our data 
suggest that THPO supports platelet production and differentiation in the developing 
mammary microenvironment.  
 Taken together, discriminate analysis data show temporal regulation of important 
signaling events during two phases of early postnatal, prepubertal mammary development. 
Differential expression of all five highly significant genes (revealed using all three methods) 
was upregulated during phase two of postnatal mammary gland development in 
comparison to their downregulated expression immediately after birth in phase one. Greater 
than 50% of the pathways utilized by differentially expressed genes were direct components 
of the immune system, indicating significant impact of both innate and adaptive immune 
system factors in regulation of postnatal developmental events. The immune system’s 
involvement in prenatal and postnatal mammary development has been gaining acceptance 
11,84–88, and our data further confirms significant involvement, specifically suggesting critical 
roles in temporal regulation during the first two months after birth.  
Pathway analysis was performed on each phase of discriminately expressed genes 
indicated mainly metabolic, gene expression, transcription and translation, and cell cycle 
pathways utilized in phase one while the larger subset of differentially expressed genes that 
were upregulated during phase two utilized mainly immune system pathways that were not 
found in differentially expressed genes of phase one. Our pathway analysis on the 
differentially expressed genes during early mammary development indicates that the adaptive 
immune system is highly utilized beginning in the period of 18-25 days after birth and 
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remains active until at least 39 days after birth, during which it contributes to developmental 
trends. Additionally, our data and the assessment of key immune regulators and markers in 
swine by other researchers suggests this is a much better model of human innate immunity 
and disease than rodents 151. Accordingly, understanding the function of immune molecules 
in normal development and their concert with other signaling mechanisms can provide 
insight into these roles during cancer development 91.  
DFA, in addition to providing novel insight regarding temporally regulated events of 
early postnatal mammary development, suggested that phase one and phase two can be 
defined as widespread biogenesis and refined differentiation, respectively. The presence of 
genes with advanced regulatory and immune function, as well as many with tumorigenic 
roles, in phase two is a unique finding; although growth is seen immediately after birth, 
maturation and differentiation seems to take three to four weeks to truly begin.  
 
There are specific trends + interactions between sets of genes that have developmental and 
biological significance over time (PRC) 
PRC analysis generated a list of genes that contribute functionally, both positively 
and negatively, over time (4-39 DOA) to our model of early postnatal mammary gland 
development. PRC identifies specific genes contributing functionally, and possibly 
interacting with each other, toward development over time, as shown in Fig. 9. Positive PRC 
gene transcripts increase in abundance with the curve over time; the top 20 are shown on the 
effect axis in green text. Conversely, the top 20 genes that are contributing negatively toward 
development over time, or decreasing in abundance with the curve, are shown in red text. 
Reactome pathway analysis plus manual pathway curation if necessary is indicated by the 
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colored box to the right of each Gene ID. In Tables 7 and 8, PRC weights are shown along 
with each Gene ID and family for the top 50 negative and positive genes. A greater PRC 
weight indicates greater contribution to the curve trend.  
  
In an RNA-seq data set that contains a  large number of response variables (genes), 
interpretation of RDA and CCA plots is complicated because interaction effects exist among 
explanatory variables 593. Initially developed by van den Brink & ter Braak 594, PRC can be 
used to study the effect of age (as a function of time) on gene expression in the early pre-
pubertal/postnatal mammary gland. PRC is based on RDA with the same assumptions and is 
frequently used in ecological studies as resulting biological and chemical data sets from 
analysis of environmental trends are large and difficult to evaluate 593–599. PRC curves 
visually show changes over time in a format that is easy to read and are usually used with an 
Figure 9: PRC identifies specific genes contributing functionally toward development 
over time (days of age); Positive PRC gene transcripts increase in abundance with the 
curve over time (top 20 are shown on the effect axis in green text). The top 20 genes that 
are contributing negatively toward development over time, or decreasing in abundance 
with the curve, are shown in red text. Reactome pathway analysis plus manual pathway 
curation if necessary is indicated by the colored box to the right of each Gene ID. 
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internal reference (overall mean, reference age, or reference year) 594,596,600. Time-dependent 
effects can be clearly isolated in PRC 174, making it a valuable tool to extract developmental 
trends from the large transcriptomic data set. This advanced technique has not yet been 
applied to data in the field of developmental or mammary biology. Shown in Fig. 9, the PRC 
plot of the transcriptomic data set illustrates a clear trend over the period of 4-39 DOA, 
indicating time-dependent effects are present. PRC identifies the set of positive genes 
contributing functionally toward development over time, increasing in abundance with the 
curve or contributing negatively toward development over time. Each gene has a unique 
weight, shown in Tables 6-7, that indicates its contribution to the curve, and therefore, its 
contribution to postnatal mammary development.  
 Tables 7 and 8 are a summary of the top 50 positively and negatively contributing 
genes to the PRC curve. It is hypothesized that the genes decreasing in abundance with the 
PRC curve are very early genes contributing to the phenotype at birth or prior; these could 
also be similar to phase one genes (upregulated during 4-18 DOA) discussed in the 
discriminant analysis section. Reactome pathway analysis indicated that the top pathways 
utilized by the top 50 genes negatively contributing to the developmental trend are: Cell 
Cycle, Mitotic, Cell Cycle, Metabolism, Metabolism of proteins, Signal Transduction, RHO 
GTPase Effectors, Signaling by Rho GTPases, Gene expression (Transcription), and Generic 
Transcription Pathway. A review of the literature and characterization using Panther 601–605 
and GeneCards 472 indicates that the main biological functions of the negatively contributing 
genes are organelle biosynthesis, transcription and gene expression, cell cycle control, RNA 
binding and processing, DNA elongation and amplification, CDK interactions, and molecular 
chaperoning. In agreement with phase one DA genes, which mainly utilized signal 
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transduction and metabolic pathways, negative PRC genes are not present innate or adaptive 
immune system pathways. 
 Conversely, it is hypothesized that the positive PRC genes, those that increase in 
abundance with the PRC curve, are developmental genes, possibly similar to phase two DA 
genes discussed previously. These positive PRC genes theoretically function synergistically 
to significantly contribute to early postnatal mammary development over time. Reactome 
pathway analysis indicated that the top pathways utilized by the top 50 genes positively 
contributing to the developmental trend are: Immune System, Metabolism of proteins, Signal 
Transduction, Adaptive Immune System, Cytokine Signaling in Immune system, Post-
translational protein modification, Axon guidance, Hemostasis, Developmental Biology, 
Interleukin-4 and 13 signaling, Signaling by Interleukins, and Innate immune system. A 
review of the literature and characterization using Panther tools 601–605 and GeneCards 472 
indicated that the main biological functions of the positively contributing PRC genes are: 
comprehensive immune system function, stem cell signaling, antigen presentation, protection 
from stress, inflammation, apoptosis and transcriptional repression, Integrin signaling, 
utilization of NFkB, Wnt, MAPK, and AKT pathways, cell migration and adhesion, epithelial 
and mesenchymal cell polarity and morphology, focal adhesion formation, adherens junction 
formation, and ECM cell spreading. Interestingly, a review of the literature indicated that 
65% of the positive PRC genes can function as oncogenes or proto-oncogenes in comparison 
with only 22% of the negative PRC genes. As shown in Fig. 9, the top 20 positive and 
negative PRC genes have the potential to utilize more than one Reactome pathway (indicated 
by colored boxes). As briefly mentioned, our analysis showed the top 20 negative genes that 
decrease in abundance with the curve are not reported to utilize any immune system or 
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developmental biology pathways in contrast with high utilization by the positive genes (as 
characterized by Reactome). Conversely, the top 20 positive genes that increase in abundance 
with the curve utilize very few cell cycle and gene expression pathways in comparison by 
high utilization by the negative genes. Taken together, PRC and pathway analysis suggests 
that development and maturation of the mammary gland during the first 39 days after birth 
heavily relies on the immune system, immune components, integrin molecules, and the ECM, 
utilizing genes known to function in development and previously uncharacterized, novel 
genes that are also likely to function as oncogenes or proto-oncogenes.  
 Since the data illustrated that a majority of the top 50 positive PRC genes are 
functionally significant, linked with cell signaling pathways of biological interest, and have 
been implicated in various types of cancers, a select subset and implications for functional 
roles in early mammary development will be discussed herein. These are: SLA-DOA, 
PINK1, DOCK4, L1CAM, FRMD4A, STARD8, VLDLR, SOX13, LIMS2, UBXN1, 
DDIT3, HGF, DMAP1, and TRAF3. TRAF3 and HGF were not able to be shown due to 
figure size limitations. These genes are a chosen subset of the most significant functional 
genes in early mammary development uncovered through PRC analysis with critical, 
widespread, and/or novel roles in the process. A full characterization for the top 50 positive 
and top 50 negative PRC genes can be found in Appendix A and B.  
 First, a large portion of genes contributing to development over time were linked with 
the innate and/or adaptive immune system. SLA-DOA, also known as HLA class II 
histocompatibility antigen do α chain (HLA-DOA), modulates HLA class II restricted 
antigen presentation pathways in B-cells and is both an MHC Class II molecule chaperone 
and an adaptive immune system constituent  472,606,607. As reviewed in Chapter 1, the role of 
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the adaptive immune system in early mammary development remains unexplored with an 
unknown what function, if any, in mammary organogenesis. An adaptive immune system 
protein with the highest positive PRC weight indicates significant involvement of this 
pathway in mammary development and also supports our previous findings of adaptive 
immune system involvement in development using disparate statistical methods including 
discriminant analysis (Fig. 8; Tables 5-6) and k-means clustering (Fig. 7). It has been 
previously established that MHC Class II molecules are frequently expressed in colorectal 
and breast carcinoma tumors with expression suspected to occur in response to hormones 
and/or cytokines 608, but correlation with disease prognosis is unknown 609 and little is 
recognized regarding roles of HLA-DOA in tumor response 607. Although HLA-DOA is 
upregulated in B-Cell Lymphoma (BCL) 610,611, the mechanism is not elucidated and to our 
knowledge, no data exist supporting a role for this molecule in postnatal mammary gland 
development. Currently, it is believed that the role of immune cells in developmental 
processes is restricted to the innate immune system with the exception of lactation 88. This 
novel data suggests that both the innate and adaptive immune system have significant roles in 
developmental trends during the first two months of postnatal organogenesis. Additional 
immune system components are present in the top 25 positive PRC genes and will be 
subsequently discussed. 
 TRAF3 encodes a protein member of the TNF receptor associated factor (TRAF) 
family, an assembly of six proteins that mediate cellular signals through association with 
members of the TNF receptor (TNFR) superfamily 472. TRAF3 is the most obscure of the six 
and participates in a variety of signaling pathways in a range of cell types: it demonstrates 
critical roles in both B and T lymphocyte development, including B cell homeostasis, 
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development, and survival, isotype switching from IgM to IgG, B-cell malignancies, cytokine 
production, CD40 signal transduction, TLR activation, T cell function, thymocyte 
development, antiviral responses, Treg cell development, and NFkB/JNK activation  612. Its 
position in the top 25 positive PRC genes suggests one or more of these critical roles exists in 
early postnatal mammary development. TRAF3 may also be responsible for oncogenic 
consequences of several molecules, including the Epstein-Barr virus encoded latent infection 
membrane protein-1 (LMP1) 613. Importantly, TRAF3 has been found to promote 
ubiquitination and proteasomal degradation of MAP3K14 614, one of the important phase two 
genes found using all three DA methods (Fig. 8), suggesting functional cooperation between 
developmental genes discovered in our transcriptomic dataset using more than one 
multivariate technique. Mouse models demonstrated that TRAF3 is critical for development 
of the marginal zone (MZ) B cell subset as well as general B-cell homeostasis and survival 
through mediation of the NF-κB2 pathway 615–617. In addition to NF-κB2 activation, TRAF3 
is thought to act as a pro-apoptotic factor and/or restrain additional pro-survival pathways 
612,615–620. Mutations inducing loss of function are seen in TRAF genes of multiple myeloma 
and some types of B cell lymphoma, indicating it plays a negative regulatory role in B 
lymphocytes, commonly as a tumor suppressor 619,621–624. TRAF3 also regulates activity 
downstream of B cell receptors; it has been seen to negatively regulate CD40 and LMP1 
613,625, bind to members of the TNFR subfamily including BAFFR, BLyS, TALL-1, TAC1, 
and APRIL (reviewed in 45,626–629), and associate with CD120b/TNFR2 630. In TLRs, TRAF3 
has been shown to positively mediate antiviral TLR signals and IFN production in myeloid 
cell responses 631–633 while also functioning as a negative regulator of B cell TLR responses, 
including TLRs 3, 4, 7, and 9 634. More recently, TRAF3 has been shown to be required for 
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multiple stages of T cell development,  production of IgG1, T- cell function in vivo, Treg 
development, invariant natural killer T (iNKT) cell signaling 635, and TCR/CD28 mediated 
signaling 618; it could be involved in these developmental events of the adaptive immune 
system in our model.  TRAF expression by B and T lymphocytes and its function in these 
immune cell types indicates the versatility, criticality, and significance of this gene in cellular 
development, homeostasis, immune function, and apoptosis. It is suspected that TRAF3 may 
impact some or all of these processes during early postnatal mammary development, 
contributing to its role as a top 25 positive PRC gene. Importantly, its dual role as a negative 
regulator of TLR responses and positive regulator of myeloid responses places this gene in 
both innate and adaptive immune system categories, suggesting contributory activity of both 
systems during the first two months of postnatal mammary development.  
 HGF, hepatocyte growth factor, encodes a protein that binds to the hepatocyte growth 
factor receptor (HGFR) to regulate a wide range of processes, including cell growth, motility 
and morphogenesis in numerous cell and tissue types; additionally, it has roles in 
angiogenesis, tumorigenesis, tissue regeneration, and MET (HGFR) activation 472. As 
reviewed in Chapter one, the mammary gland is a dynamic tissue in which differentiation and 
apoptosis occur cyclically during early development, puberty, pregnancy, and lactation and 
most mammary branching and development occurs postnatally 22. Mammary epithelial cell 
migration, growth, and proliferation depends heavily on stromal and ECM signals that 
support mammary gland morphogenesis 4. HGF, produced by mesenchymal cells/mammary 
fibroblasts 636, provides these specific signals that mainly influence cells of epithelial origin, 
acting as a paracrine mediator of epithelial interactions 636,637. HGF potentially functions as a 
paracrine mediator of mammary epithelial cell signaling and interaction in our early postnatal 
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mammary development model since the gene and its cellular receptor are carefully 
temporally regulated during mammary development to support ductal branching, 
invasiveness, and epithelial cell motility 638. The receptor, a unique transmembrane tyrosine 
kinase, is expressed in surrounding mesenchyme during development; importantly, it is also a 
product of the c-met proto-oncogene expressed in epithelial cells, providing a mechanism for 
EMT processes during development 639. In mature tissue types, c-met functions in wound 
healing and tissue regeneration 640–642; c -met and HGF are expressed in mesenchymal stem 
cells, suggesting involvement in hematopoiesis 643. The presence of HGF, and theoretically 
its receptor, suggests involvement of EMT processes during postnatal mammary gland 
development. It is widely accepted that this naturally occurring cytokine plays a significant 
role in murine 644–646 and chick embryogenesis 647–649 collaborating with the multifunctional 
cytokine, TGF-β 1-3, to  promote ductal morphogenesis. Interestingly, HGF is mitogenic for 
luminal cells but not myoepithelial cells and morphogenic to myoepithelial cells but not 
luminal cells 636,644,650. This suggests c-met/HGF signaling can control the function of luminal 
progenitors and modulate their fate during mammary development 651 and provides another 
possible role for the molecule in our model. Pursuant to our research focus, it has been shown 
in vitro that ductal morphogenesis induced by HGF is dependent on functional β1 integrin 
molecules 143. The involvement of integrin molecules in normal mammary development and 
TNBC have been reviewed in Chapters 1 and 2. Especially interesting is the finding that β4 
integrin can be activated through phosphorylation by the c-met receptor for HGF, which 
subsequently recruits the tyrosine phosphatase Shp2 and Src in order to signal through the 
Ras–ERK cascade 652,653. HGF/c-met represent a novel signaling pathway that connects β4 
integrin to ERK activation in the mammary gland 653 and the presence of HGF in the top 25 
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positive PRC genes confirms our suspicion of significant β4 integrin involvement and EMT 
in early postnatal mammary development. From Chapter one, it is recalled that breast cancer, 
metastasis, invasion, and progression require epithelial cells to enhance their normal growth 
and survival capability. Frequently, deregulated HGF/c-met signaling is observed in cancer 
with c-met, β4, and Src all commonly overexpressed (and coexpressed) 413,654,655. 
Constitutively active Src can upregulate HGF in breast carcinoma cells, promoting 
tumorigenesis 656. Also in breast cancer, c-met and PIK3CA mutations are frequent- 
dysregulation of c-met and PI3K significantly increased cell proliferation and invasion in 
vitro and in vivo, suggesting that response to MET-targeted therapy is dependent on an 
aberrant MET-HGF/PI3K axis 657. HGF/c-met signaling has recently been associated recently 
with specifically basal type breast cancers/TNBC, with mutations occuring in progenitor cells 
in the luminal mammary epithelium 658,659. C-met overexpression has been associated with 
BRCA1 mutated tumors in a mouse model where BRCA1 and p53 were deleted in the 
mammary epithelium 660; taken together, these above findings suggest functional cooperation 
between HGF/c-met, β4, and Src in order to advance cell survival and metastasis which raises 
the question of similar cooperation in early mammary development. Most of this information 
on HGF signal transduction has been derived in vitro, however, and has not been extrapolated 
to, or confirmed in the mammary gland in vivo 639 (and if it is, murine models are used). 
Swine models have not been frequently used to investigate functions of any of these genes in 
early postnatal development, adding further novelty to the approach.  
 SOX13, SRY-related HMG-box 13, encodes a member of the sox family of 
transcription factors, which are well-established regulators of developmental cell fate 
decisions that have roles in tissue homeostasis and regeneration and are also dysregulated in 
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cancers 661–663. The role of SOX13, however, is mostly undefined 661 and this gene is one of 
the lesser characterized positive PRC genes in our dataset. However, it has been identified as 
a gammadelta T-cell specific gene in the immune system- promoting development of this 
type of T-cell while opposing αβ differentiation, potentially through inhibition of signaling 
by Wnt/T cell factor (TCF) pathway  664.  
 In addition to immune involvement, protection of cells from DNA damage or 
dysfunction is critical in development and genes of this nature present in the top 25 positive 
PRC set. PINK1, PTEN induced putative kinase 1, also known as PARK6, is a highly-
conserved Parkinson’s disease-susceptibility gene whose product protects cells from 
mitochondrial dysfunction induced by stress and eradicates damaged mitochondria through 
mitophagy 665–668. PINK1 is induced by the tumor suppressor PTEN 669, a significant 
component of the PI3K/AKT pathway subject to mutations 255 PI3K/AKT and one of the 
most frequently mutated genes in breast cancer 337,670. In parallel with the discovery that 
PINK1 is induced by PTEN, increased expression of this gene was exposed in metastatic 
murine cancer cell lines 671 and loss of function mutations were discovered in several forms 
of Parkinson’s disease 672. Extensive Parkinson’s research has shown that signaling through 
PINK1 controls several other processes along with normal function in mitochondrial 
homeostasis and dynamics 673,674, including PI3K/AKT signaling, chemoresistance, and 
regulation of apoptosis in cancer cells 675. The gene has been reported to promote contrasting 
oncogenic and tumor suppressor properties 665,669,673,676–682, largely through activation of the 
PI3K/AKT/mTORC signaling pathways 675,680,681. As mentioned in Chapter 1, AKT signaling 
activates FOXO transcription factors that subsequently inhibit cyclin D1 expression and 
promote the cell cycle regulators p27kip1 and p130Rb2 259. When phosphorylated by AKT, 
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FOXO is inactive and supports cyclin D1 expression while inhibiting expression of cell cycle 
inhibitors. One specific FOXO, FOXO3a, is the only transcription factor to date shown to 
regulate PINK1 during nutrient deprivation or chemotherapeutic stress, promoting cell 
survival 683. FOXO3a can also promote production of MMPs in support of tumorigenesis and 
invasiveness 684; signaling during early mammary development also heavily relies on MMPs 
for expansion of the gland, suggesting in our model, PINK and FOXOs could collaborate to 
regulate gland expansion through MMP production. It is hypothesized that PINK1 may be 
activated by FOXO3a under nutrient deprivation as a form of short-term protection so that 
when stress if lifted, the system is ready to resume PI3K/AKT signaling 675. Additionally, 
PINK1 loss increases the susceptibility of cells to DNA damage 685, and in parallel with the 
major functional links of this gene and PI3K/AKT signaling needed for growth and survival, 
it can be hypothesized that PINK1 protects actively proliferating cells during early mammary 
development. PINK1, mitochondrial homeostasis, and cancer has been reviewed in depth by 
O’Flanagan et al 675, who showed that PINK1 is critical for cell cycle progression, G2/M and 
G0/G1 checkpoints, cell division, growth, and stress resistance in cancer 686. Importantly, 
PINK1 presents a tissue specific location in epithelial tissues 687, suggesting it probably 
functions to protect and regulate mammary epithelial cells in the postnatal mammary gland. 
This data confirms PINK1 highly contributes as a positive PRC gene to mammary growth in 
the first two months after birth and suggests PINK1 is localized in mammary epithelial cells 
where it plays similar roles in stress resistance reported in the literature.  
 Another protective gene that positively contributes to developmental trends in the 
model is DDIT3. DDIT3, DNA damage induced transcript 3, encodes a regulator of the 
cellular stress response and is induced upon DNA damage, ER stress, hypoxia, and 
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starvation, triggering either apoptosis or cell cycle arrest 472,688–708. DDIT3 is also involved in 
differentiation and specialization of varied tissue and cell types 709–713 and is versatile; it can 
be expressed either in the cytoplasm or nucleus with distinct functions 688,714. Nuclear DDIT3 
controls cellular growth and can induce G1 cell cycle arrest if needed 715 while cytoplasmic 
DDIT3 mainly inhibits migration 716. Pursuant to our developmental model, DDIT3 is 
expressed during early embryogenesis 717 and functions as a protective Wnt repressor, 
inhibiting Wnt/T-cell factor (TCF) signaling 718. It also plays a role in accumulation and 
immune system regulation of tumor suppressor cells derived from myeloid cells 719. DDIT3 
expression can block T cell responses 719, suggesting involvement in tumor-induced tolerance 
and resistance to immunotherapy. Our data suggest it has a significant, although complicated 
and unelucidated, role in early postnatal mammary development. 
 Positive PRC genes also fall into another prominent functional group with interesting 
roles in cell adhesion, adherens junctions, and cellular migration. In Chapter one, it is 
described how through basally located integrin molecules and laminins, direct attachment of 
mammary epithelial cells to the ECM can occur 138,139. Laminin-binding integrin molecules 
commonly are found in focal adhesions (FAs) and HDs, which are two adhesion complexes 
that form mechanical links between the ECM and the actomyosin cytoskeleton 140. Linking 
the ECM and the cytoskeleton is critical in regulation of a variety of processes, including 
proliferation and differentiation, and multiple supporting genes are found in the top 25 
positive PRC dataset. With a significant weight, DOCK4, Dedicator of cytokinesis protein 4 
is detected in our early mammary development model. This gene encodes a membrane-
associated, cytoplasmic protein that activates Rap GTPase in order to regulate formation of 
adherens junctions between cells and also functions in cell migration 720–724. In MDA-MB-
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231 TNBC cells, DOCK4 interacts with SH3 and SYLF domain containing protein 1 
(SH3YL1) to promote cancer cell migration 720. L1CAM, neural cell adhesion molecule L1,  
also encodes a cell adhesion protein with both a functional role in cell migration and nervous 
system development through axonin binding 472,725 and a metastatic role in the progression of 
human tumors 726. L1CAM can bind homophilically to itself or heterophilically to other cell 
adhesion molecules or integrin molecules 727, leading to two disparate functions: static, acting 
as an adhesion molecule between cells (normally in neural settings), and motile, promoting 
cell migration 728,729. The functional switch occurs when the L1CAM ectodomain is cleaved 
and free to bind integrin molecules 730. This subsequently promotes cell migration 731,732, 
resistance to apoptosis 733–735, and angiogenesis 736. Recently, studies have shown that 
L1CAM cleaved by MMPs can heterophilically bind to integrin molecules 737–740 and activate 
signaling pathways including PI3K, Rac-1, and ERK 730,741–744. Taken together, several recent 
studies suggest that L1CAM/integrin signaling can converge with growth factor signaling 
pathways, activate conventional ERK/PI3K signaling, and promote growth and development 
728,729. LICAM’s presence as a top 25 positive PRC gene demonstrates potential for a similar 
function in postnatal mammary development. L1CAM is also important in human cancers, 
appearing overexpressed in ovarian and endometrial carcinoma (EC), pancreatic ductal 
adenocarcinoma (PDAC), melanoma, and glioblastoma where it is associated with poor 
prognosis through a highly motile and invasive phenotype (reviewed 745). As an oncogene, 
L1CAM expression can induce constitutive activation of NFκB activation through IL-1β 
746,747. Interestingly, it can also indicate and promote EMT transition at the primary tumor 
site; mesenchymal tumor cell phenotypes exude high levels of vimentin, SLUG and L1CAM 
733,748. L1CAM expression in human breast cancer cell lines results in disruption adherens 
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junctions, increased β-catenin transcription, and high motility at the leading edge of cell 
monolayers 748–750 while L1CAM knockdown significantly decreases cell motility 748, 
suggesting this gene is an EMT trigger in epithelial cells. In Chapter one, it was presented 
how the ECM and stroma, including growth factors, cytokines and proteinases within these 
niches, have long been known for morphogenesis 72. Not only are ECM-cell interactions, 
adherens junction regulation, EMT, and cell migration essential for development of a 
functional mammary gland 7,73, these also play important roles in breast cancer development 
(reviewed by 74–78. Current research indicates branching morphogenesis of the mammary 
gland is controlled by interacting epithelial and mesenchymal cell populations, and cell-
cell/cell-matrix adhesions, but that this crosstalk is not comprehensively understood 79. Our 
presentation and characterization of positively influencing PRC genes in development, such 
as L1CAM, suggest previously unrealized potential roles for these molecules in postnatal 
mammary development. Taken together, the studies discussed above illustrate a relationship 
between immune cell activation, the ECM, TME, integrin molecules, cell migration, and 
L1CAM. If LICAM can induce IL-1B secretion by immune cells, it could promote 
tumorigenicity and/or inflammation. A review of the literature combined with this novel 
transcriptomic data confirming that L1CAM is one of the highest weighted genes impacting 
the PRC curve suggests this gene is functioning in early postnatal mammary development in 
conjunction with integrin molecules and laminins to promote mammary organogenesis. 
 FRMD4A, FERM domain-containing 4A (FRMD4A), is a human epidermal stem 
cell marker 751 encoding a protein that regulates epithelial cell polarity 752. FRMD4A belongs 
to the Four-point-one, Ezrin, Radixin, Moesin  (FERM) superfamily, whose members all 
contain a FERM domain 753–755. FERM domains have been shown to possess functional roles 
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in cytoskeleton organization and structure, tissue development, maintenance of cell 
morphology, cell signaling, and tumor cell migration 754,756–760.  Specifically, FRMD4A has 
been shown to control cytoskeleton protein expression and mediate the assembly of adherens 
junctions between mammary epithelial cells, essential to tissue morphogenesis, through the 
activation of a central player in actin cytoskeleton dynamics: ADP ribosylation factor 6 
(Arf6) 752.  FRMD4A has also been found upregulated in squamous cell carcinoma (SCC) 
cells, especially head and neck squamous cell carcinoma (HNSCC) 751, and rectal cancer 761, 
while FRMD4A silencing  in vitro stimulates caspase activity and expression of terminal 
differentiation markers 762. This data shows significant impact on mammary development 
through FRMD4A signaling, suggesting this gene potentially supports organization of the 
cytoskeleton and maintenance of mammary tissue morphology.  
 STARD8, START domain protein 8, also known as deleted in liver cancer 3 (DLC-
3), encodes a member of the Rho GTPase protein family 763. This protein is widely expressed 
in normal tissues but downregulated or absent in various cancers including breast cancer 764, 
suggesting it functions as a tumor suppressor. Importantly, STARD8 protein localizes to 
adherens junctions and is essential for E-cadherin function and maintaining epithelial cell–
cell contacts; deletion leads to leads to mislocalization of E-cadherin and disruption of 
adherens junctions and catenin molecules, impaired cell aggregation, and increased migration 
763,765,766. STARD8/DCL3 is best characterized as a novel negative regulator of Rho signaling 
that can promote carcinogenesis by compromising epithelial cell integrity 763. Taken together 
with the data showing STARD8 positively contributes to early postnatal mammary 
development, it may function through potential maintenance/protection of mammary 
epithelial cell integrity.  
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 LIMS2, LIM Zinc Finger Domain Containing 2, also more commonly known as 
PINCH2 (Particularly Interesting New Cys-His Protein 2) 767, is an important focal adhesion 
and/or nuclear protein which interacts with ILK (integrin-linked kinase) to mediate 
extracellular matrix adhesions 767. Importantly, LIMS2 can link integrin molecules to the 
actin cytoskeleton, activate Rac signaling, and create connections to cell surface RTKs and 
growth factor receptors, and promote mammary epithelial cell differentiation and migration 
768–771. Zhang et al characterized LIMS2/PINCH-2 in depth and novelly demonstrated that: 
PINCH-2 is co-expressed with PINCH-1 (another member of the PINCH family) in a variety 
of human cells; PINCH-2 localizes to both cell-ECM contact sites and the nucleus; PINCH-2 
forms a complex with ILK in mammalian cells; the PINCH-2 LIM1 domain, which mediates 
the association with ILK, is required for the localization of PINCH-2 to cell-ECM contact 
sites; overexpression of PINCH-2 inhibits the PINCH-1-ILK interaction and reduces cell 
spreading and migration 767. Taken together with the PRC analysis and denotation of this 
gene as highly positive, a potential role is suggested for PINCH-2/LIMS2 in postnatal 
mammary epithelial cell differentiation, migration, and adhesion.  
 Lesser characterized genes that are still significant in development are UBXN1 and 
SOX13. UBXN1, UBX domain-containing protein 1, is a ubiquitin-binding protein that 
recognizes autoubiquinated BRCA1 772. As covered in Chapter 1, one of the most important 
and well known mutations of TNBC and basal-like breast cancer is that of the 
BRCA1/BRCA2 genes and associated pathways 228–230. E3 ligase activity of the BRCA1 
complex is dramatically reduced in the presence of UBXN1, suggesting that UBXN1 
regulates the enzymatic function of BRCA1 772. UBXN1 is also a negative regulator of NFkB 
activity 773, but most of the mechanism of its function remains to be elucidated. Our data 
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suggest it highly contributes to normal mammary development, possibly as a tumor 
suppressor or regulatory element. Only just characterized in 2013, the novel F-box and 
WD40 containing protein, FBXW4, is part of a ubiquitin ligase complex with SKP1–cullin 
1–F-box protein (SCF), highly expressed in mammary gland involution, and may function as 
a novel tumor suppressor that regulates developmental processes and maintains normal cell 
growth 774.  F-Box proteins (FBPs) are responsible for ubiquitination of proteins with varied 
cellular function and can also regulate the expression and activity of oncogenes and tumor 
suppressor genes 775. However, very little is known regarding the function of FBXW4 in 
general 774, especially in mammary development; a better understanding is needed for how 
this gene may regulate critical cell signaling pathways. This data suggests it highly 
contributes to normal mammary development, possibly as a tumor suppressor or regulatory 
element. 
 Taken together, PRC analysis (Tables 7-9; Fig. 9) indicated that development and 
maturation of the mammary gland during the first 39 days after birth heavily relies on the 
immune system, immune components, integrin molecules, and the ECM, utilizing genes 
known to function in development and previously uncharacterized, novel genes that are also 
likely to function as oncogenes or proto-oncogenes. This novel data also confirms the trends 
seen in phase one vs. phase two genes from DFA; positive PRC genes have similar functions 
to phase two DFA genes and represent more refined, advanced growth and differentiation 
rather than a spurt of initial unregulated growth immediately after birth. Additionally, many 
positive PRC genes have reported links with adherens junctions, cellular migration, the ECM, 
and apoptosis, indicating the contribution of stromal and extracellular factors in 
differentiation that were not seen in phase one DFA. As seen in Table 8, the hypothesis has 
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been confirmed that phase two and positive PRC genes represent refined development and 
differentiation, while phase one and negative PRC genes function for generic biosynthesis 
and growth.  
 
Table 7: PRC positive weights 
Ranking PRC Weight Gene ID Family/Subfamily 
1 0.51559019 SLA-DOA HLA CLASS II HISTOCOMPATIBILITY 
ANTIGEN, DO Α CHAIN (PTHR19944:SF67) 
2 0.515449036 PINK1 SERINE/THREONINE-PROTEIN KINASE 
PINK1, MITOCHONDRIAL 
(PTHR22972:SF11) 
3 0.495199325 EFCC1 EF-HAND AND COILED-COIL DOMAIN-
CONTAINING PROTEIN 1-RELATED 
(PTHR11595:SF36) 
4 0.489631223 SNAPIN SNARE-ASSOCIATED PROTEIN SNAPIN 
(PTHR31305:SF3) 
5 0.461953857 DOCK4 DEDICATOR OF CYTOKINESIS PROTEIN 4 
(PTHR23317:SF89) 
6 0.454108222 ZNF613 ZINC FINGER PROTEIN 613 
(PTHR24404:SF49) 
7 0.443115828 GALNT15 POLYPEPTIDE N-
ACETYLGALACTOSAMINYLTRANSFERA
SE 15 (PTHR11675:SF77) 
8 0.422306462 L1CAM NEURAL CELL ADHESION MOLECULE L1 
(PTHR10489:SF812) 
9 0.416458647 FRMD4A FERM DOMAIN-CONTAINING PROTEIN 
4A (PTHR23281:SF29) 
10 0.412167164 STARD8 STAR-RELATED LIPID TRANSFER 
PROTEIN 8 (PTHR12659:SF11) 
11 0.410868587 ZNF174 ZINC FINGER PROTEIN 174 
(PTHR10032:SF270) 
12 0.404149309 PDE2A 3',5'-CYCLIC PHOSPHODIESTERASE PDE-
2-RELATED (PTHR11347:SF164) 
13 0.393960511 VLDLR VERY LOW-DENSITY LIPOPROTEIN 
RECEPTOR (PTHR10529:SF318) 
14 0.391076702 MPND MPN DOMAIN-CONTAINING PROTEIN 
(PTHR12802:SF80) 
15 0.381996691 SOX13 TRANSCRIPTION FACTOR SOX-13 
(PTHR10270:SF273) 
16 0.381912433 LIMS2 LIM AND SENESCENT CELL ANTIGEN-




17 0.381038717 UBXN1 UBX DOMAIN-CONTAINING PROTEIN 1 
(PTHR13020:SF47) 
18 0.380960327 DDIT3 DNA DAMAGE-INDUCIBLE TRANSCRIPT 
3 PROTEIN (PTHR16833:SF1) 
19 0.380488353 TRIM3 TRIPARTITE MOTIF-CONTAINING 
PROTEIN 3 (PTHR24103:SF458) 
20 0.379222784 FBXW4 F-BOX/WD REPEAT-CONTAINING 
PROTEIN 4 (PTHR14381:SF2) 
21 0.379074354 HGF HEPATOCYTE GROWTH FACTOR 
(PTHR24256:SF291) 
22 0.378892532 DMAP1 DNA METHYLTRANSFERASE 1-
ASSOCIATED PROTEIN 1 
(PTHR12855:SF11) 





25 0.363138248 LHX6 LIM/HOMEOBOX PROTEIN LHX6 
(PTHR24208:SF148) 
26 0.356873254 RGS18 REGULATOR OF G-PROTEIN SIGNALING 
18 (PTHR10845:SF226) 
27 0.356526442 CTIF CBP80/20-DEPENDENT TRANSLATION 




29 0.354164393 C1QTNF9 COMPLEMENT C1Q AND TUMOR 
NECROSIS FACTOR-RELATED PROTEIN 
9A-RELATED (PTHR24023:SF654) 
30 0.352729291 GNLY GRANULYSIN (PTHR15541:SF3) 
31 0.352600564 PPFIA1 LIPRIN-Α-1 (PTHR12587:SF27) 
32 0.350038204 RNF31 E3 UBIQUITIN-PROTEIN LIGASE RNF31 
(PTHR16004:SF6) 
33 0.349655753 FLI1  
34 0.349297781 A4GALT LACTOSYLCERAMIDE 4-Α-
GALACTOSYLTRANSFERASE 
(PTHR12042:SF27) 
35 0.347687199 CCDC28A COILED-COIL DOMAIN-CONTAINING 
PROTEIN 28A (PTHR13400:SF5) 
36 0.347099383 GPANK1 G PATCH DOMAIN AND ANKYRIN 
REPEAT-CONTAINING PROTEIN 1 
(PTHR20923:SF2) 
37 0.346498169 CCDC130 COILED-COIL DOMAIN-CONTAINING 
PROTEIN 130 (PTHR12111:SF5) 
38 0.341624683 CEP95 CENTROSOMAL PROTEIN OF 95 KDA 
(PTHR22545:SF1) 
39 0.341619986 CTSF CATHEPSIN F (PTHR12411:SF425) 




41 0.337943464 HMCN2 HEMICENTIN-2 (PTHR10489:SF755) 
42 0.337929917 MID2 E3 UBIQUITIN-PROTEIN LIGASE MID2-
RELATED (PTHR24103:SF450) 
43 0.336405962 ABLIM3 ACTIN-BINDING LIM PROTEIN 3 
(PTHR24213:SF24) 
44 0.334111451 CUX1 HOMEOBOX PROTEIN CUT-LIKE 1 
(PTHR14043:SF18) 
45 0.333882104 TCTP TRANSLATIONALLY-CONTROLLED 
TUMOR PROTEIN (PTHR11991:SF7) 
46 0.333209584 KCNB1 POTASSIUM VOLTAGE-GATED CHANNEL 
SUBFAMILY B MEMBER 1 
(PTHR11537:SF177) 
47 0.332306307 PTPRM RECEPTOR-TYPE TYROSINE-PROTEIN 
PHOSPHATASE MU (PTHR19134:SF391) 
48 0.331268784 CUX1 HOMEOBOX PROTEIN CUT-LIKE 1 
(PTHR14043:SF18) 
49 0.33121179 ANKRD24 ANKYRIN REPEAT DOMAIN-CONTAINING 
PROTEIN 24 (PTHR24173:SF53) 
50 0.329721287 PBLD PHENAZINE BIOSYNTHESIS-LIKE 
DOMAIN-CONTAINING PROTEIN 
(PTHR13774:SF23) 
51 0.328474016 FADS3 FATTY ACID DESATURASE 3 
(PTHR19353:SF39) 
 
Table 8: PRC negative weights 
Ranking PRC Weight Gene ID Family/Subfamily 
1 -0.755312569 CENPU CENTROMERE PROTEIN U 
(PTHR32222:SF2) 
2 -0.687764094 TIMM8A  
3 -0.678439898 CCNE2 G1/S-SPECIFIC CYCLIN-E2 
(PTHR10177:SF330) 
4 -0.650314355 NPM3 NUCLEOPLASMIN-3 (PTHR22747:SF24) 
5 -0.646226192 MYBL2 MYB-RELATED PROTEIN B 
(PTHR10641:SF744) 
6 -0.642932862 RNFT1 RING FINGER AND TRANSMEMBRANE 
DOMAIN-CONTAINING PROTEIN 1 
(PTHR15860:SF10) 
7 -0.630912134 TTC27 TETRATRICOPEPTIDE REPEAT PROTEIN 
27 (PTHR16193:SF1) 
8 -0.629593806 GAR1 H/ACA RIBONUCLEOPROTEIN 
COMPLEX SUBUNIT 1 (PTHR23237:SF9) 
9 -0.628766562 DONSON PROTEIN DOWNSTREAM NEIGHBOR OF 
SON (PTHR12972:SF1) 




11 -0.61727193 CCNE1 G1/S-SPECIFIC CYCLIN-E1 
(PTHR10177:SF288) 
12 -0.612904564 NEDD1 PROTEIN NEDD1 (PTHR22847:SF508) 
13 -0.609914388 CIT  
14 -0.608331544 WDR12 RIBOSOME BIOGENESIS PROTEIN 
WDR12 (PTHR19855:SF13) 
15 -0.606545954 DESI1 DESUMOYLATING ISOPEPTIDASE 1 
(PTHR12378:SF23) 
16 -0.601177154 NUDCD2 NUDC DOMAIN-CONTAINING PROTEIN 
2 (PTHR12356:SF22) 
17 -0.598877627 FAM64A PROTEIN FAM64A (PTHR35819:SF2) 
18 -0.595805113 GALE UDP-GLUCOSE 4-EPIMERASE 
(PTHR43725:SF5) 
19 -0.593420751 ABT1 ACTIVATOR OF BASAL 
TRANSCRIPTION 1 (PTHR12311:SF8) 
20 -0.59256649 KCNE5 POTASSIUM VOLTAGE-GATED 
CHANNEL SUBFAMILY E REGULATORY 
Β SUBUNIT 5 (PTHR15282:SF14) 
21 -0.592304891 CDKN2C CYCLIN-DEPENDENT KINASE 4 
INHIBITOR C (PTHR24148:SF54) 
22 -0.586226873 LOC102167061  
23 -0.583969995 PRELID3B PROTEIN SLOWMO HOMOLOG 2 
(PTHR11158:SF37) 
24 -0.581429846 CTPS1 CTP SYNTHASE 1 (PTHR11550:SF16) 
25 -0.578118522 DOHH DEOXYHYPUSINE HYDROXYLASE 
(PTHR12697:SF23) 
26 -0.576783145 ERCC6L DNA EXCISION REPAIR PROTEIN ERCC-
6-LIKE (PTHR10799:SF911) 
27 -0.572198441 CENPK CENTROMERE PROTEIN K 
(PTHR14401:SF7) 
28 -0.571350974 DUSP11  








31 -0.565106896 WDR74 WD REPEAT-CONTAINING PROTEIN 74 
(PTHR16038:SF5) 
32 -0.562372872 RABGGTB GERANYLGERANYL TRANSFERASE 
TYPE-2 SUBUNIT Β (PTHR11774:SF13) 
33 -0.560353639 MPHOSPH6 M-PHASE PHOSPHOPROTEIN 6 
(PTHR13582:SF1) 
34 -0.559254552 RNFT1 RING FINGER AND TRANSMEMBRANE 
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DOMAIN-CONTAINING PROTEIN 1 
(PTHR15860:SF10) 
35 -0.557948831 RRP8 RIBOSOMAL RNA-PROCESSING 
PROTEIN 8 (PTHR12787:SF1) 
36 -0.551866159 PRELID3B PROTEIN SLOWMO HOMOLOG 2 
(PTHR11158:SF37) 
37 -0.549404483 BUB1 MITOTIC CHECKPOINT 
SERINE/THREONINE-PROTEIN KINASE 
BUB1 (PTHR14030:SF10) 
38 -0.548547924 CYP26B1 CYTOCHROME P450 26B1 
(PTHR24286:SF101) 
39 -0.546993466 BCHE CHOLINESTERASE (PTHR11559:SF337) 
40 -0.545884312 MPLKIP M-PHASE-SPECIFIC PLK1-INTERACTING 
PROTEIN (PTHR22446:SF4) 
41 -0.545783381 LOC106509864  
42 -0.545548898 INCENP INNER CENTROMERE PROTEIN 
(PTHR13142:SF2) 
43 -0.54113617 MINPP1 MULTIPLE INOSITOL POLYPHOSPHATE 
PHOSPHATASE 1 (PTHR20963:SF31) 
44 -0.540628807 NQO1 NAD(P)H DEHYDROGENASE [QUINONE] 
1 (PTHR10204:SF49) 
45 -0.537488756 CSRNP1 CYSTEINE/SERINE-RICH NUCLEAR 
PROTEIN 1 (PTHR13580:SF16) 
46 -0.536682609 ANP32A ACIDIC LEUCINE-RICH NUCLEAR 
PHOSPHOPROTEIN 32 FAMILY MEMBER 
A-RELATED (PTHR11375:SF9) 
47 -0.536194601 UBE2T UBIQUITIN-CONJUGATING ENZYME E2 
T (PTHR24067:SF205) 
48 -0.535012107 ADAMTS4 A DISINTEGRIN AND 
METALLOPROTEINASE WITH 
THROMBOSPONDIN MOTIFS 4 
(PTHR13723:SF205) 
49 -0.533396073 AMD1 S-ADENOSYLMETHIONINE 
DECARBOXYLASE PROENZYME 
(PTHR11570:SF8) 
50 -0.531299615 C2H11orf31  
 
 
Table 9: Summary of PRC trends 
  Negative weight (red) Positive weight (green) 
Trend Decrease with curve 
abundance 
Increase with curve 
abundance 

























































Hypothesis These are phase one 
genes (very early 
genes) 






Cell Cycle, Mitotic Immune System 
Cell Cycle Metabolism of proteins 
Metabolism Signal Transduction 
Metabolism of proteins Adaptive Immune System 
Signal Transduction Cytokine Signaling in 
Immune system 
RHO GTPase Effectors Post-translational protein 
modification 









  Interleukin-4 and 13 
signaling 
  Signaling by Interleukins 







Organelle biosynthesis Immune function 
Transcription and gene 
expression 
Stem cell signaling 
Cell control: cycle, 
division, survival 
Antigen presentation, stress 
protection, inflammation 




DNA elongation and 
amplification 
Organelle biogenesis, cell 
fate regulation 
CDK interactions Integrin signaling- NFkB, 
Wnt, MAPK, AKT pathways 
Molecular chaperoning Migration/adhesion/epithelial 
and mesenchymal cell 
polarity and morphology 
  Focal adhesions, adherens 
junctions, and ECM 
  Cell spreading 
Oncogene 
function 
22% are potential 
oncogenes 















  FLI1 
  CTSF 
  CUX1 
  TCTP 
  PTPRM 
  SLA-DOA 
  SNAPIN 
  PDE2A 
  VLDLR 
  SOX13 
  LIMS2 
  UBXN1 
  DDIT3 
  FBXW4 
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  DMAP1 
  C1QTNF9 
  CCDC28A 
  HMCN2 
  MID2 
  KCNB1 
  PBLD 
 
 
WGCNA demonstrates functional modules in early mammary gland development 
Weighted Gene Co-Expression Network Analysis visualized the clustered 
connectivity of the top 5000 genes, by variance, with a similar expression pattern, resulting in 
functional modules which will be further explained in a pathway analysis (see Fig. 10). The 
diagonal line represents the autocorrelation between the gene to itself, resulting in a 
correlation value of 1 (perfect correlation). The distinct boxes that form around the diagonal 
line represent the functional modules that contain highly interconnected genes, by 
correlation, to other genes within the same module. Modules farther away from the diagonal 
represent inter-module relationships (connected pathways, or one pathway regulating 
another). Weighting has been used to adjust the correlation matrix such that only the 
strongest of correlations are depicted. Systems biology approaches can be applied to the 
RNA-seq data sets to identify groups of genes that are highly correlated (in this case, over 
time) to form functional modules; WGCNA exists as a popular method to do so since its 
introduction in 2005.The WGCNA method assumes that genes that are co-expressed with 
similar variances over time are present in the same subsystem and is appropriate for use here 




subsystems that were clustered based on co-variation within groups of genes (across 
all 17 samples). GCN can be used to simulate functional significance for groups of genes; 
tightly correlated gene groups can be thought of as one functional unit and related to 
Figure 10: WGCNA demonstrates functional modules in early mammary gland 
development. Heatmap plot of the top 5000 genes by variance; diagonal line 
represents the autocorrelation between the gene to itself; distinct boxes around 
diagonal line represent functional modules that contain highly interconnected 




phenotype 781. This pipeline has been used recently to: generate functional conclusions about 
signaling pathways underlying familial breast cancer susceptibility 782, identify prognostic 
biomarkers tumor state based on stromal gene expression 788, and identify modular 
heterogeneity of breast cancer subtypes 789. Based on a review of literature wherein WGCNA 
methods were applied to RNA-seq datasets, we concluded this method can be used in our 
study to identify highly correlated groups of genes with functional roles in early 
postnatal/prepubertal mammary gland development. Fig. 10 confirms the hypothesis that 
there are genuine functional modules (shown in red/orange) present within the overall RNA-
seq dataset generated from samples collected during pre-pubertal mammary gland 
development. These functional modules can be further dissected using the MCODE 
algorithm and pathway analysis.  
 
MCODE algorithm identifies highly correlated gene networks within RNA-seq dataset. 
 
MCODE, shown in Fig. 11, shows functional modules that have been isolated from 
WGCNA and filtered to exclude weak relationships. The ten highest weighted network 
modules are shown in Fig. 12 and summarized in Table 10. These modules can be further 
characterized using functional and pathway analysis to determine biological significance in 
early postnatal mammary development.  
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After suspected functional modules were identified in Fig. 10, the MCODE algorithm 
was used as a Cytoscape 429,790 plug-in to find highly interconnected molecular clusters and 
remove those with low connectivity from the original plot using the random matrix theory 791. 
MCODE identifies densely connected nodes to graphically display both nodules and 
associated weights, which can be used to sort the relationships 792, and is commonly used in 
cancer biology. The genes contributing to each functional module can be extracted as a base 
for pathway analysis and biological interpretation. Although utilized frequently in the past 
year to identify biomarkers in colorectal cancer 793 and head and neck squamous cell 
Figure 11: MCODE algorithm identifies highly correlated gene networks within 
mammary transcriptome dataset.  
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carcinoma 794, as well as attempt to isolate biomarkers and gene networks involved in breast 
cancer 795–797,  to our knowledge, MCODE has not yet been applied to developmental 
mammary biology. 
 
Functional annotation of MCODE clusters  demonstrates biological significance  
After MCODE identified densely connected nodes to graphically display both 
nodules and associated weights (Fig. 11), which can be used to sort the relationships 792, the 
genes contributing to each functional module were extracted for pathway analysis and 
biological interpretation. The top ten network modules, sorted by weight, are shown below. 
 
Table 10. Functional roles of top ten network modules 
	
Cluster Score Function 
1 26.25 1. Striated muscle contraction and actin cytoskeleton integrity. Focused 
around the activity of titin (TTN). Most factors can be found in different 
domains of muscle. Two oncogenes: TTN and EEFIA. Largest cluster. Can put 
together good signaling pathway of interactions in muscle 
development/contraction.  
2 7.684 2. Oncogenic cluster. Adopogenesis, adipocyte metabolism, immune 
function, and metabolic alterations in cancer. Involves 
AKT/Laminin/FOXO/apoptosis. FAH has a functional link with BRCA. >50% 
genes in network are oncogenes. Need to design own pathway of normal vs 
oncogenic interactions. Tissue co-expression could be important in the story 
here. Interesting interaction with the innate immune system (see Cluster 2 tab).  
3 7.417 3. Lipid and protein metabolism + cell cycle control. Common protein 
interaction: UBC. Definitely an oncogenic cluster.  
4 6 4. Keratinocyte differentiation during development. Epithelial markers. Not 
very oncogenic. Could play a role in melanoma and HPV.  
5 5.667 5. Keratinization and differentiation; oncogenic cluster. Contains markers 
for breast cancer among other types. Specifically contains markers for basal 
breast cancer and EMT.  
6 5.6 6. Muscle contraction. Low oncogenic potential, except a couple genes 
interact with BRCA1/BRCA2.  
7 5.2 7. Muscle contraction/actin binding + calcium signaling. Low oncogenic 
potential.  
8 4.75 8. Protein modification + cell-cell adhesion. Seems to have a neuronal 
connection. Mixed bag of genes; >50% of them are oncogenes. Potential 
oncogenic cluster with some laminin/integrin interactions.  
9 4.286 9. Muscle contraction and actin binding. Low oncogenic potential; contains 
several repeats from other clusters.  
10 4 10. Metabolism. Genes do not interact clearly with eachother. Some immune 
factors, muscle factors. Low oncogenic potential.  
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Table 10 shows functional roles based on review of literature, Panther characterization, and 
Reactome pathway analysis for the top ten modules. Functional annotation and visualization 
of network interaction are shown in Fig. 12. Detailed functional analysis is shown in Tables 
11-12. The overall network connectivity coefficient indicates the strength of interaction 
between individual genes in each module, demonstrating novel interactions of genes 





Figure 12. Functional annotation of MCODE clusters. The overall 
network connectivity coefficient indicates the strength of interaction 
between individual genes in each module, demonstrating novel 




Table 11: Reactome pathway summary 
Cluster Weight Top Pathways Function 
1 26.25 Muscle contraction Striated muscle contraction and 
actin cytoskeleton integrity.  Striated Muscle Contraction 
Metabolism 
2 7.684 Metabolism Adopogenesis, adipocyte 
metabolism, immune function, and 
metabolic alterations in cancer.  
Immune System 
Innate Immune System 
Neutrophil degranulation 
3 7.417 Metabolism Lipid and protein metabolism + 
cell cycle control.  Post-translational protein 
modification 
Metabolism of proteins 
Sphingolipid metabolism 
Metabolism of lipids 
Developmental Biology 
Signal Transduction 
4 6 Developmental Biology Keratinocyte differentiation during 
development.  Formation of the cornified 
envelope 
Keratinization 
FGFR1 mutant receptor 
activation 
Signaling by FGFR1 in 
disease 
Signaling by FGFR in disease 
5 5.667 Keratinization Keratinization and differentiation 
Formation of the cornified 
envelope 
Developmental Biology 
Type I hemidesmosome 
assembly 
Cell junction organization 
Cell-Cell communication 
6 5.6 Muscle contraction Muscle contraction 
Striated Muscle Contraction 
7 5.2 Muscle contraction Muscle contraction/actin binding 
+ calcium signaling Cardiac conduction 
Metabolism 
Striated Muscle Contraction 
8 4.75 RHO GTPases Activate 
ROCKs 




Receptor protein tyrosine 
phosphatases interactions 
Sema4D induced cell 
migration and growth-cone 
collapse 
Sema4D in semaphorin 
signaling 
SALM protein interactions at 
the synapses 
9 4.286 Muscle contraction Muscle contraction and actin 
binding Ion homeostasis 
Translocation of GLUT4 to 
the plasma membrane 
Cardiac conduction 
Striated Muscle Contraction 
10 4 Synthesis of pyrophosphates 
in the cytosol 
Metabolism 
mRNA Editing: C to U 
Conversion 
 





Table 12: Gene families contained in each module (cluster) 
Gene ID  Cluste
r 
Gene Name, Gene Symbol, 
Ortholog 
Family/Subfamily 
ACTA1 1 Actin, α skeletal 
muscle;ACTA1;ortholog 
ACTIN, Α SKELETAL 
MUSCLE (PTHR11937:SF348) 
AMPD1 1 Adenosine monophosphate 
deaminase 1 isoform 
M;AMPD1;ortholog 
AMP DEAMINASE 1 
(PTHR11359:SF10) 
APOBEC2 1 Probable C-U-editing enzyme 
APOBEC-
2;APOBEC2;ortholog; 
Apolipoprotein B MRNA 









CALCIUM ATPASE 1 
(PTHR42861:SF17) 
C14H10orf71 1 chromosome 14 open reading  
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frame, human C10orf71 
CAPN3 1 Calpain-3;CAPN3;ortholog CALPAIN-3 
(PTHR10183:SF328) 
CARNS1 1 Uncharacterized protein 
(Fragment);CARNS1;ortholog 
CARNOSINE SYNTHASE 1 
(PTHR10578:SF91) 
CASQ1 1 Calsequestrin;CASQ1;ortholog CALSEQUESTRIN-1 
(PTHR10033:SF20) 
CKM 1 Creatine kinase M-
type;CKM;ortholog 
CREATINE KINASE M-TYPE 
(PTHR11547:SF45) 
DHRS7C 1 Uncharacterized 
protein;DHRS7C;ortholog 
DEHYDROGENASE/REDUC
TASE SDR FAMILY 
MEMBER 7C 
(PTHR43490:SF45) 
EEF1A1 1 Elongation factor 1-
α;LOC100514912;ortholog 
SUBFAMILY NOT NAMED 
(PTHR23115:SF198) 




1 Uncharacterized protein 
(Fragment);LOC100517759;or
tholog; likely myomegalin 









MB 1 Myoglobin;MB;ortholog MYOGLOBIN 
(PTHR11442:SF57) 
MYBPC1 1 Uncharacterized 
protein;MYBPC1;ortholog 
MYOSIN-BINDING 
PROTEIN C, SLOW-TYPE 
(PTHR13817:SF24) 
MYBPC2 1 Uncharacterized 
protein;MYBPC2;ortholog 
MYOSIN-BINDING 
PROTEIN C, FAST-TYPE 
(PTHR13817:SF16) 
MYH1 1 Myosin-1;MYH1;ortholog MYOSIN-1 
(PTHR13140:SF649) 




MYOT 1 Uncharacterized 
protein;MYOT;ortholog 
 
MYOZ1 1 Myozenin-1;MYOZ1;ortholog MYOZENIN-1 
(PTHR15941:SF18) 
NEB 1 Nebulin;NEB;ortholog NEBULIN (PTHR11039:SF58) 






















TNNC1 1 Troponin C, slow skeletal and 
cardiac 
muscles;TNNC1;ortholog 
TROPONIN C, SLOW 
SKELETAL AND CARDIAC 
MUSCLES 
(PTHR23064:SF13) 
TNNT1 1 Troponin T, slow skeletal 
muscle;TNNT1;ortholog 
TROPONIN T, SLOW 
SKELETAL MUSCLE 
(PTHR11521:SF14) 
TNNT3 1 Troponin T, fast skeletal 
muscle;TNNT3;ortholog 
TROPONIN T, FAST 
SKELETAL MUSCLE 
(PTHR11521:SF18) 
TTN 1 Titin;TTN;ortholog TITIN (PTHR13817:SF35) 




ABHD15 2 Uncharacterized 
protein;ABHD15;ortholog 
ABHYDROLASE DOMAIN-
CONTAINING PROTEIN 15 
(PTHR10794:SF63) 










ADORA1 2 Adenosine receptor 
A1;ADORA1;ortholog 
ADENOSINE RECEPTOR A1 
(PTHR24246:SF35) 
AOC3 2 Amine oxidase;AOC3;ortholog MEMBRANE PRIMARY 
AMINE OXIDASE 
(PTHR10638:SF41) 
AOC3 2 Amine oxidase;AOC3;ortholog MEMBRANE PRIMARY 
AMINE OXIDASE 
(PTHR10638:SF41) 
BCAM 2 Uncharacterized 
protein;BCAM;ortholog 
BASAL CELL ADHESION 
MOLECULE 
(PTHR11973:SF23) 
CAT 2 Catalase;CAT;ortholog CATALASE 
(PTHR11465:SF29) 









GBE1 2 1,4-α-glucan-branching 1,4-Α-GLUCAN-
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enzyme;GBE1;ortholog BRANCHING ENZYME 
(PTHR43651:SF1) 
GBE1 2 Uncharacterized 
protein;LOC100157421;orthol
og 
SUBFAMILY NOT NAMED 
(PTHR10357:SF185) 
LAYN 2 Uncharacterized 
protein;LAYN;ortholog 
LAYILIN (PTHR14789:SF5) 




ORM1 2 ORM1-like protein 
3;ORMDL3;ortholog 
ORM1-LIKE PROTEIN 3 
(PTHR12665:SF20) 
PLIN1 2 Perilipin-1;PLIN1;ortholog PERILIPIN-1 
(PTHR14024:SF37) 
PLIN1 2 Perilipin;PLIN1;ortholog PERILIPIN-1 
(PTHR14024:SF37) 
PPP1R1B 2 Protein phosphatase 1 
regulatory subunit 1B 
(Fragment);PPP1R1B;ortholog 
PROTEIN PHOSPHATASE 1 
REGULATORY SUBUNIT 1B 
(PTHR15417:SF7) 
SGK2 2 Uncharacterized 
protein;SGK2;ortholog 
SERINE/THREONINE-
PROTEIN KINASE SGK2 
(PTHR24356:SF282) 




ACID TRANSPORTER 2 
(PTHR22950:SF395) 





ACER3 3 Uncharacterized 
protein;ACER3;ortholog 
ALKALINE CERAMIDASE 3 
(PTHR12956:SF43) 














AQP7 3 Aquaporin 7;AQP7;ortholog AQUAPORIN-7 
(PTHR43829:SF15) 
ARL6IP1 3 ADP-ribosylation factor-like 




INTERACTING PROTEIN 1 
(PTHR20952:SF6) 




CEBPA 3 Uncharacterized 
protein;CEBPA;ortholog 
CCAAT/ENHANCER-































PEX3 3 Uncharacterized 
protein;PEX3;ortholog 
PEROXISOMAL 
BIOGENESIS FACTOR 3 
(PTHR28080:SF2) 
RBP4 3 Retinol-binding protein 
4;RBP4;ortholog 
RETINOL-BINDING 
PROTEIN 4 (PTHR11873:SF4) 





RGCC 3 Regulator of cell cycle 
RGCC;RGCC;ortholog 
REGULATOR OF CELL 
CYCLE RGCC 
(PTHR32193:SF5) 
SFRP5 3 Uncharacterized 
protein;SFRP5;ortholog 
SECRETED FRIZZLED-
RELATED PROTEIN 5 
(PTHR11309:SF110) 
SIK2 3 Uncharacterized 
protein;SIK2;ortholog 
SERINE/THREONINE-
PROTEIN KINASE SIK2 
(PTHR24343:SF247) 
TKT 3 Transketolase;tkt;ortholog TRANSKETOLASE 
(PTHR43195:SF3) 
ASPRV1 4 Retroviral-like aspartic 
protease 1;ASPRV1;ortholog 
RETROVIRAL-LIKE 
ASPARTIC PROTEASE 1 
(PTHR37006:SF2) 
FLG 4 Uncharacterized 
protein;FLG;ortholog 
 
KRT1 4 Uncharacterized 
protein;KRT1;ortholog 
KERATIN, TYPE II 
CYTOSKELETAL 1 
(PTHR23239:SF236) 
KRT77 4 Uncharacterized KERATIN, TYPE II 
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protein;KRT77;ortholog CYTOSKELETAL 1B 
(PTHR23239:SF322) 






LOR 4 Loricrin;LOR;ortholog LORICRIN (PTHR39228:SF2) 





TRANSPORT REGULATOR 3 
(PTHR14132:SF19) 
KRT15 5 Uncharacterized 
protein;KRT15;ortholog 
KERATIN, TYPE I 
CYTOSKELETAL 15 
(PTHR23239:SF239) 
KRT5 5 Uncharacterized protein 
(Fragment);KRT5;ortholog 
KERATIN, TYPE II 
CYTOSKELETAL 5 
(PTHR23239:SF279) 















TRIM29 5 Uncharacterized 
protein;TRIM29;ortholog 
TRIPARTITE MOTIF-
CONTAINING PROTEIN 29 
(PTHR24103:SF530) 
CMYA5 6 Uncharacterized protein 
(Fragment);CMYA5;ortholog 
CARDIOMYOPATHY-




6 Myosin light chain 1/3, 
skeletal muscle 
isoform;MYL1;ortholog 
MYOSIN LIGHT CHAIN 1/3, 
SKELETAL MUSCLE 
ISOFORM (PTHR23048:SF21) 
PPP1R3A 6 Uncharacterized 
protein;PPP1R3A;ortholog 
PROTEIN PHOSPHATASE 1 
REGULATORY SUBUNIT 3A 
(PTHR12307:SF26) 
TRDN 6 Uncharacterized protein 
(Fragment);TRDN;ortholog 
TRIADIN (PTHR14106:SF2) 
TTN 6 Titin;TTN;ortholog TITIN (PTHR13817:SF35) 
YIPF7 6 Protein YIPF;YIPF7;ortholog PROTEIN YIPF7 
(PTHR21236:SF11) 





ADSSL1 7 Adenylosuccinate synthetase ADENYLOSUCCINATE 
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isozyme 1;ADSSL1;ortholog SYNTHETASE ISOZYME 1 
(PTHR11846:SF5) 






BIN1 7 Uncharacterized 
protein;BIN1;ortholog 
MYC BOX-DEPENDENT-
INTERACTING PROTEIN 1 
(PTHR10663:SF287) 











KINASE TYPE II SUBUNIT Α 
(PTHR24347:SF318) 
GAPDH 7 Glyceraldehyde-3-phosphate 
dehydrogenase;GAPDH;orthol
og 
SUBFAMILY NOT NAMED 
(PTHR10836:SF69) 




MYL2 7 Myosin regulatory light chain 
2, ventricular/cardiac muscle 
isoform;MYL2;ortholog 
MYOSIN REGULATORY 













OBSCN 7 Obscurin;OBSCN;ortholog OBSCURIN 
(PTHR10489:SF903) 














TRDN 7 Uncharacterized protein 
(Fragment);TRDN;ortholog 
TRIADIN (PTHR14106:SF2) 
XIRP2 7 Uncharacterized 
protein;XIRP2;ortholog 
SUBFAMILY NOT NAMED 
(PTHR24206:SF39) 
CCDC120 8 Uncharacterized COILED-COIL DOMAIN-
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protein;CCDC120;ortholog CONTAINING PROTEIN 120 
(PTHR16093:SF7) 
CEP170B 8 Uncharacterized 
protein;CEP170B;ortholog 
CENTROSOMAL PROTEIN 
OF 170 KDA PROTEIN B-
RELATED (PTHR15715:SF34) 
GYLTL1B 8 Uncharacterized 
protein;GYLTL1B;ortholog 
GLYCOSYLTRANSFERASE-
LIKE PROTEIN LARGE2 
(PTHR12270:SF40) 
LIMK2 8 Uncharacterized 
protein;LIMK2;ortholog 
LIM DOMAIN KINASE 2-
RELATED 
(PTHR23257:SF625) 





CONTAINING PROTEIN 6 
(PTHR16172:SF35) 
















ATYPICAL KINASE ADCK3, 
MITOCHONDRIAL 
(PTHR43851:SF1) 
CORO6 9 Coronin;CORO6;ortholog CORONIN-6 
(PTHR10856:SF29) 
MYH1 9 Myosin-1;MYH1;ortholog MYOSIN-1 
(PTHR13140:SF649) 





TNNC2 9 Troponin C, skeletal 
muscle;TNNC2;ortholog 
TROPONIN C, SKELETAL 
MUSCLE (PTHR23064:SF14) 
TRDN 9 Uncharacterized protein 
(Fragment);TRDN;ortholog 
TRIADIN (PTHR14106:SF2) 
APOBEC2 10 Probable C-U-editing enzyme 
APOBEC-
2;APOBEC2;ortholog; 
Apolipoprotein B MRNA 





EEF1A1 10 Elongation factor 1-
α;LOC100514912;ortholog 
SUBFAMILY NOT NAMED 
(PTHR23115:SF198) 









10 ncRNA  
LOC1065049
26 
10   
LOC1065092
60 
10   





After the hypothesis that there are genuine functional modules present within the 
overall transcriptomic dataset generated from samples collected during pre-pubertal 
mammary gland development was confirmed, the functional modules (‘clusters’) were 
further dissected using the MCODE algorithm and Reactome pathway analysis/Panther 
characterization and a review of the literature. Once MCODE identified densely connected 
nodes to graphically display both nodules and associated weights, which were used to sort the 
relationships from strongest to weakest 792, the genes contributing to each functional module 
were extracted for detailed pathway analysis and biological interpretation based on functional 
significance in mammary development and cancer if applicable. As shown in Table 10, ten 
functional modules were extracted from the data, ranging in MCODE weights from 26.25 
(greatest connectivity) to 4 (least connectivity). The overall network connectivity coefficient 
for Cluster 1 indicates the highest strength of interaction between the individual genes in this 
module, demonstrating a novel interactions of striated muscle contraction and actin 
cytoskeleton integrity genes that significantly contribute to early postnatal mammary 
developmental trends. In contrast, the overall network connectivity coefficient for Cluster 10 
indicates the lowest strength of interaction between the individual genes in this module, and 
pathway analysis suggests these genes have weak interaction with eachother; these could not 
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be clearly grouped by their biological function in mammary development. Approximately 
50% of the clusters contained genes with oncogenic potential, which will also be discussed.  
 Reactome pathway analysis confirms validity of the functional interactions (by 
variance) using the MCODE algorithm, by clustering of distinct pathways utilized into 
different modules. Cluster 1 genes utilized pathways of mainly striated muscle contraction 
and actin cytoskeleton integrity, and much of the activity was centered around genes 
encoding the proteins titin, troponin, actin, myomesin, myozenin, and troponin, with most 
physically located in different domains of muscle 472. Cluster 2 genes utilized pathways of 
adipogenesis, adipocyte metabolism, immune function, and metabolic alterations in cancer. 
Importantly, there was interaction with the innate immune system and >50% of the genes 
contained in this module were proto-oncogenes or oncogenes. Cluster 3 genes also were 
largely proto-oncogenes or oncogenes and utilized lipid and protein metabolism pathways 
and cell cycle control. Clusters 4 and 5 genes both utilized pathways of keratinocyte 
differentiation and development, but Cluster 5 contained entirely proto-oncogenes and 
oncogenes with significant integrin association. Clusters 6, 7, and 9 were weakly interacting 
modules of genes mainly associated with muscle contraction, actin binding, and calcium 
signaling. Interestingly, although weakly interacting, Cluster 8 contained genes involved in 
protein modification and cellular adhesion with a majority acting as proto-oncogenes or 
oncogenes. Lastly, the weakest interaction is represented by Cluster 10, which is a ‘mixed 
bag’ of mainly metabolic genes. Clusters 6, 7, 9, and 10, in addition to being weakly 
interacting modules, did not contain a majority of genes with interesting functional 
significance to early pre-pubertal mammary development and will not be discussed at length 
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here. Relevant clusters to the developmental model (Clusters 1, 2, 3, 4, 5, and 8), their 
functional significance, and interacting gene members will be subsequently discussed.  
 Cluster 1, possessing the highest MCODE connectivity weight, contained genes 
involved in actin cytoskeleton integrity and muscle contraction, which are both important 
events during postnatal mammary development. This module included the most genes: 
ACTA1, AMPD1, APOBEC2, ATP2A1, C14H10orf71, CAPN3, CARNS1, CASQ1, CKM, 
DHRS7C, EEF1A1, ENO3, MB, MYBPC1, MYBPC2, MYH1, MYOM2, MYOT, MYOZ1, 
NEB, NT5C1A, PDE4DIP, PYGM, TMOD4, TNNC1, TNNT1, TNNT3, TTN, TXLNB, and 
two uncharacterized LOC IDs. MCODE modeling has been used to isolate biomarkers and 
gene networks involved in breast cancer 795–797, but MCODE has not yet been applied to 
developmental mammary biology. The applicability of this multivariate technique has been 
confirmed for developmental biology through recognition of the known interactions of 
Cluster 1 genes with each other in the literature, reports of Cluster 1 gene presence in 
mammary epithelial cells, relationships between Cluster 1 genes and developmental DA/PRC 
genes, and the widely accepted importance of the actin cytoskeleton in epithelial cell 
adhesion and migration to promote mammary development 152,377,798–801. Striated muscle 
involvement in the mammary gland was reported as early as 1988 by Griffiths et al 802; it is 
not surprising that this pathway is utilized by strongly coordinating genes in this instance. As 
reviewed in Chapter 1, mammary epithelial cells physically associate with each other through 
adherens junctions; this association allows formation and mediation of stable 
hemidesmosomes on the basal cell surface that link the cellular cytoskeleton with the BM 133. 
The actin cytoskeleton is directly associated with this process through physical support of 
hemidesmosomes, cell junctions, epithelial cell assembly, and cellular maintenance and 
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migration 803–806; the prominence of actin complexes within the highest weighted module 
further suggests significant involvement of cytoskeletal dynamics in early pre-pubertal, 
postnatal mammary gland development. Additionally, the actin cytoskeleton has been shown 
to regulate EMT, an important process in early development, in normal and cancerous cells 
807. Pursuant to this research focus, integrin molecules promote assembly of the actin 
cytoskeleton through recruitment of molecules to promote actin polymerization and 
relocation of actin to cell adhesion sites 808 ; these adhesions are predominantly governed 
through Rac signaling 269,809–811. ACTA1 (skeletal muscle actin α), presented in Cluster 1, is a 
marker of basal epithelial cell differentiation 812,813, elucidating affiliation between actin 
dynamics and mammary epithelial cell growth and maturation. ACTA1 is also a member of 
the highly conserved family of actin isoforms that exhibit functional redundancy; this family 
includes smooth muscle α-actin (ACTA2) that has recently been proven required specifically 
for lactation in mammals 800. Additionally, it has been shown that during postnatal 
development, mammary myoepithelial cells acquire a differentiated phenotype while gaining 
expression of smooth muscle markers, associating muscular genes with epithelial cell 
differentiation 801. It is hypothesized that a similar functional relationship is depicted with the 
Cluster 1 module of genes. Discriminate analysis in Fig X. showed that during phase two of 
development, Type VIII collagen was upregulated. Hou et al investigated smooth muscle cell 
(SMC) migration via type VIII collagen and concluded its effects are mediated by α2β1 and 
α1β1 integrin receptors as well as MMP-2 and MMP-9 expression 488, further suggesting 
validity of the novel cluster results. A functional link between the network module in Cluster 
1 and the positive PRC curve (consisting of genes supporting normal postnatal mammary 
development) is demonstrated by the role of PINCH-2 in both the top 25 positive PRC genes 
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and in the literature in actin dynamics; actin polymerization is stimulated at integrin 
clustering sites through via recruitment of a complex of proteins, commonly ILK–PINCH-2 
814. This increases confidence and usability in the novel application of these multivariate 
techniques, frequently only used in ecological studies, to mammary biology and 
developmental biology. In adaptive immune system development, the actin cytoskeleton has 
critical roles in T-cell activation, development, and motility, helping to form immunological 
synapses 815. Furthermore, the Cluster 1 gene Elongation factor 1-α (EEF1A1) behaves as a T 
helper 1 (Th1) cell-specific translation factor and is involved in Th1 cytokine production 816. 
EEF1A is also commonly applied as an internal control gene when normalizing 
transcriptional data of mammary epithelial cells, confirming its widespread presence in the 
mammary gland 817. However, with roles in proliferation, invasion and migration of cancer 
cells, its overexpression has been seen in cancers of the head and neck, breast, as well as 
leukemia and hepatocarcinoma 818. Taken together, Cluster 1 module networks suggest that 
the muscle-related genes are, in a coordinated fashion, supporting correct actin dynamics for 
mammary epithelial cell migration, differentiation, and signaling; the links with published 
literature and developmental genes discovered using other methods (DA/PRC) confirm 
validity of the novel approach to characterize early pre-pubertal mammary development.  
 Cluster 2 is a highly interconnected module of genes utilizing metabolic and immune 
system pathways to execute functional roles in adipogenesis, adipocyte metabolism, and 
innate immune function; metabolic alterations present in cancers also appear in this module 
430,431,472. Greater than 50% of the genes in this module are proto-oncogenes or oncogenes, 
leading to our characterization of this module as an ‘oncogenic cluster’. Genes included in 
this module are: ABHD15, ACAA1, ACO1, ADORA1, AOC3, BCAM, CAT, EPHX2, FAH, 
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LAYN, LIPE, ORM1, PLIN1, PPP1R1, SGK2, SLC36A2, and UNC93A; top Reactome 
pathways utilized were metabolism, immune system, innate immune system, and neutrophil 
degranulation. The significant involvement of adipogenesis in this postnatal mammary 
development module can be explained by the concept that shortly after birth, adipocytes 
densely packed in the fat pad begin to mature and become capable of supporting further 
mammary epithelial cell morphogenesis 46,47.  Adipocytes were formerly viewed as a storage 
depot for energy; it is accepted currently that they also have endocrine functions and 
metabolic roles in regulating whole body homeostasis, promoting inflammation, and 
secretion of a range of factors 819. Cluster 2 suggests that as the mammary epithelial ducts 
penetrate the surrounding mesenchyme during development, utilizing invasive cell signaling 
detected with our PRC and DA analysis, surrounding fibroblasts and adipocytes play a large 
role in the processes 9,10. It has been demonstrated that the absence of adipocytes in the 
mammary gland results in disruption of ECM signaling events and normal mammary 
development, suggesting these cells do regulate and sustain epithelial cell growth 820,821. 
Furthermore, adipose-derived stem cells (ASCs) are capable of differentiating into both 
adipocytes and epithelial cells in the mammary gland 822. Literature suggests that adipocytes 
are critical for proper mammary gland development during puberty and for the maintenance 
of the ductal architecture in the adult mammary gland 823; Cluster 2 supports this notion while 
illustrating similar functions that could be essential for early postnatal mammary gland 
development. Additionally, in tumors, there exists a complex metabolic collaboration 
between TME adipocytes and cancer cells that promotes invasiveness and metastasis 824, 
suggesting potential interaction between mammary epithelial cells and adipocytes during 
normal mammary organogenesis. Knowledge of adipocyte metabolism and mammary 
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development is simultaneously improving, but many factors (and genes generated by our 
functional modules) remain to be studied and characterized. The Cluster 2 gene α/β-hydrolase 
domain containing protein 15 (ABHD15) is a direct target gene of peroxisome proliferator-
activated receptor gamma (PPARγ), the master regulator of adipogenesis 825–827 and is 
upregulated during adipocyte development. Knockdown of ABHD15 in vitro resulted in 
apoptosis and a reduced proliferation capability of the cells 828. Prokesch et al in 2014 
presented the idea of reciprocal transdifferentiation between mammary adipocytes and 
epithelial cells; the researchers hypothesize it is one way in which the mammary gland 
accomplishes cyclical remodeling throughout development, pregnancy, and lactation 829. 
Importantly, they determined Perilipin1 (PLIN1; a Cluster 2 gene) is a critical regulator of 
mammary transdifferentiation and detected cells with an intermediate phenotype – termed 
‘adipoepithelial’ cells – in tissue during pregnancy that may be regulated by integrin 
complexes 829. The presence of PLIN1 in a module aside adipogenesis genes suggests 
possible transdifferentiation between adipocytes and mammary epithelial cells during 
postnatal pre-pubertal mammary development.  
 Several Cluster 2 genes are overexpressed in breast cancers: adenosine A1 receptor 
(ADORA1) and Protein Phosphatase 1 Regulatory Inhibitor Subunit 1B (PP1R1B; also 
known as DARPP-32). ADORA1 is a member of the G protein-coupled receptor superfamily 
that may regulate both normal and tumor cell development through promotion of survival and 
inhibition of apoptosis. This gene acts as an E2/ERα target and a regulator of ERα 
transcriptional activity, promoting breast cancer growth 830 and is overexpressed in breast 
cancer cell lines 831, suggesting it is a mediator of estrogen activity in mammary epithelial 
cell growth. PP1R1B/DARPP-32 is a signal transduction molecule, possibly linked to Wnt5a 
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signaling 832, expressed in both normal and malignant breast tissue 833, with knockout in vivo 
demonstrating decreased tumor growth 833. However, phosphorylation sites of DARPP-32 
and their downstream effects indicate a complicated network of positive and negative 
feedback/feedforward loops; several studies suggest its presence actually inhibits cell growth 
833,834, and thus its function in development remains largely unknown 835. Detection of 
DARPP-32 in Cluster 2 suggests a relationship with genes regulating adipogenesis and 
adipocyte metabolism. The Layilin (LAYN) gene encodes a cell surface glycoprotein thought 
to function in cell migration by membrane anchorage and promotion of F-actin binding and 
integrin/focal adhesion complexes 836; it is also a Treg cell-signature gene 837. LAYN is 
present in Cluster 2, suggesting it may interact with adipocytes for cell migration during 
postnatal mammary development and branching of the gland. Pursuant to our focus is the 
activity of Basal Cell Adhesion Molecule (B-CAM; also known as Lutheran), a Cluster 2 
gene proven to compete with integrin molecules for laminin α5 association in the BM in 
order to maintain balance between static and migratory cell behaviors 838. Studies also 
suggest BCAM may act as a suppressive oncogene 839 and/or join with AKT to form a 
BCAM/AKT fusion kinase that is constitutively activated in ovarian carcinoma 840. Taken 
together, the results of Cluster 2 module suggest a unique collaborative relationship between 
adipocytes, the ECM, and mammary epithelial cells with some integrin involvement in 
promotion of growth of the mammary gland.  
 Cluster 3 contains genes mainly involved in lipid metabolism, protein metabolism, 
and cell cycle control. Reactome pathway analysis indicated the most common signaling 
pathways utilized were: Metabolism, Post-translational protein modification, Metabolism of 
proteins, Sphingolipid metabolism, Metabolism of lipids, Developmental Biology, and Signal 
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Transduction. There are also several functional immune genes present in this cluster. Genes 
included in this module were: ACER3, the uncharacterized LOCID LOC100739362, 
ACKR4, ADIPOR2, APOL6, AQP7, ARL6IP1, ARSD, CEBPA, CLSTN3, PC, IDH1, 
MMD, PC, PDE8B, PEX3, RBP4, RETSAT, RGCC, SFRP5, SIK2, and TKT. Immune-
related genes in Cluster 3 include ACKR4 (Atypical chemokine receptor 4), CEBPA 
(CCAAT/enhancer binding protein A), and MMD (Monocyte-Macrophage Differentiation). 
Not immediately obvious from pathway analysis results was the prevalence of several 
important immune system relationships in this cluster, specifically those of CEBPA and 
MMD, which will be discussed. ACKR4 is an atypical chemokine receptor that plays a role 
in the migration of immune cells expressing chemokine receptors CCR7 and CCR9 by 
reducing the availability of CCL19, CCL21, and CCL25 841–844 and in cancer cells, may 
promote metastasis via an effect on EMT signaling 843. CEBPA, encoding the CCAAT 
enhancer-binding protein-α (C/EBPα) is a member of a large family of C/EBP proteins that 
regulate energy metabolism, immunity, inflammation, hematopoiesis, and adipogenesis 845–
849. C/EBPα is expressed by early myeloid progenitors and may regulate monocyte and 
macrophage development 850–852 and has a lesser understood, but important, impact on energy 
metabolism of surrounding cells 853. Studies have shown that this gene regulates other non-
immune cell types and controls genes required for lipid accumulation and glycogen storage 
854,855, illustrating another potential association between immune development and 
adipogenesis in the mammary gland. However, there is conflicting evidence for the presence 
and role of C/EBPα in the mammary gland; some data suggest C/EBPα levels are low and 
static throughout mouse mammary gland development 856,857 while others suggest dynamic 
upregulation during different developmental phases 858. This data, indicating the presence of 
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this gene in a highly interconnected cluster of other adipogenesis and mammary development 
genes suggest that it is indeed active and sustains a functional role in development of the 
gland. Interestingly, a separate Cluster 3 gene is also expressed by differentiated 
macrophages; as its name indicates, MMD (monocyte to macrophage differentiation) 
supports differentiation of monocytes to macrophages after they migrate through the 
endothelial membrane 859. Differentiated macrophages can then subsequently secrete growth 
factors, cytokines, and chemoattractants to recruit additional monocytes, support smooth 
muscle cell development 860, and assist in lipoprotein binding through proteoglycan secretion 
861. A significant matrix effect, including integrin involvement, on monocyte to macrophage 
differentiation has been recently demonstrated 862. In breast cancer models, initiation of 
mammary tumors by tumor-associated macrophages results mainly from monocyte to 
macrophage differentiation (reviewed by 863), further suggesting a role for MMD in the 
growth of epithelial cells and ECM integrity and function.864 In Chapter 1, the contribution of 
macrophages in mammary development was reviewed 91. Taken together with reports that in 
the developing mammary gland, regulation of genes contributing to macrophage function 
(immunity and defense, lipid, fatty acid and steroid metabolism, cell adhesion, carbohydrate 
metabolism, amino acid metabolism, and endocytosis) are found 865, it is hypothesized that 
MMD has a significant role within Cluster 3.  The unique network of genes presented in the 
Cluster 3 module further confirms the collaboration between immune cells, adipocytes, and 
mammary epithelial cells during early mammary organogenesis.  
 Cluster 4 mainly contains genes utilizing pathways of keratinization during 
development; these are predominantly epithelial cell markers that support keratinocyte 
differentiation and structural integrity of epithelial cells 472,603 with low oncogenic potential. 
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Interestingly, Cluster 5 utilizes the same pathways as Cluster 4, but is a small and highly 
oncogenic cluster with multiple genetic markers of basal breast cancer and EMT. The 
significance of the ECM, adherens junctions, and epithelial cell interactions in mammary 
development has already been thoroughly covered in the discussion above; the same 
significance applies here. The genes included in Cluster 5 are FXYD3, KRT15, KRT5, 
RAB25, SPTLC3, TACSTD2, and TRIM29. Importantly, 100% of the genes in this cluster 
have been reported to function as oncogenes or proto-oncogenes. FXYD3, also known as 
mammary tumor protein 8, is an enzyme and chloride ion channel or chloride channel 
regulator 866, but also a biomarker for breast 867,868, endometrial 869, colon and thyroid cancer 
870 and is suspected to support extensive cellular proliferation. KRT15, keratin 15, has been 
identified as a biomarker in TNBC and mammary stem cells 364. KRT5, keratin 5, is a marker 
of basal epithelial differentiation that mediates cell-cell adhesion and hemidesmosome 
formation in conjunction with integrin molecules 871. As a desmosome anchor for basal cells, 
KRT5 has been implicated in the ECM-dependent transition of tumor cells in basal breast 
cancer 872. RAB25, a member of the rat sarcoma (RAS) family of small GTPases, encodes a 
protein whose functional role is recycling of cell surface receptors and signaling proteins and 
regulation of cellular processes including proliferation, signal transduction, apoptosis, 
microtubule organization, and integrin trafficking 873–881. Importantly, RAB-mediated 
trafficking that contributes to invasion targets and upregulates integrin α6β4 while not 
affecting levels of α3β1 integrin 873. This gene has also been reported to act as both a tumor 
suppressor and tumor initiator, acting through multiple pathways to promote tumorigenesis in 
TNBC 881, suggesting a functional relationship between RAB25 and α6β4 integrin could 
influence TNBC development. SPTLC3 (Serine Palmitoyltransferase Long Chain Base 
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Subunit 3), a sphingolipid biosynthesis gene, has been implicated in hepatocellular carcinoma 
882 while TACSTD2 (Tumor-associated calcium signal transducer 2; also known as TROP2), 
a calcium signal transducer with roles in maintenance of the epithelial barrier through 
regulation of proper localization of tight junction proteins 883,884, has been seen overexpressed 
in epithelial tumors 885 and TNBC 886,887 where it promotes stem cell renewal 885, EMT 
signaling 888,889, PI3K activation 890, and β catenin signaling 885 – all processes leading to 
cellular proliferation, migration, and metastasis. However, contradictory data by Wang et al 
uncover a role for TACSTD2 loss in tumorigenesis in SCC. Despite its expression in a wide 
range of cancers, little is known about normal TACSTD2 signaling or downstream targets 
and its role in cell adhesion to the ECM is unclear 885. Interestingly, it was demonstrated 
recently that TACSTD2 inhibits prostate cancer cell adhesion to fibronectin and promotes β1 
integrin activation of the Src/FAK signaling pathway 891. Another related molecule also 
found in Cluster 5 that has an important role in EMT and regulation of ECM components is 
Tripartite motif–containing 29 (TRIM29) 892–897. It has been demonstrated that TRIM29 
suppresses the activity of integrin β1and regulates the p63-mediated pathway in cervical 
cancer p63 892, reduces PTEN expression and increases phosphorylated AKT levels which 
induces proliferation through the PTEN/AKT/mTOR pathway in nasopharyngeal carcinoma 
(NPC) 898, and  directly binds p53 to increase proliferation by sequestering it outside the 
nucleus 893. Clearly, the roles of TRIM29 across different cell types is still not completely 
understood. Cluster 5 is an important functional module of genes present in our 
transcriptomic data set – not only are all of the included genes oncogenes or proto-
oncogenes, they all function mainly to maintain epithelial integrity, mediates cell-cell 
adhesion, and have direct links with integrin molecules.  
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  Clusters 6-10 have weaker interactions; Clusters 6, 7, and 9 all contain genes mainly 
related to muscle contraction while Cluster 10 does not have strong organization. Cluster 8 is 
a group of genes that do have some function in cell adhesion, but the most significant 
functional modules from our transcriptomic dataset were Clusters 1-3 and 5. Taken together, 
application of the MCODE algorithm to transcriptomic data collected over time in early 
postnatal mammary development generated distinct modules, or clusters, containing highly 
interconnected genes. These clusters each had a unique biological function and strong 
implications for the novel mammary development model.  
 A model has been provided to achieve what was previously lacking in mammary 
biology: continuous developmental data collected from the same live animal over time. In 
contrast with previous attempts using necropsy samples from different animals at different 
ages 144, which does not completely control for variability between animals, mammary tissue 
has been obtained from the same animal throughout a period of early postnatal development 
without adverse effect to the animal or tissue. Anatomically and physiologically, the swine 
model is more closely related to that of the human; this data supports this concept and the 
swine model proved a good tool for histologic and transcriptomic evaluation of early 
mammary development 150. Availability of the swine genome sequence that shows high 
homology with humans 150 was especially helpful in interpretation of the data. Since the 
immune system of humans varies considerably from that of the mouse, the previously 
accepted model, this data suggests the use of swine to study immune system development in 
mammals. Along with the assessment of key immune regulators and markers in swine, this 
data supports use of the swine model to study human innate immunity and disease instead of 
rodents 151. Additionally, multiple advanced multivariate techniques frequently applied to 
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microbial ecology and less frequently, mammary biology, were utilized to generate several 
models of postnatal, pre-pubertal mammary development. With the application of statistical 
techniques to a new area of biology, there exists concerns of reproducibility; it is important to 
note that these methods do not necessarily build on each other, meaning that the output of 
one method does not always generate the input for the next method. The whole data set, or a 
subset of variables sorted by variance, is used as the input for each method, so an incorrect 
output of an earlier method (for example, DFA) would not lead to an inherent inaccuracy in a 
latter method (for example, WGCNA).  
 As discussed, studying early mammary development is critical both due to the 
suspected links between development and invasive cancer and the conflicting views of 
researchers on the presence of developmental activity between birth and puberty. In contrast 
with the popular perspective that postnatally, the mammary gland exists as a rudimentary 
organ that remains quiescent and dormant until puberty 6–9, this data suggests that there is 
significant growth occurring immediately after birth, including events previously suspected 
such as epithelial cell proliferation, branching, and expansion11–14 as well as significant 
immune system and ECM involvement. It is also accepted that in humans, the formation of 
the breast in the embryo and early postnatal development contains some events akin to early 
breast carcinogenesis16. This data supports this concept and the main signaling pathways 
responsible for early postnatal mammary development and patterning over time have been 
identified and characterized. Awareness of their downstream effects and targets has both 
advanced the understanding of developmental biology and could provide future areas of 




Chapter two results and discussion  
Given the disclosure of many proto-oncogenes or oncogenes involved in novel 
interactions contributing to early postnatal mammary developmental trends in Chapter 1, the 
hypothesis was strengthened that there are transcriptional similarities in early postnatal 
mammary development and TNBC that can be modulated through the α6β4 integrin signaling 
pathway. Therefore, it is expected that the MDA-MB-231 TNBC cell line should utilize 
growth pathways similar to those uncovered in early postnatal mammary development which 
are potentially affected by treatment with the recombinant rG3 protein. In this Chapter, the 
effect of rG3 on viability is evaluated in multiple cell lines across species, while RNA 
sequencing data reveal the prominent cell signaling pathways influenced by rG3 treatment, 
suggesting this recombinant protein can be used as a novel tool to study apoptosis signaling 











Production of purest form of rG3  
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Figure 13. a) rG3 Western Blot using anti-polyhistidine monoclonal antibody 
after in-house production. Lane 1: Marker. Lane 2: First isolation elution. 
Lane 3: Second isolation elution. Lane 4: Third isolation elution. Lane 5: 
Fourth isolation elution. kDa size marker shown on left. b) rG3 Western Blot 
using anti-polyhistidine monoclonal antibody after Vanderbilt production and 






















































Fig 13. shows the purity of rG3 after production in-house or after further purification by 
MSRC Proteomics Laboratory at Vanderbilt University School of Medicine. In the Qiagen 
Fast Start Ni-NTA Kit used for in-house production, rG3 elution is repeated four times to 
maximize protein yield. In the first elution, the majority of rG3 is captured, and the highest 
concentration of protein is present at the ~27 kDa (rG3) band. The newest purified rG3 
produced using Vanderbilt’s technique can be seen in the Western Immunoblot in Figure 
13B. Lanes 4-15 contain the fractions from purification. The cleanest fractions were chosen 
to be used in subsequent assays and can be seen in Lanes 8, 9, and 12. For the final 
experiments, production and isolation of rG3 were modified to obtain the purest form of rG3 
since purification of rG3 in-house using the Ni-NTA Fast Start purification yielded a protein 
with two main components (as seen in Figure 13B at approximately 27 kDa and 
approximately 57 kDa). Since the active portion of rG3 is at approximately 27 kDa, any non-
specific proteins are a concern. 
rG3 isolation was confirmed by both gel electrophoresis and Western Blotting using 
an anti-polyhistidine monoclonal antibody (As previously demonstrated by Turner in 2005, 
the molecular weight of rG3 including the histidine tag is ~27 kDa). Figure X confirms the 
presence of rG3 with the histidine tag, but the inclusion of larger MW bands contain the 
histidine tag suggest the presence of larger protein fragments (~70 kDa, band 2) that are an 
rG3 protein complex. As shown in Figure XB, Vanderbilt’s purification procedure did yield 
cleaner fractions. The cleanest fractions, in Lanes 8, 9, and 12, were chosen for subsequent 
assays. Mass spectrometry results confirmed that the upper MW band contains the chaperone 
heat shock Protein 60 complexed with the rG3 protein (by sequence) and the majority of the 
lower band is the rG3 protein sequence. Mass spectrometry, also performed at Vanderbilt, 
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confirmed that the upper MW band is the chaperone heat shock Protein 60 (accession number 
CH60_ECOLI).  
 
Evaluation of hsp-60 effect on viability  
MTT viability assay results using representative concentrations of pure heat shock 




The MTT results suggest that pure hsp-60, up to 10µg/mL, does not have a 
significant effect on MDA-MB-231 cell viability. Therefore, it is likely that the biological 
Figure 14. MTT results for MDA-M-231 cell line after 24 hr treatment in vitro 
with 0 – 10µg/mL pure hsp-60. 
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effect of rG3 is specifically due to the recombinant portion of Laminin-5 G3 domain and not 




Evaluation of rG3 effect on TNBC viability in vitro 
MTT viability assays were performed with 0, 20, 30, 40, and 50 µg/ml concentrations 
of rG3. As shown in Fig. 15., all concentrations of rG3 induced % SI values that were 
significantly different from each other. At 20 µg/mL, the 231s have the most significant 
reduction in viability (% SI) compared to 0 µg/mL. At 20 µg/mL, primary swine fibroblasts 
do not show a significant reduction in viability compared to 0 µg/mL and have a significantly 
* 
* 
Figure 15. MTT results for MDA-M-231, MCF-10A, and primary swine fibrolast 
cell line after 24 hr treatment in vitro with 0 – 30µg/mL rG3. 
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higher viability in comparison with the 231s (p ≤ 0.0001).  Although the remaining cell line 
(MCF-10A) has a higher viability than the 231s at 20 µg/mL, their SI values are not 
significantly greater than the 231 cells at this concentration. 
At 20 µg /mL, the lowest concentration where significant reduction in proliferation 
was seen (Fig 15), MDA-MB 231 exhibit the highest inhibition of proliferation. MCF10A 
cells, the “normal” mammary epithelial cell line, exhibit a significant decrease in viability at 
20 µg/mL, which raises questions regarding the suitability of these cells as a control as 
previously discussed 146,899. Any response of MCF10A cells to rG3 treatment may be due to 
the level of integrin ß4 expression on these cells (Fig. 17) being comparable to the level of 




Figure 16. Western Blotting for p53 after treatment with 20ug/mL rG3 in vitro using MCF-








Analysis of integrin ß4 and p53 protein expression after rG3 treatment in multiple cell lines 
To understand at what level integrin ß4, the indirect target of rG3, is expressed in the 
cell lines used for in vitro assays, Western Immunoblotting was performed using an anti- 
integrin ß4 antibody on cell lysates collected from MDA-MB-231 cells, MCF-10A cells, and 
primary swine Fibroblasts. All images were analyzed at n=3 and integrin ß4 expression was 
normalized to β actin expression in respective samples. ANOVA indicated significant 
differences in means among the three different cell types, so Tukey HSD analysis was chosen 
to determine if tumorigenic cell types (MDA-MB-231) express significantly more integrin 
ß4. To understand how rG3 treatment is affecting downstream protein expression of a 
common apoptosis marker, p53, Western Immunoblotting was performed on cell lysates 
collected from MDA-MB-231 cells, MCF-10A cells, and primary swine Fibroblasts with and 
without 24 hr of treatment with 20 µg/mL rG3. All images were analyzed at n=3 and integrin 
Figure 17. Western Blotting for integrin ß4 in vitro using MCF-10A, MDA-MB-231, and 
primary swine fibroblast lysate. MCF10 and MDA-MB-231 lysate showed significantly 





ß4 expression was normalized to β actin expression in respective samples. ANOVA indicated 
differences in means among the three cell types and between treatments, so Tukey HSD 
analysis was chosen to determine if MDA-MB-231 cells expressed significantly more p53 
after treatment than the other three non-tumorigenic cell types. In Figure 16, these differences 
are shown between cell lines and with or without rG3 treatment.  
In Figure 17, integrin ß4 protein expression is significantly higher (p = 0.0016) in the 
MDA-MB-231 and MCF-10A cell lines in comparison to the primary swine fibroblasts, 
which have low integrin ß4 protein expression. MDA-MB-231 cells are the only cell line that 
has a significant increase in p53 expression (p ≤ 0.001) after 24 hours of 20 µg/mL rG3 
treatment. MCF-10A cells do not indicate a significant difference in p53 protein expression 
after 24 hours of 20 µg/mL rG3 treatment. Additionally, p53 expression after rG3 treatment 
in the MCF-10A cells is significantly lower than MDA-MB-231 cells after rG3 treatment (p 
≤ 0.001). Primary swine fibroblasts do not show significantly different p53 expression levels 
with or without 24 hours of 20 µg/mL rG3 treatment. Cell death due to p53-dependent 
apoptosis typically follows the mitochondrial pathway, however p53 can also modulate cell 
death through death receptors 900; it is suspected that one or both of these p53 associated 
pathways are utilized upon binding of rG3 to the integrin ß4 ligand. As shown in Figure 16, 
significantly increased p53 expression after rG3 treatment was only detected in the MDA-
MB-231 cell line and not MCF10A or fibroblast cells, indicating induction of the p53-
specific apoptotic pathway in MDA-MB-231 cells only. It is important to note that although 
MCF10A cells show expression of integrin ß4 (Fig 17) and a decrease in viability after rG3 
treatment (Fig 15), a significant increase of apoptotic protein p53 is not seen after treatment. 
This could indicate that although rG3 affects viability of these cells, it is not through a p53-
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dependent manner and therefore they are not an appropriate control or tool to study p53-
mediated apoptosis induction and were not included in subsequent assays. 
 
RNA sequencing confirms primary swine fibroblasts utilized generic growth pathways and 
are appropriate control  
RNA sequencing provided data for approximately 25,000 gene transcripts for the 
primary swine fibroblast line. After 24 hours of growth in vitro, the most commonly utilized 
Reactome pathways by fibroblasts were metabolism of proteins, immune system, signal 
transduction, metabolism, Post-translational protein modification, Gene expression 
(Transcription), Innate Immune System, RNA Polymerase II Transcription, Metabolism of 
RNA, Cytokine Signaling in Immune system, Generic Transcription Pathway, 
Developmental Biology, and Adaptive Immune System.  
As mentioned and seen in MTT results (Fig. 15), MCF-10A cells can exhibit stem 
cell-like features and possess a variable phenotype dependent on culture conditions146. Due to 
the discrepancy in results using MCF10As, and the anatomical and physiological 
resemblance to human tissue 147,150, swine mammary tissue was collected in vivo and a 
primary cell line was established in vitro. Fibroblasts are the most common cells of 
connective tissue in mammals 901; these cells can direct cell-cell interactions, release various 
factors, and modulate ECM interactions 902. These properties led to the choice of primary 
swine fibroblasts as a control cell line for rG3 studies because of their close association with 
mammary tissue and low β4 integrin expression, which is the indirect target of rG3 (see Fig. 
17). Additionally, a primary cell line serves as a better control for in vitro assays than an 
immortalized cell line due to the loss of the p53 tumor suppressor pathway function in many 
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immortalized lines 903–905 which is a major pathway focus of this dissertation. Interestingly, 
Reactome analysis of transcripts after RNA sequencing indicates pathways utilized by 
primary swine fibroblasts are very similar to those identified by K-means clustering in early 
mammary development, including immune system, metabolism, signal transduction, cell 
cycle regulation, gene transcription, and protein translation, as shown in Table 3. 
Importantly, TP53 and CASP genes, critical inducers of apoptosis 906, are not found 
expressed in the top 5% of genes expressed while integrin β4, integrin β1, and integrin α6 are 
among the top 5%  genes expressed (see Appendix C). As seen in Fig. 17, integrin ß4 protein 
expression is significantly higher (p = 0.0016) in the MDA-MB-231 and MCF-10A cell lines 
in comparison to the primary swine fibroblasts, but RNA sequencing results confirm that 
integrin ß4 is still expressed to some level in this line. Panther analysis for biological process 
of the top 5% of expressed transcripts indicates generic cellular and metabolic processes are 
being executed for growth, suggesting this line is a good choice for comparison against the 
MDA-MB-231 cell line (Fig. 18).  
 
Table 13: Reactome analysis of top 15 pathways utilized by fibroblasts in vitro after 24 hr growth 
Pathway 
identifier 
Pathway name  #Entities found #Entities 
total 
R-HSA-168256 Immune System 187 2765 
R-HSA-1430728 Metabolism 172 3461 
R-HSA-162582 Signal Transduction 169 3002 
R-HSA-392499 Metabolism of proteins 119 2373 
R-HSA-1266738 Developmental Biology 104 1175 
R-HSA-1280215 Cytokine Signaling in Immune system 103 1222 
R-HSA-74160 Gene expression (Transcription) 97 1619 
R-HSA-168249 Innate Immune System 92 1632 
R-HSA-73857 RNA Polymerase II Transcription 90 1440 
 
 159 
R-HSA-597592 Post-translational protein modification 88 1530 
R-HSA-556833 Metabolism of lipids 87 1316 
R-HSA-449147 Signaling by Interleukins 85 910 
R-HSA-212436 Generic Transcription Pathway 84 1300 
R-HSA-372790 Signaling by GPCR 65 1509 












localization reproduction biological regulation 











Swine fibroblasts are unaffected by rG3 treatment at 20ug/mL 
Differential gene expression analysis performed on primary swine fibroblasts treated 
with 20ug/mL rG3 or with media further confirms the usage of this cell line as an in vitro 
control for rG3 studies. After normalization, the maximum shift change between treated and 
untreated fibroblasts was <31 with only 0.33% of the whole transcriptome resulting in a shift 
change >5 with rG3 treatment. For the differentially expressed genes that increased with 
treatment by a shift change of ³5, Reactome analysis indicated the pathways differentially 
utilized were: Immune System, Signal Transduction, Metabolism, Cytokine Signaling in 
Immune system, Metabolism of proteins, Innate Immune System, Gene expression 
(Transcription), RNA Polymerase II Transcription, Generic Transcription Pathway, Signaling 
by Interleukins, Post-translational protein modification, and Developmental Biology. A 
summary of rG3 effect on primary swine fibroblasts can be seen in Table 14. Taken together 
with the MTT results (Fig. 15), this transcriptome data indicates the primary swine 
fibroblasts are largely unaffected by rG3 treatment, although they express the receptor for 
rG3. This confirms their suitability as a control for subsequent in vitro assays.  
 








R-HSA-168256 Immune System 187 2765 
R-HSA-1430728 Metabolism 172 3461 
R-HSA-162582 Signal Transduction 169 3002 
R-HSA-392499 Metabolism of proteins 119 2373 
R-HSA-1266738 Developmental Biology 104 1175 
R-HSA-1280215 Cytokine Signaling in Immune system 103 1222 
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R-HSA-74160 Gene expression (Transcription) 97 1619 
R-HSA-168249 Innate Immune System 92 1632 
R-HSA-73857 RNA Polymerase II Transcription 90 1440 
R-HSA-597592 Post-translational protein modification 88 1530 
R-HSA-556833 Metabolism of lipids 87 1316 
R-HSA-449147 Signaling by Interleukins 85 910 
R-HSA-212436 Generic Transcription Pathway 84 1300 
R-HSA-372790 Signaling by GPCR 65 1509 
R-HSA-1280218 Adaptive Immune System 57 1189 
R-HSA-382551 Transport of small molecules 56 987 
R-HSA-109582 Hemostasis 56 798 
R-HSA-1643685 Disease 55 1496 
R-HSA-422475 Axon guidance 51 611 
R-HSA-166520 Signalling by NGF 45 615 
R-HSA-5653656 Vesicle-mediated transport 43 828 
R-HSA-199991 Membrane Trafficking 40 667 
R-HSA-388396 GPCR downstream signaling 38 1140 
R-HSA-6785807 Interleukin-4 and 13 signaling 37 212 
R-HSA-1474244 Extracellular matrix organization 36 329 
R-HSA-1433557 Signaling by SCF-KIT 34 468 
R-HSA-186797 Signaling by PDGF 33 520 
R-HSA-187037 NGF signalling via TRKA from the 
plasma membrane 
33 527 
R-HSA-194315 Signaling by Rho GTPases 32 445 
R-HSA-186763 Downstream signal transduction 31 489 
R-HSA-2454202 Fc epsilon receptor (FCERI) signaling 31 594 
R-HSA-177929 Signaling by EGFR 31 502 
R-HSA-2424491 DAP12 signaling 30 492 
R-HSA-2172127 DAP12 interactions 30 509 
R-HSA-112316 Neuronal System 29 425 
R-HSA-6809371 Formation of the cornified envelope 28 137 
R-HSA-6805567 Keratinization 28 225 
R-HSA-881907 Gastrin-CREB signalling pathway via 
PKC and MAPK 
28 504 
R-HSA-194138 Signaling by VEGF 28 381 
R-HSA-1989781 PPARA activates gene expression 27 177 





receptor α (PPARα) 
R-HSA-6798695 Neutrophil degranulation 27 480 
R-HSA-4420097 VEGFA-VEGFR2 Pathway 27 372 
R-HSA-1852241 Organelle biogenesis and maintenance 26 334 
R-HSA-8957322 Metabolism of steroids 25 316 
R-HSA-983169 Class I MHC mediated antigen processing 
& presentation 
25 464 
R-HSA-5683057 MAPK family signaling cascades 25 324 
R-HSA-8953897 Cellular responses to external stimuli 25 598 
R-HSA-375165 NCAM signaling for neurite out-growth 24 306 
R-HSA-74752 Signaling by Insulin receptor 24 349 
R-HSA-76002 Platelet activation, signaling and 
aggregation 
24 305 
R-HSA-5663202 Diseases of signal transduction 24 463 
R-HSA-451927 Interleukin-2 family signaling 23 288 
R-HSA-512988 Interleukin-3, 5 and GM-CSF signaling 23 293 
R-HSA-448424 Interleukin-17 signaling 23 332 
R-HSA-5688426 Deubiquitination 23 289 
R-HSA-2262752 Cellular responses to stress 23 511 
R-HSA-194840 Rho GTPase cycle 22 144 
R-HSA-912526 Interleukin receptor SHC signaling 22 277 
R-HSA-8853659 RET signaling 22 292 
R-HSA-2428928 IRS-related events triggered by IGF1R 22 325 
R-HSA-2428924 IGF1R signaling cascade 22 326 
R-HSA-2404192 Signaling by Type 1 Insulin-like Growth 
Factor 1 Receptor (IGF1R) 
22 327 
R-HSA-74751 Insulin receptor signalling cascade 22 324 
R-HSA-425407 SLC-mediated transmembrane transport 22 413 
R-HSA-500792 GPCR ligand binding 22 592 
R-HSA-112315 Transmission across Chemical Synapses 22 278 
R-HSA-2871796 FCERI mediated MAPK activation 21 377 
R-HSA-112399 IRS-mediated signalling 21 321 
R-HSA-913531 Interferon Signaling 21 292 
R-HSA-3700989 Transcriptional Regulation by TP53 21 485 
R-HSA-5673001 RAF/MAP kinase cascade 20 267 
R-HSA-112412 SOS-mediated signalling 20 267 
R-HSA-187706 Signalling to p38 via RIT and RIN 20 272 




Table 15. Shift change values for rG3 treated fibroblasts 
Condition Shift 
change 
GeneID Gene Name 
rG3 treated 
fibroblasts at 24 
hours. Formula = 
(Fibro treated 24 
hr - Fibro control 
24 hr)/(Fibro 
control 24 hr) 
31.00 RND1 Rho-related GTP-binding protein 
Rho6;RND1;ortholog 
13.33 EGR3 Early growth response protein 
3;EGR3;ortholog 
13.25 CHI3L2 Chitinase-3-like protein 2;CHI3L2;ortholog 
13.00 KLHL9 Kelch-like protein 9;KLHL9;ortholog 
13.00 RORC Nuclear receptor ROR-
gamma;RORC;ortholog 
12.00 ALOX5AP Arachidonate 5-lipoxygenase-activating 
protein;ALOX5AP;ortholog 
10.00 RASIP1 Ras-interacting protein 1;RASIP1;ortholog 
10.00 MLXIPL Carbohydrate-responsive element-binding 
protein;MLXIPL;ortholog 
9.14 TRIB1 Tribbles homolog 1;TRIB1;ortholog 
9.00 NR4A3 Nuclear receptor subfamily 4 group A 
member 3;NR4A3;ortholog 
8.33 SLC16A1 Monocarboxylate transporter 
1;SLC16A1;ortholog 
8.00 WDFY4 WD repeat- and FYVE domain-containing 
protein 4;WDFY4;ortholog 
8.00 TTC21A Tetratricopeptide repeat protein 
21A;TTC21A;ortholog 
8.00 GATM Glycine amidinotransferase, 
mitochondrial;GATM;ortholog 
8.00 SOST Sclerostin;SOST;ortholog 
8.00 NLRP3 NACHT, LRR and PYD domains-
containing protein 3;NLRP3;ortholog 
8.00 SRCIN1 SRC kinase signaling inhibitor 
1;SRCIN1;ortholog 
8.00 IQSEC3 IQ motif and SEC7 domain-containing 
protein 3;IQSEC3;ortholog 
7.32 DUSP5 Dual specificity protein phosphatase 
5;DUSP5;ortholog 
7.00 TCF7L1 Transcription factor 7-like 
1;TCF7L1;ortholog 
7.00 RASGEF1A Ras-GEF domain-containing family 
member 1A;RASGEF1A;ortholog 
7.00 LTB Lymphotoxin-β;LTB;ortholog 
6.95 HES1 Transcription factor HES-1;HES1;ortholog 
6.60 OLFM1 Noelin;OLFM1;ortholog 




6.00 PIANP PILR α-associated neural 
protein;PIANP;ortholog 
6.00 TMC4 Transmembrane channel-like protein 
4;TMC4;ortholog 
6.00 TMEM198 Transmembrane protein 
198;TMEM198;ortholog 
6.00 FAM189A2 Protein FAM189A2;FAM189A2;ortholog 
6.00 MYH7B Myosin-7B;MYH7B;ortholog 
5.64 EGR2 E3 SUMO-protein ligase 
EGR2;EGR2;ortholog 
5.50 USP2 Ubiquitin carboxyl-terminal hydrolase 
2;USP2;ortholog 
5.50 LRRK2 Leucine-rich repeat serine/threonine-protein 
kinase 2;LRRK2;ortholog 
5.33 SLC7A8 Large neutral amino acids transporter small 
subunit 2;SLC7A8;ortholog 
5.25 ZNF404 Zinc finger protein 404;ZNF404;ortholog 
5.25 ZNF704 Zinc finger protein 704;ZNF704;ortholog 
5.17 DOCK8 Dedicator of cytokinesis protein 
8;DOCK8;ortholog 
5.00 NRARP Notch-regulated ankyrin repeat-containing 
protein;NRARP;ortholog 
5.00 ARHGAP30 Rho GTPase-activating protein 
30;ARHGAP30;ortholog 
5.00 KCNK1 Potassium channel subfamily K member 
1;KCNK1;ortholog 
5.00 RAB37 Ras-related protein Rab-
37;RAB37;ortholog 
5.00 RGL3 Ral guanine nucleotide dissociation 
stimulator-like 3;RGL3;ortholog 
5.00 TTC22 Tetratricopeptide repeat protein 
22;TTC22;ortholog 
5.00 NCF4 Neutrophil cytosol factor 4;NCF4;ortholog 




MDA-MB-231 TNBC transcriptome from in vitro growth suggests signaling similarities with 
early postnatal mammary development in vivo  
RNA sequencing provided data for approximately 58,000 gene transcripts for the 
MDA-MB-231 TNBC cell line, 30,000 of which were actively expressed (raw transcript 
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count ³ 1). As seen in Table 16, after 24 hours of growth in vitro, the most frequently utilized 
Reactome pathways by the TNBC cells were: Metabolism of proteins, Immune System, 
Signal Transduction, Metabolism, Post-translational protein modification, Innate Immune 
System, Disease, Gene expression (Transcription), Metabolism of RNA, Cytokine Signaling 
in Immune system, Developmental Biology, RNA Polymerase II Transcription, Adaptive 
Immune System, Signaling by Interleukins, and Generic Transcription Pathway. Importantly, 
the top pathways utilized by the MDA-MB-231 during normal growth and proliferation 
cycles are almost identical to the signaling pathways identified by K-means clustering in 
early mammary development AND the pathways utilized by primary swine fibroblasts during 
growth.  
The MDA-MB-231 line is an invasive breast cancer cell line that lacks expression of 
estrogen (ER) α, progesterone (PR) and human epidermal growth factor receptor 2 (HER2), 
and is classified as a TNBC line 378. As previously discussed, MDA-MB-231 cells express 
some level of integrin α6 and integrin ß4 284,312,373–377, and the α6ß4 complex is necessary for 
the tumorigenic properties of these cells 303. In addition to the Western Blotting results in Fig. 
17, the expression of these integrin molecules is confirmed through RNA sequencing. 
Importantly, TP53 and CASP genes, critical inducers of apoptosis 906, are not found 
expressed in the top 5% of active genes (see Appendix C) expressed in untreated, normally 
proliferating MDA-MB-231 cells in vitro. Panther analysis for biological process indicates 
common cellular and metabolic processes are being executed for growth of this TNBC cell 





Table 16: Reactome pathways utilized by MDA-MB-231 cells after 24 hrs growth in vitro 
Pathway 
identifier 
Pathway name #Entities found #Entities 
total 
R-HSA-392499 Metabolism of proteins 511 2373 
R-HSA-168256 Immune System 464 2765 
R-HSA-162582 Signal Transduction 427 3002 
R-HSA-1430728 Metabolism 344 3461 
R-HSA-597592 Post-translational protein modification 289 1530 
R-HSA-168249 Innate Immune System 279 1632 
R-HSA-1643685 Disease 271 1496 
R-HSA-74160 Gene expression (Transcription) 255 1619 
R-HSA-8953854 Metabolism of RNA 249 782 
R-HSA-1280215 Cytokine Signaling in Immune system 245 1222 
R-HSA-1266738 Developmental Biology 229 1175 
R-HSA-73857 RNA Polymerase II Transcription 225 1440 
R-HSA-1280218 Adaptive Immune System 223 1189 
R-HSA-449147 Signaling by Interleukins 215 910 
R-HSA-212436 Generic Transcription Pathway 193 1300 
R-HSA-5653656 Vesicle-mediated transport 184 828 
R-HSA-422475 Axon guidance 172 611 
R-HSA-199991 Membrane Trafficking 171 667 
R-HSA-5663205 Infectious disease 163 531 
R-HSA-1640170 Cell Cycle 154 680 
R-HSA-166520 Signalling by NGF 150 615 
R-HSA-8953897 Cellular responses to external stimuli 141 598 
R-HSA-69278 Cell Cycle, Mitotic 140 566 
R-HSA-186797 Signaling by PDGF 135 520 
R-HSA-71291 Metabolism of amino acids and 
derivatives 
133 656 
R-HSA-2262752 Cellular responses to stress 133 511 
R-HSA-187037 NGF signalling via TRKA from the 
plasma membrane 
133 527 
R-HSA-382551 Transport of small molecules 133 987 





























Figure 19. Panther Biological Processes utilized by MDA-MB-231 transcriptome 
after 24 hrs growth in vitro 
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Differential expression analysis of MDA-MB-231 cells with and without 20ug/mL rG3 
treatment for 24 hours indicates widespread apoptotic induction and downregulation of 
extracellular matrix organization  
In contrast with the primary swine fibroblasts (Table 14), when MDA-MB-231 cells 
were treated with rG3, 18% of the active transcriptome showed an upregulation in gene 
expression (shift change >5; maximum 14,000) and 5.8% of the active transcriptome was 
downregulated (shift change < -5). In contrast with fibroblast controls and untreated 231s, 
Reactome analysis indicates the top 75 pathways utilized by upregulated genes are indicative 
of apoptosis and cellular damage, as shown in Table 17.  Seventy-five was chosen as a cutoff 
due to the decrease in functional significance of pathways below this. The top 75 pathways 
utilized by upregulated genes with a significant z-score (> 2), shown in Table 18, are 
similarly indicative of apoptosis and IFN (link to TRAIL and p53) signaling. The top 75 
pathways utilized by downregulated genes with significant z-score (Table 19) are: 
Extracellular matrix organization, ECM proteoglycans, Integrin cell surface interactions, 
Degradation of the extracellular matrix, Immune System, Signal Transduction, Non-integrin 
membrane-ECM interactions, Cytokine Signaling in Immune system, Collagen chain 
trimerization, Assembly of collagen fibrils and other multimeric structures, Collagen 
degradation, Collagen biosynthesis and modifying enzymes, Collagen formation, MET 
activates PTK2 signaling, MET promotes cell motility, and Signaling by MET. Importantly, 
Transcriptional regulation by TP53 is not present in this Reactome list and apoptosis and 
programmed cell death are not present in the top 100 pathways generated.  
This indicates a much greater effect of rG3 on the transcriptome of MDA-MB-231 
cells than primary swine fibroblast control cells. A literature review indicates that 56% of the 
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genes in the top 0.15% of differentially expressed genes after rG3 treatment (normalized by 
control) are positive regulators of apoptosis (with 10% both positive and negative), 14% are 
negative, and 18% are unknown or unconfirmed. When z-scores are applied, 40% of 
upregulated genes with a z-score >2 could function as positive apoptosis regulators.  
Interestingly, genes downregulated with rG3 treatment (Table 19) predominantly fall 
into ECM organization and stability categories and are similar to those genes that contribute 
positively to early postnatal mammary gland development (as seen in Fig. 9). Since direct 
attachment of mammary epithelial cells to the ECM can occur through focal adhesions (FAs) 
and HDs, which are two adhesion complexes that form mechanical links between the ECM 
and the actomyosin cytoskeleton 140, linking the ECM and the cytoskeleton is critical in 
regulation of a variety of processes, including proliferation and differentiation. Additionally, 
apoptosis is frequently characterized largely by a large loss of cellular contact with the matrix 
907, so the downregulation of ECM genes after rG3 treatment of TNBC cells in vitro suggest 
that rG3 leads to decreased stability and integrity of the ECM and cell cytoskeleton, 
supporting apoptosis. Taken together, functional analysis of differentially expressed genes 
after rG3 treatment indicates widespread apoptotic induction in MDA-MB-231 cells in 
comparison to treated fibroblasts and suggests TP53- dependent signaling is partially 
responsible.  
 
Table 17. Top 75 Reactome pathways utilized by differentially expressed genes in rG3 
treated MDA-MB-231s 
Pathway identifier Pathway name #Entities found #Entities 
total 
R-HSA-168256 Immune System 364 2765 
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R-HSA-1430728 Metabolism 335 3461 
R-HSA-392499 Metabolism of proteins 217 2373 
R-HSA-1280215 Cytokine Signaling in Immune system 208 1222 
R-HSA-162582 Signal Transduction 189 3002 
R-HSA-168249 Innate Immune System 177 1632 
R-HSA-74160 Gene expression (Transcription) 169 1619 
R-HSA-1280218 Adaptive Immune System 156 1189 
R-HSA-73857 RNA Polymerase II Transcription 153 1440 
R-HSA-212436 Generic Transcription Pathway 147 1300 
R-HSA-597592 Post-translational protein modification 135 1530 
R-HSA-556833 Metabolism of lipids 132 1316 
R-HSA-913531 Interferon Signaling 117 292 
R-HSA-983169 Class I MHC mediated antigen 
processing & presentation 
109 464 
R-HSA-1643685 Disease 98 1496 
R-HSA-877300 Interferon gamma signaling 97 176 
R-HSA-6798695 Neutrophil degranulation 95 480 
R-HSA-449147 Signaling by Interleukins 90 910 
R-HSA-909733 Interferon α/β signaling 90 141 
R-HSA-198933 Immunoregulatory interactions between 
a Lymphoid and a non-Lymphoid cell 
87 316 
R-HSA-1266738 Developmental Biology 85 1175 
R-HSA-1236975 Antigen processing-Cross presentation 83 186 
R-HSA-1236974 ER-Phagosome pathway 80 164 
R-HSA-8953897 Cellular responses to external stimuli 79 598 
R-HSA-382551 Transport of small molecules 78 987 
R-HSA-2262752 Cellular responses to stress 76 511 
R-HSA-983170 Antigen Presentation: Folding, 
assembly and peptide loading of class 
I MHC 
76 102 
R-HSA-1236977 Endosomal/Vacuolar pathway 74 82 
R-HSA-1640170 Cell Cycle 71 680 
R-HSA-109582 Hemostasis 68 798 
R-HSA-3700989 Transcriptional Regulation by TP53 67 485 
R-HSA-8953854 Metabolism of RNA 60 782 
R-HSA-69278 Cell Cycle, Mitotic 57 566 
R-HSA-372790 Signaling by GPCR 56 1509 
R-HSA-5653656 Vesicle-mediated transport 55 828 
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R-HSA-199991 Membrane Trafficking 52 667 
R-HSA-422475 Axon guidance 44 611 
R-HSA-1428517 The citric acid (TCA) cycle and 
respiratory electron transport 
44 219 
R-HSA-72766 Translation 43 381 
R-HSA-166520 Signalling by NGF 42 615 
R-HSA-8957322 Metabolism of steroids 42 316 
R-HSA-425407 SLC-mediated transmembrane transport 39 413 
R-HSA-1852241 Organelle biogenesis and maintenance 39 334 
R-HSA-68886 M Phase 39 390 
R-HSA-163200 Respiratory electron transport, ATP 
synthesis by chemiosmotic coupling, and 
heat production by uncoupling proteins. 
39 146 
R-HSA-73894 DNA Repair 38 348 
R-HSA-71291 Metabolism of amino acids and 
derivatives 
37 656 
R-HSA-2172127 DAP12 interactions 37 509 
R-HSA-71387 Metabolism of carbohydrates 36 414 
R-HSA-211859 Biological oxidations 36 548 
R-HSA-196854 Metabolism of vitamins and cofactors 36 356 
R-HSA-187037 NGF signalling via TRKA from the 
plasma membrane 
35 527 
R-HSA-1474244 Extracellular matrix organization 34 329 
R-HSA-186797 Signaling by PDGF 34 520 
R-HSA-2424491 DAP12 signaling 34 492 
R-HSA-194315 Signaling by Rho GTPases 34 445 
R-HSA-388396 GPCR downstream signaling 34 1140 
R-HSA-611105 Respiratory electron transport 34 115 
R-HSA-177929 Signaling by EGFR 33 502 
R-HSA-6785807 Interleukin-4 and 13 signaling 33 212 
R-HSA-2454202 Fc epsilon receptor (FCERI) signaling 32 594 
R-HSA-186763 Downstream signal transduction 32 489 
R-HSA-72312 rRNA processing 32 239 
R-HSA-1433557 Signaling by SCF-KIT 31 468 
R-HSA-8978868 Fatty acid metabolism 30 435 
R-HSA-69620 Cell Cycle Checkpoints 30 279 
R-HSA-72306 tRNA processing 30 205 
R-HSA-5663205 Infectious disease 29 531 
R-HSA-3371556 Cellular response to heat stress 29 133 
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R-HSA-5368287 Mitochondrial translation 29 143 
R-HSA-1483257 Phospholipid metabolism 28 315 
R-HSA-446203 Asparagine N-linked glycosylation 28 420 
R-HSA-5357801 Programmed Cell Death 28 187 
R-HSA-109581 Apoptosis 28 179 




Table 18: Top 75 pathways utilized by upregulated genes in MDA-MB-231 cells after rG3 
treatment (with significant z-score) 
Pathway identifier Pathway name #Entities found #Entities 
total 
R-HSA-168256 Immune System 107 2765 
R-HSA-1280215 Cytokine Signaling in Immune system 91 1222 
R-HSA-1280218 Adaptive Immune System 69 1189 
R-HSA-983169 Class I MHC mediated antigen 
processing & presentation 
63 464 
R-HSA-913531 Interferon Signaling 63 292 
R-HSA-983170 Antigen Presentation: Folding, 
assembly and peptide loading of class 
I MHC 
61 102 
R-HSA-1236974 ER-Phagosome pathway 61 164 
R-HSA-1236975 Antigen processing-Cross 
presentation 
61 186 
R-HSA-877300 Interferon gamma signaling 60 176 
R-HSA-198933 Immunoregulatory interactions 
between a Lymphoid and a non-
Lymphoid cell 
59 316 
R-HSA-1236977 Endosomal/Vacuolar pathway 58 82 
R-HSA-909733 Interferon α/β signaling 57 141 
R-HSA-1430728 Metabolism 50 3461 
R-HSA-392499 Metabolism of proteins 39 2373 
R-HSA-168249 Innate Immune System 32 1632 
R-HSA-449147 Signaling by Interleukins 31 910 
R-HSA-1643685 Disease 30 1496 
R-HSA-8953854 Metabolism of RNA 28 782 
R-HSA-162582 Signal Transduction 26 3002 
R-HSA-109582 Hemostasis 25 798 
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R-HSA-6798695 Neutrophil degranulation 20 480 
R-HSA-5663205 Infectious disease 19 531 
R-HSA-72312 rRNA processing 18 239 
R-HSA-597592 Post-translational protein modification 18 1530 
R-HSA-382551 Transport of small molecules 16 987 
R-HSA-5653656 Vesicle-mediated transport 16 828 
R-HSA-71387 Metabolism of carbohydrates 15 414 
R-HSA-2262752 Cellular responses to stress 15 511 
R-HSA-8953897 Cellular responses to external stimuli 15 598 
R-HSA-1428517 The citric acid (TCA) cycle and 
respiratory electron transport 
14 219 
R-HSA-76002 Platelet activation, signaling and 
aggregation 
14 305 
R-HSA-199991 Membrane Trafficking 14 667 
R-HSA-74160 Gene expression (Transcription) 14 1619 
R-HSA-114608 Platelet degranulation  13 137 
R-HSA-76005 Response to elevated platelet cytosolic 
Ca2+ 
13 144 
R-HSA-1266738 Developmental Biology 13 1175 
R-HSA-447115 Interleukin-12 family signaling 12 95 
R-HSA-422475 Axon guidance 12 611 
R-HSA-212436 Generic Transcription Pathway 12 1300 
R-HSA-73857 RNA Polymerase II Transcription 12 1440 
R-HSA-6785470 tRNA processing in the mitochondrion 11 47 
R-HSA-8868766 rRNA processing in the mitochondrion 11 41 
R-HSA-72306 tRNA processing 11 205 
R-HSA-1474244 Extracellular matrix organization 11 329 
R-HSA-168255 Influenza Life Cycle 10 183 
R-HSA-8950505 Gene and protein expression by JAK-
STAT signaling after Interleukin-12 
stimulation 
10 74 
R-HSA-168254 Influenza Infection 10 194 
R-HSA-72766 Translation 10 381 
R-HSA-3700989 Transcriptional Regulation by TP53 10 485 
R-HSA-1640170 Cell Cycle 10 680 
R-HSA-556833 Metabolism of lipids 10 1316 
R-HSA-163200 Respiratory electron transport, ATP 
synthesis by chemiosmotic coupling, 





R-HSA-2172127 DAP12 interactions 9 509 
R-HSA-372790 Signaling by GPCR 9 1509 
R-HSA-156902 Peptide chain elongation 8 99 
R-HSA-70171 Glycolysis 8 108 
R-HSA-156842 Eukaryotic Translation Elongation 8 104 
R-HSA-611105 Respiratory electron transport 8 115 
R-HSA-70326 Glucose metabolism 8 139 
R-HSA-2408522 Selenoamino acid metabolism 8 189 
R-HSA-168273 Influenza Viral RNA Transcription and 
Replication 
8 171 
R-HSA-917937 Iron uptake and transport 8 83 
R-HSA-6785807 Interleukin-4 and 13 signaling 8 212 
R-HSA-69275 G2/M Transition 8 210 
R-HSA-453274 Mitotic G2-G2/M phases 8 212 
R-HSA-381119 Unfolded Protein Response (UPR) 8 160 
R-HSA-71291 Metabolism of amino acids and 
derivatives 
8 656 
R-HSA-69278 Cell Cycle, Mitotic 8 566 
R-HSA-2424491 DAP12 signaling 8 492 
R-HSA-72689 Formation of a pool of free 40S subunits 7 106 
R-HSA-72764 Eukaryotic Translation Termination 7 108 
R-HSA-975956 Nonsense Mediated Decay (NMD) 
independent of the Exon Junction 
Complex (EJC) 
7 102 
R-HSA-156827 L13a-mediated translational silencing of 
Ceruloplasmin expression 
7 118 
R-HSA-1799339 SRP-dependent cotranslational protein 
targeting to membrane 
7 120 
 
Table 19: Top 75 pathways utilized by downregulated genes with significant z-score 
Pathway 
identifier 




Extracellular matrix organization 14 329 
R-HSA-
3000178 
ECM proteoglycans 12 78 
R-HSA-216083 Integrin cell surface interactions 10 87 




R-HSA-168256 Immune System 9 2765 
R-HSA-162582 Signal Transduction 9 3002 
R-HSA-
3000170 








Cytokine Signaling in Immune system 7 1222 
R-HSA-
8948216 
Collagen chain trimerization 6 44 
R-HSA-
2022090 





Collagen degradation 6 69 
R-HSA-
1650814 





Collagen formation 6 104 
R-HSA-
6785807 
Interleukin-4 and 13 signaling 6 212 
R-HSA-186797 Signaling by PDGF 6 520 
R-HSA-449147 Signaling by Interleukins 6 910 
R-HSA-
8874081 
MET activates PTK2 signaling 5 32 
R-HSA-
8875878 
MET promotes cell motility 5 45 
R-HSA-
6806834 
Signaling by MET 5 87 
R-HSA-
2173782 
Binding and Uptake of Ligands by 
Scavenger Receptors 
5 169 
R-HSA-397014 Muscle contraction 5 216 
R-HSA-76002 Platelet activation, signaling and 
aggregation 
5 305 
R-HSA-375165 NCAM signaling for neurite out-growth 5 306 
R-HSA-422475 Axon guidance 5 611 
R-HSA-109582 Hemostasis 5 798 
R-HSA-
5653656 
Vesicle-mediated transport 5 828 
R-HSA-
1266738 
Developmental Biology 5 1175 
R-HSA-
1643685 
Disease 5 1496 
R-HSA-390522 Striated Muscle Contraction 4 40 
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R-HSA-419037 NCAM1 interactions 4 44 
R-HSA-
3781865 
Diseases of glycosylation 4 190 
R-HSA-597592 Post-translational protein modification 4 1530 
R-HSA-392499 Metabolism of proteins 4 2373 
R-HSA-
1430728 
Metabolism 4 3461 
R-HSA-445355 Smooth Muscle Contraction 3 39 
R-HSA-
3560782 





Scavenging by Class A Receptors 3 50 
R-HSA-76009 Platelet Aggregation (Plug Formation) 3 52 
R-HSA-
8957275 
Post-translational protein phosphorylation 3 109 
R-HSA-381426 Regulation of Insulin-like Growth Factor 
(IGF) transport and uptake by Insulin-like 
Growth Factor Binding Proteins (IGFBPs) 
3 127 
R-HSA-114608 Platelet degranulation  3 137 





Glycosaminoglycan metabolism 3 183 
R-HSA-202733 Cell surface interactions at the vascular 
wall 
3 256 
R-HSA-198933 Immunoregulatory interactions between a 
Lymphoid and a non-Lymphoid cell 
3 316 
R-HSA-71387 Metabolism of carbohydrates 3 414 
R-HSA-
1280218 
Adaptive Immune System 3 1189 
R-HSA-
3595174 





Defective CHST3 causes SEDCJD 2 9 
R-HSA-
3595177 
Defective CHSY1 causes TPBS 2 10 
R-HSA-430116 GP1b-IX-V activation signalling 2 12 
R-HSA-
2022923 
Dermatan sulfate biosynthesis 2 13 
R-HSA-
2214320 
Anchoring fibril formation 2 15 
R-HSA-75892 Platelet Adhesion to exposed collagen 2 16 
R-HSA-
3560801 















Crosslinking of collagen fibrils 2 24 
R-HSA-
2022870 
Chondroitin sulfate biosynthesis 2 25 
R-HSA-
2024101 
CS/DS degradation 2 29 
R-HSA-
1971475 
A tetrasaccharide linker sequence is 




Molecules associated with elastic fibres 2 38 
R-HSA-
1566948 
Elastic fibre formation 2 46 
R-HSA-114604 GPVI-mediated activation cascade 2 64 
R-HSA-
1793185 





RUNX1 regulates genes involved in 










Transcriptional regulation by RUNX1 2 260 
R-HSA-212436 Generic Transcription Pathway 2 1300 
R-HSA-73857 RNA Polymerase II Transcription 2 1440 
R-HSA-74160 Gene expression (Transcription) 2 1619 
R-HSA-
1566977 
Fibronectin matrix formation 1 7 
R-HSA-
3656244 


























Figure 20. Panther Biological Process utilized by top genes expressed with negative z-

































PI3 kinase pathway Cytoskeletal 






























Figure 21. Panther Pathway utilized by top genes expressed with positive z-score 




Figure 22. Panther Biological Process utilized by top genes expressed with positive z-
























rG3 binds to integrin α-6 β-4 to modulate downstream signaling 
Integrin transcript expression, shown in Figure 23, indicates that rG3 highly 
upregulates the expression of ITGA2, ITGA3, ITGA6, ITGB1, ITGB4, and ITGB5 on the 
MDA-MB-231 cell surface after 24 hours of in vitro treatment. Additionally, the α6β4 
signaling pathway specific to rG3 originally proposed is shown in Fig. 24 with RNA 
sequencing results applied. Taken together with the heat map in Figure 24, these results show 
modulation of the PI3K/AKT pathway through integrin expression by rG3 treatment.  
As previously discussed, any normal cellular signaling and ECM pathways 
containing integrin receptors are deregulated in cancer to allow cellular migration, as 








Integrin transcript counts in MDA-MB-231 cells
J C 0 J T 24 J C 24 J T 0
Figure 23. Integrin transcript expression in MDA-MB-231 cells at 0 and 
after 24 hours of in vitro treatment. JC = control; JT = rG3 treated.  
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atypical hyperplasia, ductal carcinoma in situ (DCIS) and invasive tumors 307. α6β4 integrin 
is thought to remodel the ECM through interaction with the PI3K and RhoA cell signaling 
pathways 308,309, supporting PI3K activation through different receptor tyrosine kinases 
(RTKs) 312. targeted therapies 137. Notably, α6β4 integrin may modulate oncogenic signaling 
through association with Laminin molecules in the ECM. Modulation of integrin transcript 
expression after rG3 treatment indicates that this recombinant form of Laminin-5 is binding 


























Figure 24: α6β4 integrin modulation and signaling in MDA-MB-231 cells with and without 
rG3 treatment. Left half of node represents untreated cells; right half of node represents 
treated cells. Blue represents expression levels of 0-1. Shades of red represent high 




Modulation of the α6β4 integrin signaling pathway through rG3 
RNA seq transcript count values between rG3 treated and untreated MDA-MB-231 
cells were used to curate pathways using PathVisio and WikiPathways 435–438; raw counts for 
rG3 treated and untreated MDA-MB-231 cells and primary swine fibroblasts were 
normalized and prepared into heat maps with Genesis 428. Blue = downregulation/low 
expression; red = upregulation /high expression; Pathvisio gray = no change; heatmap gray = 
gene not found. For comparison of human and swine genes, swine gene orthologs were 
included if possible using OrthoDB 439. After rG3 treatment, upregulation of multiple 
members of the PI3K/AKT pathway is shown in Fig 24. Upregulated gene transcripts include 
ITGA6 and ITGB4; especially important for apoptosis are the upregulated gene transcripts of 
BIM, BCL2, BAX, P53, BAD, and CASP9.  
Upon binding to its ligand, ITGA6 and ITGB4 are likely upregulated due to “inside-
out” signaling characteristic of integrin molecules 908 that allow intracellular signals to 
increase the affinity of integrin molecules to their extracellular ligands. Downstream, our data 
suggests slight upregulation in PTEN, a multifunctional tumor suppressor previously 
discussed 337,909–911. However, pro-survival signaling molecules such as Paxillin and AKT1 
are not downregulated, but pro-apoptosis molecules downstream of AKT1 including BIM, 
BLC2, BAX, P53, BAD, and CASP9 are upregulated with rG3 treatment. This suggests that 
the signaling mechanisms between ITGA6 and ITGB4 induction and apoptosis induction are 
more complicated than the original hypothesis, and will be elucidated using a more 





Differential expression analysis of MDA-MB-231 cells with and without 20ug/mL rG3 
treatment for 24 hours indicates widespread apoptotic signaling and modulation of cell death 
pathways 
RNA seq transcript count values between rG3 treated and untreated MDA-MB-231 
cells were used to curate pathways using PathVisio and WikiPathways 435–438; raw counts for 
rG3 treated and untreated MDA-MB-231 cells and primary swine fibroblasts were 
normalized and prepared into heat maps in Genesis 428. Blue = downregulation/low 
expression; red = upregulation /high expression; Pathvisio gray = no change; heatmap gray = 
gene not found. For comparison of human and swine genes, swine gene orthologs were 
included if possible using OrthoDB 439. Pathway analysis demonstrates the widespread 
apoptotic signaling that occurs with rG3 treatment after 24 hours (Figure 25).  
A better understanding of the diverse modes of cell death in TNBC cells could 
provide a molecular basis for new strategies targeting apoptotic molecules and programmed 
cell death pathways. Our results elucidate further the cell signaling pathways and factors that 
may modulate apoptosis; widespread apoptotic signaling is seen after rG3 treatment in MDA-
MB-231 cells, confirming the results of rG3 effect on cell viability in Fig 25. Apoptosis, or 
programmed cell death, is tightly regulated process possessing a critical role in cellular 
functions such as cell turnover, homeostasis, growth regulation, early development, immune 
system function, and disease 906,912–916. This defensive mechanism acts to remove infected, 
mutated, or damaged cells in response to a variety of internal and external stimuli, and is 
characterized primarily by a large loss of cellular contact with the matrix 907. Apoptosis can 
occur extrinsically, through activation of death receptors, or intrinsically, through the 
mitochondria 913,914,917; evidence supports that in some cases these two pathways may be 
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converging rather than distinct entities 907. As shown in Fig 25 and 26, rG3 treatment of 
TNBC cells in vitro leads to upregulation of multiple apoptotic molecules and modulation of 
both intrinsic and extrinsic apoptosis, suggesting crosstalk between the two cell signaling 
pathways is induced by rG3 treatment. A series of steps in either the extrinsic or intrinsic 
pathway leads to activation of effector cysteine protease molecules known as caspases. In a 
cascade of apoptotic activity, caspase molecules cleave both each other and nuclear and 
cytoplasmic substrates responsible for the maintenance of nuclear integrity, cell cycle 
progression, and DNA repair 918. Although less frequently, apoptosis can occur independently 
of caspase molecules 919.  
Caspases can be initiated extrinsically in several different ways, including ligation of 
transmembrane members of the TNF receptor superfamily, specifically CD95/Fas or TNF-
related apoptosis-inducing ligand (TRAIL) 920–922. Upregulated apoptotic molecules after rG3 
treatment include the transmembrane members of the TNF receptor superfamily capable of 
downstream apoptosis induction (TRAIL, TRAIL-R4, TRAIL-R1, TRAIL-R2, TNFR-1, 
TNFR-2) and FAS. These data suggest that rG3 treatment is initiating caspases extrinsically, 
which leads to downstream apoptotic signaling modulation. Extrinsic initiation results in 
activation of the initiator caspase-8, which cleaves downstream effector caspases including 
caspase-3 920. Results show that after rG3 treatment, through activation of the TRAIL 
receptors, FADD, CASP8, and CASP10 are upregulated in comparison to untreated TNBC 
cells.  
A wide range of signals in the extrinsic apoptosis pathway are stimulated by p53, the 
most extensively studied and tightly regulated tumor suppressor that can be activated by 
DNA damage, hypoxia, or oncogene expression 923. Our results also show an upregulation of 
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TP53 and TP53 targets (Fig. 26), after rG3 treatment, indicating this tumor suppressor is 
highly involved in apoptosis induced by rG3. When triggered by stress, p53 selectively 
regulates cell cycle arrest, DNA repair, and apoptosis to protect genomic stability and prevent 
tumor formation 264; p53 is often mutated in metastatic tumors; somatic p53 mutations occur 
in greater than 50% of tumors and almost every cancer type 235,265,266. p53 is important in 
therapeutic development as p53-dependent apoptosis contributes to cell death induced by 
chemotherapy 924 and loss of p53 function has been associated with chemoresistance in 
certain tumor types 925,926. Research suggests that p53-mediated apoptosis proceeds primarily 
through the intrinsic apoptotic pathway 927, but the extrinsic pathway is also regulated by p53 
though poorly understood 923. A greater understanding of the p53 modulated apoptosis 
pathways and their crosstalk in response to rG3 treatment suggests rG3 is a valuable tool for 
understanding the molecular mechanisms of cancer development, diagnosis, and therapy. 
The most significant link between p53 activation and apoptosis comes from its ability 
to control pro-apoptotic members of the Bcl-2 family, including Bax, Noxa, Puma, and Bid 
928–932. The intrinsic apoptosis pathway relies upon the the Bcl-2 protein family for release of 
cytochrome c from the mitochondria 933–935, further linking p53 activation to intrinsic 
apoptosis. Much remains to be uncovered regarding the mechanism of apoptotic control by 
p53 targets, but it is accepted that the net effect is increase of the ratio of pro- to anti- 
apoptotic proteins, shifting the balance to favor caspase activation and cell death 923. Bax-
induced release of cytochrome c from the mitochondria subsequently activates caspase-9 
929,936. Interestingly, Bax has been recently shown to participate in apoptosis as an indirect 
p53 target with the primary target  being PUMA/BBC3 937. Noxa is thought to be involved in 
p53 mediated apoptosis in a similar fashion to PUMA/BBC3 and Bax 938. The pro-apoptotic 
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protein Bid has a unique role in uniting the extrinsic death pathway to the intrinsic pathway 
through activation of mitochondrial disruption 929; impact of both pathways may be enhanced 
when these converge through Bid 929. After rG3 treatment of MDA-MB-231 cells in vitro, 
intrinsic apoptotic factors are highly upregulated, including BID, BAK1, BOK, BNIP3, 
NOXA, PUMA, CYTOC, and CASP9 (seen in Fig 25 and 26 in red). Interestingly, although 
anti-apoptotic BCL-XL 939 is upregulated after rG3 treatment, expression of BAK and BOK 
is not inhibited. Modulation of apoptosis through cell cycle regulation is an important cell 
signaling event, and the cell cycle regulator p16(INK4A) (p16) has been reported to be 
upregulated in cervical cancer tissues where it promotes cell survival 940. After rG3 treatment, 
expression of p16 is highly downregulated, suggesting it no longer can positively regulate 
growth. Importantly, we do not see the same upregulation of pro-apoptotic factors in rG3 
treated fibroblasts, although these genes are present; they remain mostly unchanged, as seen 
in Fig. 25. 
Extrinsically, p53 can induce mRNA expression of Fas receptor (CD95/Apo-1), a 
member of the TNF-R family of receptors and a key component of the extrinsic death 
pathway that is activated by binding of its ligand expressed predominantly on T-cells, 
FasL/TNFSF6 941–943. When overexpressed, p53 can also stimulate Fas levels on the cell 
surface, rapidly sensitizing cells to Fas-induced apoptosis before transcription-dependent 
effects are seen 944. In human tumors, there is often a decrease in or disappearance of the 
expression of Fas receptor (Apo-1; CD95) on the cell surface, inhibiting or decreasing Fas-
mediated death signaling that normally would recruit FADD and caspase-8 to the Fas 
receptor to form the death-inducing signaling complex 945,946. In some cases, loss of Fas 
expression can be a result of silencing by STAT-3 and CJUN, which is regulated by PI3K 
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signaling 947,948. FAP-1 has been shown to suppress Fas-mediated apoptosis, but the specific 
mechanisms of inhibition remain unknown 949. FAP-1, in association with either DPP4, 
PLAUR or integrin molecules, is a negative regulator of apoptosis that is involved in 
proteolysis of the extracellular matrix to promote cell adhesion, migration, and invasion; it 
can also enhance tumor growth progression and reducing antitumor response of the immune 
system. During autophagy, FAP-1 protein is degraded, promoting apoptosis 950. Our results 
show that FAP-1 is highly downregulated during rG3 induced apoptosis where it is not able 
to efficiently inhibit FADD/CASP8 signaling. PRKD1, another molecule capable of 
inhibiting FADD/CASP8 signaling, is linked to increased proliferation and survival when 
activated or expressed in various cell lines 951–957. After rG3 treatment in vitro, PRKD1 
expression is highly downregulated, indicating its contribution to the decrease in cell 
survival. 
p53 can also induce TRAIL-R2, as confirmed by our results, which is the death-
domain-containing receptor for TNF-related apoptosis-inducing ligand (TRAIL) 958. PERP, 
p53 apoptosis effector related to PMP-22, is another gene that is a direct p53 transcriptional 
target and novel effector of apoptosis 959, but it remains to be defined how specifically this 
gene contributes to p53-mediated apoptosis 960. However, it is known that PERP is induced 
during apoptosis only and not during cell cycle arrest 961. After rG3 treatment in vitro, the 
PERP gene is highly upregulated (see Appendix C).  Elevation of the PERP protein 
positively influences p53 through enhancement of nuclear localization and stabilization, 
revealing a potential target for exploitation in enhancing p53 activity 961. Normally, caspase-8 
and -10 respond to external death ligands while caspase-2 and -9 sense changes in 
mitochondrial potential from the intrinsic pathway 929. After treatment, upregulation of 
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CASP8, CASP10, CASP2, and CASP9 is seen, in addition to upregulation of CASP7, 
CASP3, CASP4, CASP6, and DFFA indicating rG3 activates both the extrinsic and intrinsic 
apoptotic pathway and modulates caspase signaling (Fig. 25/26).  
P53, in addition to its ability to activate genes directly supporting apoptosis, can also 
regulate genes that elude typical anti-apoptotic pathways.  Pursuant to our focus, p53 has the 
ability to regulate PTEN, the negative regulator of the PI3K/AKT pathway 962 Normally, the 
PI3K pathway phosphorylates the major inhibitor of p53, Mdm2, in order to promote cell 
survival under normal conditions 929. During stress-induced activation of p53, however, 
caspase-mediated cleavage and degradation of the AKT protein 929,963 and expression of the 
PTEN tumor suppressor gene (which dephosphorylates PI3K), are induced, impairing 
PI3K/AKT signaling function 964. Our data show upregulation of PTEN and modulation of 
the PI3K cell signaling pathway after rG3 treatment (Fig. 24). Taken together, this indicates 
that p53-dependent apoptosis induced by rG3 treatment allows cells to counteract survival 
signals - although still present - possibly reducing the threshold required for pro-apoptotic 
factors to activate apoptotic signaling and again shifting the balance from survival to 
apoptosis. This data, demonstrating widespread apoptotic signaling, suggests that by 
simultaneously targeting multiple pathways of the apoptotic process, p53 increases the 
probability of successful programmed cell death. The ability of rG3 to induce such a 
widespread p53-dependednt effect makes it an incredibly valuable research tool. 
Additionally, since different cell types have different induction programs after p53 activation 




Interestingly, some upregulation of pro-survival factors can be seen with rG3 
treatment, though the effect is not extreme in comparison to the upregulation of pro-apoptotic 
factors (Fig. 24), suggesting that apoptosis is about shifting a balance between two programs, 
rather than specifically silencing all growth signals. An important PI3K/AKT factor that is 
downregulated with rG3 treatment is PIK3R2, which normally promotes cell growth and 
survival 965. Interestingly, GSK3 is also downregulated with rG3 treatment. GSK3 
hyperactivation has been implicated in inflammation, neurological disorders, and 
tumorigenesis 966. It is also implicated in the Wnt-β-catenin signaling pathway with a  
positive role in Wnt signal transduction by phosphorylating the Wnt receptors low density 
lipoprotein receptor-related protein (LRP5/6) 966. As seen in Fig. 24/25, MDM2 is slightly 
regulated with treatment, but possibly cannot inhibit p53 efficiently due to highly upregulated 
p53 activator molecules such as BAX.  
Taken together, the modulation of the apoptotic pathway seen with rG3 treatment, 
especially the induction of p53-depending signaling, suggests this recombinant protein has 
significant potential for use as a research tool to further study the complicated interaction of 





Figure 25: Apoptosis modulation and signaling in MDA-MB-231 cells with and without rG3 treatment. Left half of node represents 
untreated cells; right half of node represents treated cells. Blue represents expression levels of 0-1. Shades of red represent high 










Figure 26: TP53 signaling modulation and signaling in MDA-MB-231 cells with and without 
rG3 treatment. Left half of node represents untreated cells; right half of node represents treated 




CHAPTER FIVE: SUMMARY AND CONCLUSIONS 
Using a global transcriptomic approach, biomarkers, signaling events, and novel 
pathways of early postnatal mammary gland development were elucidated. Multivariate 
techniques that are not frequently applied to developmental biology were used to analyze the 
developing mammary transcriptome with success. PCA confirmed the hypothesis that there 
are unique signaling events occurring over time and confirmed our transcriptomic data set 
allows for evaluation of mammary development throughout time without interference from 
variability between animals used. RDA confirmed that although variability in animals 
sampled does exist, it does not interfere with the variable of interest: that of over time (age). 
CLA confirmed trends are present in the transcriptomic data set correlating to time; K-means 
clustering of our RNA-seq data set in Genesis generated unique gene sets demonstrating 
similar gene expression over time which were further elucidated using discriminant function 
analysis. Discriminate analysis of gene expression during the two phases chosen from 
histological analysis revealed temporal regulation of important signaling events and 
importantly, confirmed significant involvement of the immune system in early mammary 
development, specifically during the first two months after birth. Pathway analysis on the 
differentially expressed genes during early mammary development also indicated that the 
adaptive immune system is highly utilized beginning in the period of 18-25 days after birth 
and remains active until at least 39 days after birth, during which it contributes to 
developmental trends. PRC analysis further confirmed these results, indicating that these 
same immune pathways are utilized by genes with positive PRC values (increasing in 
abundance with the curve). Uniquely, PRC allowed identification of specific genes 
contributing functionally, and possibly interacting with each other, toward development over 
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time. We hypothesized that the genes decreasing in abundance with the PRC curve are very 
early genes contributing to the phenotype at birth or prior; these could also be similar to 
phase one genes (upregulated during 4-18 DOA) discussed in the discriminant analysis 
section, which was successfully confirmed. Conversely, we hypothesized that the positive 
PRC genes, those that increase in abundance with the PRC curve, are developmental genes, 
possibly similar to phase two DA genes discussed previously. Our data suggest that these 
positive PRC genes function synergistically to significantly contribute to early postnatal 
mammary development over time. WGCNA was used to confirm the hypothesis that there 
are genuine functional modules present within the overall RNA-seq dataset generated from 
samples collected during pre-pubertal mammary gland development, which were dissected 
using the MCODE algorithm and pathway analysis. Several clusters were significant to our 
research, especially those demonstrating a collaborative relationship between adipocytes, 
immune cells, the ECM, and mammary epithelial cells with some integrin involvement in 
promotion of growth of the mammary gland.  
To our knowledge, swine models have not been used to investigate functions of any 
of these genes in early postnatal development, adding further novelty to our approach. Taken 
together, our data and the assessment of key immune regulators and markers in swine by 
other researchers suggests this is a much better model of human innate immunity and disease 
than rodents. Accordingly, understanding the function of immune molecules in normal 
development and their concert with other signaling mechanisms can provide insight into 
these roles during cancer development. In Chapter 1, we have provided a model to achieve 
what was previously lacking in mammary biology: continuous developmental data collected 
from the same live animal over time.  
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Our data suggested that there is significant growth occurring immediately after birth, 
including events previously suspected such as epithelial cell proliferation, branching, and 
expansion, as well as significant immune system interaction. The presence of oncogenes and 
proto-oncogenes in our model suggest that a better understanding of developmental 
mammary biology and could provide future areas of study for carcinogenesis and breast 
cancer treatment, leading us to investigate cellular signaling at the same global transcriptomic 
level in a TNBC model in vitro.  
 In Chapter 2, a recombinant laminin protein (rG3) with significant potential to be 
used as a research tool was evaluated to study apoptosis in both normal and tumorigenic 
models. By using primary swine fibroblasts as a control in comparison to the frequently 
debated MCF-10A line, we were able to confirm that signaling pathways utilized by this 
normal cell line were very similar to those identified by K-means clustering in early 
mammary development, including immune system, metabolism, signal transduction, cell 
cycle regulation, gene transcription, and protein translation. The fibroblasts lacked TP53 and 
CASP in the top 5% of genes expressed while integrin β4, integrin β1, and integrin α6 were 
still present. Combined with the absence of an rG3 effect at 20ug/mL, these cells 
demonstrated appropriateness as a control. Interestingly, the top pathways utilized by the 
MDA-MB-231 cells during normal growth and proliferation cycles were almost identical to 
the signaling pathways identified by K-means clustering in early mammary development and 
the pathways utilized by primary swine fibroblasts during growth.   
Possibly the most significant finding in Chapter 2 is the widespread apoptotic 
induction and downregulation of extracellular matrix organization that occurs when rG3 is 
applied in vitro. Further functional analysis of differentially expressed genes after rG3 
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treatment indicated TP53- dependent signaling is partially responsible, and suggest crosstalk 
between intrinsic and extrinsic apoptotic pathways. A greater understanding of a range of 
apoptosis pathways and their crosstalk can be gained by using rG3 as a tool.  
 The original hypothesis of this dissertation has been confirmed; there are specific 
transcriptional differences and a unique interaction of a gene set over time that contributes to 
postnatal mammary gland development, and this model clearly shares similarities and 
signaling pathways with oncogenic development. Now that we have a better understanding of 
normal development using high throughput analysis and a clinically relevant animal model, it 
is obvious which pathways should be studied in depth to better understand oncogenic 
development- those of the adaptive and innate immune system, ECM remodeling and integrin 
interactions, and extrinsic and intrinsic TP53-mediated apoptosis, which could lead to early 
detection of potential tumorigenic growth and identification of potential treatment avenues. 
Presented is a novel, comprehensive, transcriptomic model of early mammary development 
along with several panels of biomarkers that possess a role in normal mammary development, 
are involved in aggressive cancers, and are affected by apoptosis induced by rG3 treatment. 
These biomarkers and the cell signaling modules discussed in this dissertation are highly 











APPENDIX A.  PRC Top 50 positive weighted genes 
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APPENDIX B. PRC Top 50 negative genes 
PRC 
Weight 
Gene ID Gene ID2 Mapped 
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KCNB1 Potassium voltage-gated 












































ENSG00000169429 CXCL8 14400 
ENSG00000175061 LRRC75A-AS1 7937 
ENSG00000151651 ADAM8 7685 
ENSG00000090339 ICAM1 6827 
ENSG00000162645 GBP2 6697 
ENSG00000198840 MT-ND3 6521 
ENSG00000183696 UPP1 6440 
ENSG00000186480 INSIG1 5968 
ENSG00000214049 UCA1 5799.5 
ENSG00000196352 CD55 5793.5 
ENSG00000073008 PVR 5616 
ENSG00000021355 SERPINB1 5519 
ENSG00000117335 CD46 5257 
ENSG00000197249 SERPINA1 4855 
ENSG00000160932 LY6E 4722 
ENSG00000049245 VAMP3 4634 
ENSG00000204592 HLA-E 4584 
ENSG00000128340 RAC2 4534 
ENSG00000162433 AK4 4517 
ENSG00000163739 CXCL1 4480 
ENSG00000138771 SHROOM3 4386 
ENSG00000107959 PITRM1 3633 
ENSG00000126860 EVI2A 3608 
ENSG00000141682 PMAIP1 3559 
ENSG00000197971 MBP 3464 
ENSG00000275216 RP11-54H7.4 3463.8 
ENSG00000198695 MT-ND6 3459 
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ENSG00000204388 HSPA1B 3355 
ENSG00000135373 EHF 3347 
ENSG00000137210 TMEM14B 3235 
ENSG00000091317 CMTM6 3184 
ENSG00000019582 CD74 3025 
ENSG00000176171 BNIP3 3020.25 
ENSG00000162892 IL24 2958 
ENSG00000166710 B2M 2946.5 
ENSG00000177410 ZFAS1 2908 
ENSG00000160213 CSTB 2890 
ENSG00000173432 SAA1 2858 
ENSG00000189143 CLDN4 2856 
ENSG00000234741 GAS5 2849 
ENSG00000183255 PTTG1IP 2828 
ENSG00000119917 IFIT3 2816 
ENSG00000130303 BST2 2773 
ENSG00000110218 PANX1 2739 
ENSG00000182952 HMGN4 2721 
ENSG00000158825 CDA 2669 
ENSG00000011422 PLAUR 2652 
ENSG00000099204 ABLIM1 2644.5 
ENSG00000204520 MICA 2630 
ENSG00000172137 CALB2 2571 
ENSG00000121797 CCRL2 2544 
ENSG00000087074 PPP1R15A 2418.8 
ENSG00000138772 ANXA3 2369.666667 
ENSG00000133142 TCEAL4 2345 
ENSG00000002586 CD99 2335.5 
ENSG00000204381 LAYN 2291 
ENSG00000108679 LGALS3BP 2201.111111 
ENSG00000160326 SLC2A6 2177 
ENSG00000134802 SLC43A3 2133.142857 
ENSG00000211459 MT-RNR1 2116.8 
ENSG00000085063 CD59 2105.333333 
ENSG00000204387 C6orf48 2085.5 
ENSG00000111846 GCNT2 2064 
ENSG00000146678 IGFBP1 2050 
ENSG00000101846 STS 2048 
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ENSG00000212907 MT-ND4L 2032.5 
ENSG00000186866 POFUT2 2030 
ENSG00000184584 TMEM173 1995 
ENSG00000185499 MUC1 1977 
ENSG00000165949 IFI27 1933 
ENSG00000112379 ARFGEF3 1912 
ENSG00000107984 DKK1 1910.166667 
ENSG00000166920 C15orf48 1884 
ENSG00000198712 MT-CO2 1867.666667 
ENSG00000132334 PTPRE 1853 
ENSG00000163235 TGFA 1843 
ENSG00000137275 RIPK1 1816 
ENSG00000132561 MATN2 1788.5 
ENSG00000130513 GDF15 1745.5 
ENSG00000163694 RBM47 1735 
ENSG00000101439 CST3 1675.2 
ENSG00000148346 LCN2 1675 
ENSG00000166145 SPINT1 1661 
ENSG00000108064 TFAM 1660 
ENSG00000222041 LINC00152 1652 
ENSG00000198886 MT-ND4 1644.311475 
ENSG00000128487 SPECC1 1640 
ENSG00000198804 MT-CO1 1630.527027 
ENSG00000132821 VSTM2L 1629 
ENSG00000198113 TOR4A 1627 
ENSG00000198899 MT-ATP6 1623.428571 
ENSG00000164818 DNAAF5 1616 
ENSG00000136205 TNS3 1612.2 
ENSG00000185567 AHNAK2 1604.25 
ENSG00000117151 CTBS 1594 
ENSG00000198768 APCDD1L 1591 
ENSG00000177106 EPS8L2 1579 
ENSG00000169129 AFAP1L2 1575 
ENSG00000125538 IL1B 1569 
ENSG00000248527 MTATP6P1 1560.666667 
ENSG00000003436 TFPI 1559.666667 
ENSG00000149564 ESAM 1554 
 
 207 
ENSG00000136244 IL6 1548.4 
ENSG00000127399 LRRC61 1532.666667 
ENSG00000198938 MT-CO3 1529.179487 
ENSG00000133321 RARRES3 1519 
ENSG00000013588 GPRC5A 1481.818182 
ENSG00000198888 MT-ND1 1479.6 
ENSG00000069122 ADGRF5 1462.4 
ENSG00000140950 TLDC1 1454 
ENSG00000228253 MT-ATP8 1439.5 
ENSG00000167642 SPINT2 1410 
ENSG00000171606 ZNF274 1401 
ENSG00000027697 IFNGR1 1388 
ENSG00000150403 TMCO3 1388 
ENSG00000164251 F2RL1 1383 
ENSG00000146833 TRIM4 1381 
ENSG00000116701 NCF2 1373 
ENSG00000198763 MT-ND2 1364.615385 
ENSG00000162511 LAPTM5 1351 
ENSG00000104611 SH2D4A 1340 
ENSG00000163814 CDCP1 1329.08 
ENSG00000128567 PODXL 1321.25 
ENSG00000141524 TMC6 1321 
ENSG00000122862 SRGN 1311 
ENSG00000050344 NFE2L3 1307 
ENSG00000206053 HN1L 1302 
ENSG00000142166 IFNAR1 1286.5 
ENSG00000112096 SOD2 1286.018868 
ENSG00000181381 DDX60L 1267 
ENSG00000099940 SNAP29 1260 
ENSG00000065923 SLC9A7 1248 
ENSG00000214113 LYRM4 1238 
ENSG00000089327 FXYD5 1227.333333 
ENSG00000099998 GGT5 1223 
ENSG00000137699 TRIM29 1213.666667 
ENSG00000169174 PCSK9 1195 
ENSG00000138134 STAMBPL1 1187 
ENSG00000204604 ZNF468 1185 
ENSG00000105612 DNASE2 1158 
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ENSG00000132182 NUP210 1153 
ENSG00000101191 DIDO1 1122 
ENSG00000109519 GRPEL1 1119 
ENSG00000112763 BTN2A1 1111 
ENSG00000198142 SOWAHC 1075 
ENSG00000160285 LSS 1072.888889 
ENSG00000196743 GM2A 1056.5 
ENSG00000117984 CTSD 1056.333333 
ENSG00000115648 MLPH 1053 
ENSG00000188112 C6orf132 1046.2 
ENSG00000104368 PLAT 1046 
ENSG00000120889 TNFRSF10B 1043.75 
ENSG00000163565 IFI16 1037.333333 
ENSG00000172270 BSG 1035.136364 
ENSG00000164096 C4orf3 1031.75 
ENSG00000188707 ZBED6CL 1026.5 
ENSG00000111057 KRT18 1026.5 
ENSG00000130707 ASS1 1022 
ENSG00000171067 C11orf24 1011 
ENSG00000116815 CD58 1001 
ENSG00000214944 ARHGEF28 996.5 
ENSG00000130312 MRPL34 991 
ENSG00000133216 EPHB2 991 
ENSG00000228300 C19orf24 987 
ENSG00000125657 TNFSF9 970 
ENSG00000240694 PNMA2 946 
ENSG00000198727 MT-CYB 945.8636364 
ENSG00000059804 SLC2A3 942.25 
ENSG00000148300 REXO4 939 
ENSG00000170949 ZNF160 937 
ENSG00000163597 SNHG16 895.5 
ENSG00000106305 AIMP2 889 
ENSG00000203875 SNHG5 886.5 
ENSG00000135114 OASL 875 
ENSG00000219481 NBPF1 874 
ENSG00000181104 F2R 866 
ENSG00000123843 C4BPB 862 
ENSG00000170542 SERPINB9 859.5 
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ENSG00000197077 KIAA1671 859 
ENSG00000181634 TNFSF15 858.3333333 
ENSG00000181885 CLDN7 855 
ENSG00000231925 TAPBP 853.8823529 
ENSG00000008394 MGST1 853.2 
ENSG00000210082 MT-RNR2 852.990099 
ENSG00000227507 LTB 836 
ENSG00000176974 SHMT1 834 
ENSG00000182307 C8orf33 824 
ENSG00000174652 ZNF266 822 
ENSG00000176340 COX8A 819.6 
ENSG00000130023 ERMARD 818 
ENSG00000107738 C10orf54 813 
ENSG00000041353 RAB27B 803 
ENSG00000196878 LAMB3 802.7083333 
ENSG00000198910 L1CAM 802.3 
ENSG00000146670 CDCA5 801.5 
ENSG00000198585 NUDT16 789 
ENSG00000151388 ADAMTS12 788.75 
ENSG00000132846 ZBED3 785 
ENSG00000184292 TACSTD2 778.5 
ENSG00000184281 TSSC4 773 
ENSG00000189223 PAX8-AS1 772.6666667 
ENSG00000026751 SLAMF7 772.5 
ENSG00000145623 OSMR 767.4761905 
ENSG00000127666 TICAM1 765 
ENSG00000075218 GTSE1 762 
ENSG00000185803 SLC52A2 758.6666667 
ENSG00000141504 SAT2 755.5 
ENSG00000221963 APOL6 754.5 
ENSG00000134955 SLC37A2 747.7692308 
ENSG00000105355 PLIN3 747 
ENSG00000172927 MYEOV 743 
ENSG00000214026 MRPL23 737 
ENSG00000181192 DHTKD1 733 
ENSG00000166801 FAM111A 732 
ENSG00000169689 STRA13 730 
ENSG00000204525 HLA-C 727.95 
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ENSG00000165512 ZNF22 724 
ENSG00000198546 ZNF511 719 
ENSG00000063241 ISOC2 717 
ENSG00000197608 ZNF841 712 
ENSG00000242485 MRPL20 711 
ENSG00000145365 TIFA 704 
ENSG00000166012 TAF1D 703.6 
ENSG00000065809 FAM107B 702.4285714 
ENSG00000117602 RCAN3 701 
ENSG00000148677 ANKRD1 698.2666667 
ENSG00000137274 BPHL 683 
ENSG00000163257 DCAF16 680 
ENSG00000181061 HIGD1A 678.5 
ENSG00000146859 TMEM140 672 
ENSG00000204054 LINC00963 671 
ENSG00000247271 ZBED5-AS1 669 
ENSG00000159212 CLIC6 662 
ENSG00000198931 APRT 661.5 
ENSG00000135929 CYP27A1 659 
ENSG00000121858 TNFSF10 657 
ENSG00000232774 FLJ22447 654 
ENSG00000204941 PSG5 648 
ENSG00000006453 BAIAP2L1 647.5 
ENSG00000186283 TOR3A 644 
ENSG00000119673 ACOT2 642 
ENSG00000198959 TGM2 641.893617 
ENSG00000163191 S100A11 639.7916667 
ENSG00000108342 CSF3 639 
ENSG00000119922 IFIT2 636.6666667 
ENSG00000167034 NKX3-1 634 
ENSG00000163975 MELTF 628.8333333 
ENSG00000127870 RNF6 624.6666667 
ENSG00000065518 NDUFB4 624.5 
ENSG00000159128 IFNGR2 623 
ENSG00000142252 GEMIN7 622 
ENSG00000111335 OAS2 613 
ENSG00000136193 SCRN1 612.8571429 
ENSG00000091592 NLRP1 612 
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ENSG00000173272 MZT2A 603 
ENSG00000059378 PARP12 595 
ENSG00000103888 CEMIP 592.5151515 
ENSG00000148773 MKI67 586.2 
ENSG00000046604 DSG2 581 
ENSG00000174718 KIAA1551 580 
ENSG00000130304 SLC27A1 580 
ENSG00000103381 CPPED1 580 
ENSG00000163013 FBXO41 579 
ENSG00000134070 IRAK2 578.8 
ENSG00000130193 THEM6 578 
ENSG00000213654 GPSM3 576 
ENSG00000060558 GNA15 575 
ENSG00000272398 CD24 575 
ENSG00000160336 ZNF761 574 
ENSG00000101187 SLCO4A1 574 
ENSG00000109452 INPP4B 570.75 
ENSG00000119888 EPCAM 564 
ENSG00000132256 TRIM5 558 
ENSG00000067066 SP100 558 
ENSG00000248092 NNT-AS1 557 
ENSG00000162777 DENND2D 553 
ENSG00000106538 RARRES2 553 
ENSG00000166900 STX3 552.5714286 
ENSG00000006744 ELAC2 552.5 
ENSG00000197586 ENTPD6 547.3333333 
ENSG00000185862 EVI2B 545 
ENSG00000163435 ELF3 542 
ENSG00000196422 PPP1R26 542 
ENSG00000175567 UCP2 541.25 
ENSG00000147689 FAM83A 540 
ENSG00000123609 NMI 533 
ENSG00000164744 SUN3 532 
ENSG00000171425 ZNF581 532 
ENSG00000104689 TNFRSF10A 531.5 
ENSG00000147676 MAL2 531 
ENSG00000128335 APOL2 527 
ENSG00000029534 ANK1 525 
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ENSG00000151690 MFSD6 524.75 
ENSG00000090661 CERS4 522 
ENSG00000130775 THEMIS2 521 
ENSG00000125798 FOXA2 521 
ENSG00000134905 CARS2 519.5 
ENSG00000122644 ARL4A 518 
ENSG00000128510 CPA4 515 
ENSG00000186814 ZSCAN30 510 
ENSG00000189339 SLC35E2B 510 
ENSG00000100426 ZBED4 506.5 
ENSG00000157870 FAM213B 505.5 
ENSG00000171051 FPR1 500 
ENSG00000148426 PROSER2 499 
ENSG00000085662 AKR1B1 497.5935484 
ENSG00000074416 MGLL 496.7142857 
ENSG00000156711 MAPK13 496.6666667 
ENSG00000069998 CECR5 495 
ENSG00000244045 TMEM199 489 
ENSG00000197467 COL13A1 488.5 
ENSG00000170421 KRT8 485.8461538 
ENSG00000227036 LINC00511 483 
ENSG00000160953 MUM1 482 
ENSG00000109390 NDUFC1 480 
ENSG00000168393 DTYMK 479.5 
ENSG00000260032 NORAD 478.9545455 
ENSG00000185608 MRPL40 477 
ENSG00000198169 ZNF251 475 
ENSG00000149792 MRPL49 474 
ENSG00000183828 NUDT14 473 
ENSG00000250462 LRRC37BP1 472 
ENSG00000172031 EPHX4 470 
ENSG00000167767 KRT80 469.5714286 
ENSG00000142794 NBPF3 465 
ENSG00000168653 NDUFS5 465 
ENSG00000168528 SERINC2 463.0625 
ENSG00000106610 STAG3L4 462 
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ENSG00000106853 PTGR1 460.6666667 
ENSG00000183421 RIPK4 460 
ENSG00000164509 IL31RA 459 
ENSG00000163956 LRPAP1 456.1666667 
ENSG00000122952 ZWINT 455.5 
ENSG00000046651 OFD1 454 
ENSG00000226137 BAIAP2-AS1 454 
ENSG00000146674 IGFBP3 452.125 
ENSG00000251003 ZFPM2-AS1 452 
ENSG00000115041 KCNIP3 452 
ENSG00000186281 GPAT2 451 
ENSG00000198756 COLGALT2 445 
ENSG00000223547 ZNF844 444 
ENSG00000117525 F3 443.5 
ENSG00000048052 HDAC9 441.7777778 
ENSG00000149798 CDC42EP2 441 
ENSG00000001460 STPG1 440.5 
ENSG00000103018 CYB5B 438 
ENSG00000186918 ZNF395 437.3333333 
ENSG00000152078 TMEM56 437 
ENSG00000167595 PROSER3 435 
ENSG00000154319 FAM167A 433 
ENSG00000090263 MRPS33 432 
ENSG00000008283 CYB561 430.1666667 
ENSG00000156411 C14orf2 429.3333333 
ENSG00000112186 CAP2 429 
ENSG00000100422 CERK 425.5 
ENSG00000204370 SDHD 424 
ENSG00000166452 AKIP1 421 
ENSG00000113070 HBEGF 420.6 
ENSG00000153558 FBXL2 419 
ENSG00000167378 IRGQ 418 
ENSG00000162976 PQLC3 417 
ENSG00000141179 PCTP 416 
ENSG00000134463 ECHDC3 415.5 
ENSG00000223891 OSER1-AS1 415 
ENSG00000203805 PLPP4 415 
ENSG00000155850 SLC26A2 414 
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ENSG00000182325 FBXL6 412 
ENSG00000105053 VRK3 411.6666667 
ENSG00000186532 SMYD4 408 
ENSG00000164171 ITGA2 405.5 
ENSG00000198743 SLC5A3 403.3214286 
ENSG00000100814 CCNB1IP1 403.25 
ENSG00000169252 ADRB2 401 
ENSG00000173193 PARP14 400 
ENSG00000197620 CXorf40A 399 
ENSG00000145536 ADAMTS16 395 
ENSG00000137965 IFI44 393 
ENSG00000122711 SPINK4 393 
ENSG00000170647 TMEM133 391 
ENSG00000150433 TMEM218 390 
ENSG00000181924 COA4 387.5 
ENSG00000166689 PLEKHA7 386.25 
ENSG00000196139 AKR1C3 384.1111111 
ENSG00000231074 HCG18 383.2 
ENSG00000169093 ASMTL 383 
ENSG00000130589 HELZ2 382.6666667 
ENSG00000081692 JMJD4 382 
ENSG00000106078 COBL 382 
ENSG00000125148 MT2A 381.4545455 
ENSG00000168116 KIAA1586 381 
ENSG00000173818 ENDOV 379 
ENSG00000156675 RAB11FIP1 378.4 
ENSG00000188015 S100A3 377.2 
ENSG00000131115 ZNF227 377 
ENSG00000183291 42993 375.8 
ENSG00000184985 SORCS2 375.75 
ENSG00000167700 MFSD3 373 
ENSG00000204287 HLA-DRA 370.5 
ENSG00000110628 SLC22A18 370 
ENSG00000185917 SETD4 369 
ENSG00000255737 AGAP2-AS1 369 
ENSG00000176396 EID2 369 
ENSG00000124275 MTRR 367.5 
ENSG00000242125 SNHG3 362.5 
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ENSG00000137331 IER3 360.8582677 
ENSG00000158828 PINK1 360.3333333 
ENSG00000189067 LITAF 358.6666667 
ENSG00000163283 ALPP 356.6666667 
ENSG00000167173 C15orf39 355.8333333 
ENSG00000131943 C19orf12 354.5 
ENSG00000187609 EXD3 347 
ENSG00000204267 TAP2 347 
ENSG00000198624 CCDC69 346.8571429 
ENSG00000081041 CXCL2 346.5833333 
ENSG00000174749 C4orf32 346 
ENSG00000173530 TNFRSF10D 346 
ENSG00000133317 LGALS12 346 
ENSG00000112679 DUSP22 344 
ENSG00000180921 FAM83H 344 
ENSG00000189114 BLOC1S3 342.5 
ENSG00000121966 CXCR4 341 
ENSG00000105928 DFNA5 340.6666667 
ENSG00000140545 MFGE8 338.8 
ENSG00000138166 DUSP5 338.6428571 
ENSG00000219200 RNASEK 338 
ENSG00000148399 DPH7 338 
ENSG00000100014 SPECC1L 337.5 
ENSG00000106479 ZNF862 337 
ENSG00000119986 AVPI1 336.8 
ENSG00000062582 MRPS24 335 
ENSG00000188321 ZNF559 332 
ENSG00000105048 TNNT1 331.1666667 
ENSG00000215012 C22orf29 331 
ENSG00000179958 DCTPP1 331 
ENSG00000072135 PTPN18 330 
ENSG00000227706 RP11-301G19.1 327 
ENSG00000164054 SHISA5 326.1428571 
ENSG00000112977 DAP 325.3714286 
ENSG00000180448 ARHGAP45 324.2222222 
ENSG00000196917 HCAR1 324 
ENSG00000110031 LPXN 323.5 
ENSG00000180573 HIST1H2AC 323 
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ENSG00000151503 NCAPD3 322.5 
ENSG00000103160 HSDL1 320.3333333 
ENSG00000164379 FOXQ1 316 
ENSG00000119900 OGFRL1 315.4358974 
ENSG00000272391 POM121C 315 
ENSG00000217555 CKLF 315 
ENSG00000143845 ETNK2 311.5 
ENSG00000232119 MCTS1 310.2 
ENSG00000189180 ZNF33A 309.75 
ENSG00000023191 RNH1 308.4736842 
ENSG00000206503 HLA-A 306.7357143 
ENSG00000135925 WNT10A 305 
ENSG00000198168 SVIP 305 
ENSG00000144645 OSBPL10 304.8 
ENSG00000078237 TIGAR 304 
ENSG00000270231 NBPF8 303.5 
ENSG00000100058 CRYBB2P1 303 
ENSG00000242259 C22orf39 301 
ENSG00000130202 NECTIN2 299.8947368 
ENSG00000105877 DNAH11 299 
ENSG00000110013 SIAE 297.3333333 
ENSG00000146066 HIGD2A 297.2 
ENSG00000155275 TRMT44 297 
ENSG00000112877 CEP72 297 
ENSG00000067064 IDI1 296.875 
ENSG00000104979 C19orf53 295.1666667 
ENSG00000253161 LINC01605 295 
ENSG00000186951 PPARA 294.8333333 
ENSG00000102699 PARP4 293.625 
ENSG00000096696 DSP 292.5384615 
ENSG00000114544 SLC41A3 291.6666667 
ENSG00000171943 SRGAP2C 290 
ENSG00000255248 MIR100HG 288.75 
ENSG00000111348 ARHGDIB 288 
ENSG00000168394 TAP1 286.7692308 
ENSG00000253910 PCDHGB2 283 
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ENSG00000133101 CCNA1 283 
ENSG00000112343 TRIM38 282.2 
ENSG00000188827 SLX4 281 
ENSG00000173898 SPTBN2 281 
ENSG00000166592 RRAD 280.5 
ENSG00000198786 MT-ND5 279.7851852 
ENSG00000131941 RHPN2 278.6666667 
ENSG00000093010 COMT 278 
ENSG00000141562 NARF 278 
ENSG00000099194 SCD 277.3877551 
ENSG00000142920 AZIN2 277 
ENSG00000156510 HKDC1 276.8461538 
ENSG00000164535 DAGLB 276.2 
ENSG00000163945 UVSSA 275 
ENSG00000239887 C1orf226 274 
ENSG00000171490 RSL1D1 273.4375 
ENSG00000141030 COPS3 272.625 
ENSG00000179532 DNHD1 272 
ENSG00000196843 ARID5A 270 
ENSG00000253729 PRKDC 269.48 
ENSG00000234608 MAPKAPK5-AS1 269 
ENSG00000132740 IGHMBP2 268.6666667 
ENSG00000088888 MAVS 268.5 
ENSG00000122778 KIAA1549 268.2 
ENSG00000168884 TNIP2 268 
ENSG00000176485 PLA2G16 266.4210526 
ENSG00000091622 PITPNM3 265.5 
ENSG00000229833 PET100 265 
ENSG00000111843 TMEM14C 263.4375 
ENSG00000225630 MTND2P28 263.3333333 
ENSG00000161277 THAP8 263 
ENSG00000108021 FAM208B 261.7272727 
ENSG00000065609 SNAP91 260 
ENSG00000164919 COX6C 258 
ENSG00000137337 MDC1 256.9 
ENSG00000100034 PPM1F 256.25 
ENSG00000108179 PPIF 256.2083333 
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ENSG00000167705 RILP 255.5 
ENSG00000153363 LINC00467 255 
ENSG00000131591 C1orf159 255 
ENSG00000187266 EPOR 252.5 
ENSG00000085117 CD82 250.8125 
ENSG00000183161 FANCF 248 
ENSG00000103152 MPG 248 
ENSG00000067182 TNFRSF1A 245.8571429 
ENSG00000132109 TRIM21 245.5 
ENSG00000130270 ATP8B3 245 
ENSG00000128578 STRIP2 244.5 
ENSG00000179526 SHARPIN 244 
ENSG00000152443 ZNF776 243.5 
ENSG00000167397 VKORC1 242.5 
ENSG00000173821 RNF213 242.3913043 
ENSG00000247516 MIR4458HG 242 
ENSG00000028277 POU2F2 241.75 
ENSG00000058335 RASGRF1 241 
ENSG00000124588 NQO2 240.875 
ENSG00000118197 DDX59 240 
ENSG00000120256 LRP11 239.8 
ENSG00000242498 ARPIN 238.5 
ENSG00000106789 CORO2A 238.25 
ENSG00000141556 TBCD 237.4285714 
ENSG00000170006 TMEM154 237 
ENSG00000139410 SDSL 237 
ENSG00000003402 CFLAR 236.9230769 
ENSG00000196449 YRDC 236.75 
ENSG00000056558 TRAF1 236.2222222 
ENSG00000205763 RP9P 236 
ENSG00000170791 CHCHD7 236 
ENSG00000135953 MFSD9 235 
ENSG00000160072 ATAD3B 234 
ENSG00000275342 SGK223 233.3333333 
ENSG00000246273 SBF2-AS1 233 
ENSG00000130489 SCO2 233 
ENSG00000137936 BCAR3 232.7272727 
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ENSG00000197208 SLC22A4 232 
ENSG00000138744 NAAA 232 
ENSG00000139178 C1RL 231 
ENSG00000116285 ERRFI1 230.3252033 
ENSG00000119655 NPC2 229.3030303 
ENSG00000204922 UQCC3 229 
ENSG00000120875 DUSP4 228.9607843 
ENSG00000214194 LINC00998 228.6666667 
ENSG00000188938 FAM120AOS 227 
ENSG00000113845 TIMMDC1 227 
ENSG00000127124 HIVEP3 226.75 
ENSG00000149948 HMGA2 226.4285714 
ENSG00000142556 ZNF614 226 
ENSG00000275993 CH507-42P11.8 225.3333333 
ENSG00000116260 QSOX1 225.3088235 
ENSG00000165609 NUDT5 224.3 
ENSG00000104823 ECH1 221.6666667 
ENSG00000122687 MRM2 221.25 
ENSG00000088876 ZNF343 221 
ENSG00000163624 CDS1 220 
ENSG00000002587 HS3ST1 220 
ENSG00000181274 FRAT2 219 
ENSG00000159733 ZFYVE28 218.5 
ENSG00000129355 CDKN2D 218.3333333 
ENSG00000183087 GAS6 217.8695652 
ENSG00000141526 SLC16A3 217.6190476 
ENSG00000180190 TDRP 217.5 
ENSG00000103253 HAGHL 217 
ENSG00000076351 SLC46A1 217 
ENSG00000154328 NEIL2 217 
ENSG00000154134 ROBO3 216.5 
ENSG00000109084 TMEM97 216.4285714 
ENSG00000111321 LTBR 216.1666667 
ENSG00000182362 YBEY 216 
ENSG00000224531 SMIM13 215.3333333 
ENSG00000129422 MTUS1 215.3 
ENSG00000100099 HPS4 213.5 
ENSG00000188785 ZNF548 213 
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ENSG00000185442 FAM174B 212.5 
ENSG00000160062 ZBTB8A 212 
ENSG00000104679 R3HCC1 212 
ENSG00000123146 ADGRE5 211.7777778 
ENSG00000212916 MAP10 211 
ENSG00000154710 RABGEF1 211 
ENSG00000196976 LAGE3 211 
ENSG00000008513 ST3GAL1 210.1111111 
ENSG00000181458 TMEM45A 209.5 
ENSG00000188157 AGRN 209.3829787 
ENSG00000124614 RPS10 208.4814815 
ENSG00000138759 FRAS1 208 
ENSG00000196372 ASB13 207.5 
ENSG00000039068 CDH1 207.3333333 
ENSG00000143740 SNAP47 206.8 
ENSG00000177685 CRACR2B 206 
ENSG00000109062 SLC9A3R1 206 
ENSG00000078401 EDN1 206 
ENSG00000146410 MTFR2 205.5 
ENSG00000115107 STEAP3 204.8421053 
ENSG00000146232 NFKBIE 204.5 
ENSG00000167536 DHRS13 203 
ENSG00000113645 WWC1 202.2083333 
ENSG00000205476 CCDC85C 201.75 
ENSG00000179271 GADD45GIP1 200.7142857 
ENSG00000133678 TMEM254 200 
ENSG00000013810 TACC3 200 
ENSG00000078804 TP53INP2 199.6666667 
ENSG00000170271 FAXDC2 199 
ENSG00000165684 SNAPC4 199 
ENSG00000099330 OCEL1 198.6666667 
ENSG00000198286 CARD11 198.6666667 
ENSG00000165480 SKA3 198.3333333 
ENSG00000105341 ATP5SL 198.25 
ENSG00000253352 TUG1 197.8235294 
ENSG00000143786 CNIH3 197.75 
ENSG00000010219 DYRK4 197.5 
ENSG00000028137 TNFRSF1B 196.25 
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ENSG00000185022 MAFF 195.9285714 
ENSG00000075643 MOCOS 194.7 
ENSG00000168765 GSTM4 193.8571429 
ENSG00000182957 SPATA13 193 
ENSG00000172888 ZNF621 192.8333333 
ENSG00000147804 SLC39A4 192.5 
ENSG00000122376 FAM35A 192.3333333 
ENSG00000198721 ECI2 191.2666667 
ENSG00000026103 FAS 191 
ENSG00000157510 AFAP1L1 190.3333333 
ENSG00000185298 CCDC137 189.3333333 
ENSG00000152558 TMEM123 189.2631579 
ENSG00000120217 CD274 189 
ENSG00000160961 ZNF333 188 
ENSG00000185127 C6orf120 187.125 
ENSG00000168672 FAM84B 186 
ENSG00000173706 HEG1 185.3739837 
ENSG00000157601 MX1 185.25 
ENSG00000163131 CTSS 185.0833333 
ENSG00000171813 PWWP2B 184.3333333 
ENSG00000070814 TCOF1 182.5833333 
ENSG00000256683 ZNF350 182 
ENSG00000173210 ABLIM3 181 
ENSG00000137185 ZSCAN9 181 
ENSG00000054277 OPN3 180 
ENSG00000157895 C12orf43 180 
ENSG00000137198 GMPR 179.5714286 
ENSG00000164142 FAM160A1 178.5 
ENSG00000182858 ALG12 178.5 
ENSG00000165689 SDCCAG3 178.3333333 
ENSG00000167969 ECI1 177.5 
ENSG00000231365 RP11-418J17.1 177 
ENSG00000184371 CSF1 176.4083333 
ENSG00000219665 CTD-2006C1.2 176 
ENSG00000237550 RPL9P9 175.8571429 
ENSG00000128833 MYO5C 175 
ENSG00000259974 LINC00261 174 
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ENSG00000137642 SORL1 174 
ENSG00000179242 CDH4 173.5 
ENSG00000117877 CD3EAP 173 
ENSG00000100104 SRRD 172.6666667 
ENSG00000131697 NPHP4 172.5 
ENSG00000188002 RP11-43F13.1 172 
ENSG00000165832 TRUB1 171.5 
ENSG00000112584 FAM120B 171.2222222 
ENSG00000214087 ARL16 170.6666667 
ENSG00000272888 LINC01578 170.375 
ENSG00000078114 NEBL 170 
ENSG00000166278 C2 169.75 
ENSG00000067606 PRKCZ 169.5 
ENSG00000160299 PCNT 169.1111111 
ENSG00000167840 ZNF232 169 
ENSG00000101017 CD40 168.6 
ENSG00000065054 SLC9A3R2 168.0625 
ENSG00000171224 C10orf35 168 
ENSG00000213366 GSTM2 168 
ENSG00000107159 CA9 167 
ENSG00000115339 GALNT3 166.6666667 
ENSG00000131944 FAAP24 166 
ENSG00000164211 STARD4 165.8461538 
ENSG00000172493 AFF1 165.7916667 
ENSG00000135451 TROAP 165.6666667 
ENSG00000175764 TTLL11 164 
ENSG00000110721 CHKA 163.3888889 
ENSG00000126709 IFI6 163 
ENSG00000189057 FAM111B 163 
ENSG00000269001 CTD-2245F17.3 162 
ENSG00000161249 DMKN 162 
ENSG00000232434 C9orf172 162 
ENSG00000096080 MRPS18A 161.6666667 
ENSG00000254470 AP5B1 161.4285714 
ENSG00000131389 SLC6A6 161.2368421 
ENSG00000163082 SGPP2 161 
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ENSG00000154447 SH3RF1 160.5 
ENSG00000170915 PAQR8 160 
ENSG00000006432 MAP3K9 159.6 
ENSG00000073350 LLGL2 157.6666667 
ENSG00000197037 ZSCAN25 157.3333333 
ENSG00000221947 XKR9 156.5 
ENSG00000233461 RP11-295G20.2 155 
ENSG00000276180 HIST1H4I 155 
ENSG00000146648 EGFR 154.8288288 
ENSG00000102181 CD99L2 154.5714286 
ENSG00000179403 VWA1 154.5 
ENSG00000167695 FAM57A 154.4545455 
ENSG00000184792 OSBP2 154 
ENSG00000167880 EVPL 153.6666667 
ENSG00000223552 RP11-24F11.2 153.5 
ENSG00000165983 PTER 153.3333333 
ENSG00000157911 PEX10 153.25 
ENSG00000095383 TBC1D2 153.1666667 
ENSG00000171450 CDK5R2 153 
ENSG00000213066 FGFR1OP 153 
ENSG00000178229 ZNF543 153 
ENSG00000147509 RGS20 153 
ENSG00000164828 SUN1 152.2083333 
ENSG00000132326 PER2 152 
ENSG00000147996 CBWD5 151 
ENSG00000169084 DHRSX 151 
ENSG00000114541 FRMD4B 151 
ENSG00000204386 NEU1 150.877193 
ENSG00000156587 UBE2L6 150.7777778 
ENSG00000083812 ZNF324 150.5 
ENSG00000125814 NAPB 150 
ENSG00000083457 ITGAE 150 
ENSG00000241258 CRCP 149.2222222 
ENSG00000204642 HLA-F 149 
ENSG00000131037 EPS8L1 149 
ENSG00000100263 RHBDD3 148 
ENSG00000158792 SPATA2L 148 
ENSG00000272620 AFAP1-AS1 147 
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ENSG00000243701 DUBR 147 
ENSG00000183914 DNAH2 146.7142857 
ENSG00000168159 RNF187 146.4074074 
ENSG00000171792 RHNO1 146.2857143 
ENSG00000160179 ABCG1 146 
ENSG00000281376 ABALON 146 
ENSG00000197903 HIST1H2BK 145.8 
ENSG00000164284 GRPEL2 144.75 
ENSG00000133313 CNDP2 144.21875 
ENSG00000184898 RBM43 144 
ENSG00000186272 ZNF17 144 
ENSG00000140464 PML 143.5 
ENSG00000213853 EMP2 143.3333333 
ENSG00000244509 APOBEC3C 143.1666667 
ENSG00000264247 LINC00909 143 
ENSG00000165891 E2F7 142.55 
ENSG00000137393 RNF144B 142 
ENSG00000103145 HCFC1R1 141.3571429 
ENSG00000197321 SVIL 141 
ENSG00000185838 GNB1L 141 
ENSG00000128849 CGNL1 141 
ENSG00000165264 NDUFB6 140.8571429 
ENSG00000104892 KLC3 140 
ENSG00000166578 IQCD 139 
ENSG00000175906 ARL4D 139 
ENSG00000204438 GPANK1 138.8333333 
ENSG00000135749 PCNX2 138.5 
ENSG00000141934 PLPP2 138 
ENSG00000074621 SLC24A1 138 
ENSG00000204540 PSORS1C1 138 
ENSG00000090971 NAT14 137.75 
ENSG00000175756 AURKAIP1 137.7 
ENSG00000168734 PKIG 137.25 
ENSG00000158169 FANCC 136.8 
ENSG00000125482 TTF1 136.3333333 
ENSG00000010278 CD9 136.2777778 
ENSG00000165661 QSOX2 136.2142857 
ENSG00000174607 UGT8 135.3333333 
 
 225 
ENSG00000130803 ZNF317 135.1818182 
ENSG00000169306 IL1RAPL1 135 
ENSG00000188242 PP7080 135 
ENSG00000244187 TMEM141 134.4 
ENSG00000189306 RRP7A 133.7272727 
ENSG00000187957 DNER 133.6666667 
ENSG00000170017 ALCAM 133.6470588 
ENSG00000153395 LPCAT1 133.25 
ENSG00000182118 FAM89A 133 
ENSG00000177427 MIEF2 133 
ENSG00000087269 NOP14 133 
ENSG00000139209 SLC38A4 132.25 
ENSG00000149218 ENDOD1 132.1666667 
ENSG00000101160 CTSZ 132.1 
ENSG00000174059 CD34 132 
ENSG00000243667 WDR92 132 
ENSG00000005884 ITGA3 131.7424658 
ENSG00000064199 SPA17 131.5 
ENSG00000169241 SLC50A1 131 
ENSG00000136866 ZFP37 130 
ENSG00000101400 SNTA1 129.3 
ENSG00000152464 RPP38 129.25 
ENSG00000165102 HGSNAT 129.2307692 
ENSG00000143842 SOX13 129.1 
ENSG00000214013 GANC 128.3333333 
ENSG00000110921 MVK 128.25 
ENSG00000215548 FRG1JP 128 
ENSG00000069974 RAB27A 128 
ENSG00000058085 LAMC2 127.4761905 
ENSG00000030582 GRN 127.3762376 
ENSG00000099337 KCNK6 127 
ENSG00000161653 NAGS 126.5 
ENSG00000185414 MRPL30 126.5 
ENSG00000107281 NPDC1 126.5 
ENSG00000134202 GSTM3 126.4090909 
ENSG00000154146 NRGN 126 
ENSG00000211445 GPX3 125.09375 
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ENSG00000203780 FANK1 125 
ENSG00000198515 CNGA1 125 
ENSG00000175592 FOSL1 124.6973684 
ENSG00000139725 RHOF 124.5 
ENSG00000130638 ATXN10 124.3636364 
ENSG00000169710 FASN 124 
ENSG00000182578 CSF1R 124 
ENSG00000167889 MGAT5B 124 
ENSG00000111775 COX6A1 123.96 
ENSG00000183077 AFMID 123.6666667 
ENSG00000055332 EIF2AK2 123.6 
ENSG00000148396 SEC16A 123.2285714 
ENSG00000118193 KIF14 122.6 
ENSG00000178719 GRINA 122.5555556 
ENSG00000174547 MRPL11 122.4444444 
ENSG00000116661 FBXO2 122.4285714 
ENSG00000180537 RNF182 122 
ENSG00000183691 NOG 121.7058824 
ENSG00000103150 MLYCD 121.5 
ENSG00000103528 SYT17 121 
ENSG00000161692 DBF4B 120.8 
ENSG00000125430 HS3ST3B1 120.75 
ENSG00000147394 ZNF185 120.6666667 
ENSG00000185033 SEMA4B 120.3478261 
ENSG00000177951 BET1L 120.2777778 
ENSG00000165215 CLDN3 120 
ENSG00000254614 AP003068.23 120 
ENSG00000171608 PIK3CD 119.625 
ENSG00000158156 XKR8 119.625 
ENSG00000197763 TXNRD3 119.5 
ENSG00000184428 TOP1MT 119.375 
ENSG00000144821 MYH15 119 
ENSG00000237039 AC018738.2 119 
ENSG00000161267 BDH1 118.7142857 
ENSG00000196227 FAM217B 118.3333333 
ENSG00000163950 SLBP 118.1538462 
ENSG00000164687 FABP5 118 
ENSG00000176953 NFATC2IP 118 
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ENSG00000158062 UBXN11 117.5 
ENSG00000116213 WRAP73 117.3333333 
ENSG00000164751 PEX2 117.25 
ENSG00000228672 PROB1 117 
ENSG00000260822 GS1-358P8.4 116.5 
ENSG00000130921 C12orf65 116.125 
ENSG00000106868 SUSD1 116 
ENSG00000138821 SLC39A8 115.8888889 
ENSG00000076944 STXBP2 115.75 
ENSG00000114626 ABTB1 115.4285714 
ENSG00000082458 DLG3 115.3333333 
ENSG00000119705 SLIRP 115.1666667 
ENSG00000171729 TMEM51 115.1428571 
ENSG00000172889 EGFL7 115 
ENSG00000163701 IL17RE 115 
ENSG00000234745 HLA-B 114.7589577 
ENSG00000169908 TM4SF1 114.75 
ENSG00000176720 BOK 114.6 
ENSG00000119632 IFI27L2 114.4 
ENSG00000267673 FDX2 114 
ENSG00000228594 FNDC10 114 
ENSG00000146109 ABT1 113.8181818 
ENSG00000123240 OPTN 113.7010309 
ENSG00000273604 C17orf96 113.5 
ENSG00000049089 COL9A2 113.5 
ENSG00000125898 FAM110A 113.5 
ENSG00000007520 TSR3 113.25 
ENSG00000213694 S1PR3 113 
ENSG00000004961 HCCS 113 
ENSG00000144026 ZNF514 113 
ENSG00000167685 ZNF444 113 
ENSG00000188636 LDOC1L 113 
ENSG00000112208 BAG2 112.6666667 
ENSG00000077157 PPP1R12B 112.5 
ENSG00000132591 ERAL1 112.4705882 
ENSG00000156313 RPGR 112.3333333 
ENSG00000050730 TNIP3 112 
ENSG00000231721 LINC-PINT 112 
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ENSG00000215908 CROCCP2 112 
ENSG00000150281 CTF1 112 
ENSG00000172171 TEFM 111.5 
ENSG00000128626 MRPS12 111.4444444 
ENSG00000112541 PDE10A 111 
ENSG00000145439 CBR4 110.75 
ENSG00000152291 TGOLN2 110.3571429 
ENSG00000148082 SHC3 110.3333333 
ENSG00000183474 GTF2H2C 110 
ENSG00000251602 RP11-521B24.3 110 
ENSG00000177150 FAM210A 109.9375 
ENSG00000167740 CYB5D2 109.75 
ENSG00000166016 ABTB2 109.4 
ENSG00000130164 LDLR 109.2515723 
ENSG00000070882 OSBPL3 109.1896552 
ENSG00000170684 ZNF296 109 
ENSG00000103168 TAF1C 109 
ENSG00000167680 SEMA6B 109 
ENSG00000011132 APBA3 108.7142857 
ENSG00000184860 SDR42E1 108.5 
ENSG00000196150 ZNF250 108.5 
ENSG00000157538 DSCR3 108.48 
ENSG00000180758 GPR157 108.3333333 
ENSG00000173276 ZBTB21 108.2307692 
ENSG00000217165 ANKRD18EP 108 
ENSG00000149054 ZNF215 108 
ENSG00000185860 CCDC190 108 
ENSG00000133027 PEMT 107.75 
ENSG00000075407 ZNF37A 107.6153846 
ENSG00000025772 TOMM34 107.52 
ENSG00000116096 SPR 107.5 
ENSG00000112902 SEMA5A 107.2 
ENSG00000145819 ARHGAP26 107.1666667 
ENSG00000178026 LRRC75B 107 
ENSG00000197016 ZNF470 106.875 
ENSG00000165752 STK32C 106.8571429 
ENSG00000111412 C12orf49 106.75 
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ENSG00000119899 SLC17A5 106.1886792 
ENSG00000092929 UNC13D 105.8787879 
ENSG00000160209 PDXK 105.6333333 
ENSG00000111674 ENO2 105.5576923 
ENSG00000124787 RPP40 105.5 
ENSG00000182253 SYNM 105.5 
ENSG00000174327 SLC16A13 105.4615385 
ENSG00000171552 BCL2L1 105.3555556 
ENSG00000101255 TRIB3 105.3018868 
ENSG00000172164 SNTB1 105.25 
ENSG00000103005 USB1 104.862069 
ENSG00000134324 LPIN1 104.7222222 
ENSG00000163251 FZD5 104.6666667 
ENSG00000130731 METTL26 104.3333333 
ENSG00000164808 SPIDR 104.3 
ENSG00000125648 SLC25A23 104.2 
ENSG00000141198 TOM1L1 104.1 
ENSG00000146555 SDK1 104 
ENSG00000215193 PEX26 103.9 
ENSG00000196730 DAPK1 103.6666667 
ENSG00000204611 ZNF616 103.5 
ENSG00000071655 MBD3 103.4230769 
ENSG00000176978 DPP7 103.3157895 
ENSG00000001630 CYP51A1 103.2857143 
ENSG00000143674 RP5-862P8.2 103.2 
ENSG00000212747 FAM127C 103.2 
ENSG00000178971 CTC1 103.1666667 
ENSG00000277462 ZNF670 103 
ENSG00000160298 C21orf58 103 
ENSG00000242802 AP5Z1 102.5454545 
ENSG00000054148 PHPT1 102.4375 
ENSG00000090530 P3H2 102.2727273 
ENSG00000165806 CASP7 102.125 
ENSG00000176046 NUPR1 102 
ENSG00000215375 MYL5 102 
ENSG00000196550 FAM72A 102 
ENSG00000099624 ATP5D 101.8181818 
ENSG00000153046 CDYL 101.5454545 
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ENSG00000120306 CYSTM1 101.2 
ENSG00000168994 PXDC1 101.1428571 
ENSG00000257093 KIAA1147 100.8333333 
ENSG00000148296 SURF6 100.7777778 
ENSG00000143774 GUK1 100.7241379 
ENSG00000112378 PERP 100.6363636 
ENSG00000086232 EIF2AK1 100.4444444 
ENSG00000100302 RASD2 100.25 
ENSG00000072042 RDH11 100.1578947 
ENSG00000116883 RP11-268J15.5 100 
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